0001580149
false
0001580149
2023-08-18
2023-08-18
0001580149
dei:BusinessContactMember
2023-08-18
2023-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
As
filed with the Securities and Exchange Commission on August 18, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BIOVIE
INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation or organization) |
|
46-2510769
(I.R.S.
Employer Identification Number) |
680
W Nye Lane Suite 204
Carson City, NV 89703
(775) 888-3162
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Cuong
Do
Chief
Executive Officer
c/o
BioVie Inc.
680 W Nye Lane Suite 204
Carson City, NV 89703
(775)
888-3162
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Michael
S. Lee, Esq.
Mark
G. Pedretti, Esq.
Reed
Smith LLP
599
Lexington Avenue
New
York, NY 10022
Tel:
(212) 521-5400
Fax:
(212) 521-5450
Approximate
date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.
If
the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box. ☐
If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, as amended (Securities Act), other than securities offered only in connection with dividend
or interest reinvestment plans, check the following box. ☒
If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act Registration Statement number of the earlier effective Registration Statement for the same
offering. ☐
If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act Registration Statement number of the earlier effective Registration Statement for the same offering. ☐
If
this Form is a Registration Statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer
and smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with section 8(a) of the Securities Act or until this registration statement shall become effective on such date as
the Commission acting pursuant to said section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED AUGUST 18, 2023
PROSPECTUS
Primary
Offering of
$300,000,000
Class
A Common Stock
Preferred
Stock
Warrants
Debt
Securities
Rights
Units
and
Secondary
Offering of
Up
to 311,002 Shares of Class A Common Stock Offered by the Selling Stockholders
This
prospectus relates to the offer and sale, from time to time, by BioVie Inc. (we, us, or the Company),
in one or more offerings, any combination of Class A common stock (as defined below), preferred stock, warrants, debt securities, rights
to purchase Class A common stock or other securities or units having a maximum aggregate offering price of $300,000,000. When we decide
to sell a particular class or series of securities, we will provide specific terms of the offered securities in a prospectus supplement.
This
prospectus also relates to the offer and resale, from time to time, by the selling stockholders named under the heading Selling
Stockholders in this prospectus (the Selling Stockholders), and their donees, pledgees, transferees or other successors-in-interest,
of up to 311,002 shares (the Shares) of common stock, par value $0.0001 per share (the Class A common stock),
of the Company, issuable upon the exercise of the warrants to purchase 311,002 shares of Class A common stock at an exercise price per
share equal to $5.82 (the Lender Warrants) held by the Selling Stockholders. We are registering the offer and sale of the
Shares issuable upon exercise of the Lender Warrants held by the Selling Stockholders to satisfy the registration rights they were granted
by the Company pursuant to the Loan and Security Agreement and the Supplement to the Loan and Security Agreement, each entered into on
November 30, 2021 (together, the Loan Agreement) with Avenue Venture Opportunities Fund II, L.P. (AVOPII)
and Avenue Venture Opportunities Fund, L.P. (AVOPI and, together with AVOPII, the Lenders).
Discounts,
concessions, commissions and similar selling expenses attributable to the sale of Shares covered by this prospectus will be borne by
the Selling Stockholders. We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating
to the registration of the Shares with the Securities and Exchange Commission (the SEC).
The
prospectus supplements may also add, update or change information contained in or incorporated by reference into this prospectus. However,
no prospectus supplement shall offer a security that is not registered and described in this prospectus at the time of its effectiveness. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated
by reference into this prospectus, carefully before you invest. This prospectus may not be used to offer or sell our securities unless
accompanied by a prospectus supplement relating to the offered securities.
Our
Class A common stock is listed on the Nasdaq Capital Market under the symbol BIVI. On August 17, 2023, the closing price
for our Common Stock, as reported on The Nasdaq Capital Market was $3.57 per share. Each prospectus supplement will contain
information, where applicable, as to our listing on the Nasdaq Capital Market or on any other securities exchange of the securities
covered by the prospectus supplement.
These
securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or through
a combination of these methods. Additionally, the Selling Stockholders may sell or otherwise dispose of the Shares covered by this prospectus
in a number of different ways and at varying prices. See Plan of Distribution in this prospectus. We may also describe
the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers
are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the
nature of our arrangements with them in a prospectus supplement. The net proceeds we expect to receive from any such sale will also be
included in a prospectus supplement.
We
will not receive any proceeds from the sales of Shares by the Selling Stockholders. Upon any exercise of the Lender Warrants by payment
of cash, we will receive the cash exercise price paid by the holders of the Lender Warrants. We intend to use those proceeds, if any,
for working capital and general corporate purposes.
An
investment in our securities involves a high degree of risk. Please carefully read the information under the headings Risk
Factors beginning on page 5 of this prospectus, the applicable prospectus supplement and Item 1A – Risk
Factors of our most recent Annual Report on Form 10-K and in any Quarterly Report on Form 10-Q that is incorporated by
reference in this prospectus before you invest in our securities.
We
may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments or supplements carefully before you make your investment decision.
Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is , 2023
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a Registration Statement that we filed with the SEC using a shelf registration process. Under this
shelf registration process, we may offer from time to time securities having a maximum aggregate offering price of $300,000,000. In addition,
the Selling Stockholders may from time to time sell up to an aggregate of 311,002 shares of Class A common stock issuable upon exercise
of the Lender Warrants. Each time we or the Selling Stockholders offer any type or series of securities under this prospectus, we will
prepare and file with the SEC a prospectus supplement that contains more specific information about the terms of that offering. We may
also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The
prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change
information contained in this prospectus or the documents incorporated herein by reference. You should read carefully both this prospectus,
any prospectus supplement and any related free writing prospectuses we have authorized for use in connection with a specific offering,
together with additional information described below under the caption Where You Can Find More Information, before
buying any of the securities being offered.
This
prospectus does not contain all the information provided in the Registration Statement we filed with the SEC. For further information
about us or our securities offered hereby, you should refer to that Registration Statement, which you can obtain from the SEC as described
below under Where You Can Find More Information.
Neither
we nor the Selling Stockholders have authorized anyone to provide any information other than that contained or incorporated by reference
in this prospectus or in any applicable prospectus supplement or any applicable free writing prospectus that we have authorized. We take
no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. The securities
offered hereby are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information
contained in or incorporated by reference in this prospectus is accurate as of any date other than the respective dates of such document.
Our business, financial condition, results of operations and prospects may have changed since those dates.
We
and the Selling Stockholders may sell securities through underwriters or dealers, through agents, directly to purchasers or through any
combination of these methods. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase
of securities. The prospectus supplement, which we will prepare and file with the SEC each time we offer securities, will set forth the
names of any underwriters, agents or others involved in the sale of securities, and any applicable fee, commission or discount arrangements
with them. See Plan of Distribution.
Unless
the context otherwise indicates, references in this prospectus to, BioVie, the Company, we,
our, or us mean BioVie, Inc., a Nevada corporation. The term Selling Stockholders refers, collectively,
to the selling stockholders named under the heading Selling Stockholders in this prospectus and their donees, pledgees,
transferees or other successors-in-interest.
PROSPECTUS
SUMMARY
This
prospectus summary highlights certain information about our company and other information contained elsewhere in this prospectus or in
documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment
decision. You should carefully read the entire prospectus, any prospectus supplement, including the matters set forth under the section
of this prospectus entitled Risk Factors and the financial statements and related notes and other information that we incorporate
by reference herein, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, before making an investment
decision.
Our
Company
We
are a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and
advanced liver disease.
Neurodegenerative
Disease Program
In neurodegenerative disease, the Company’s
drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (“ERK”) and Nuclear factor
kappa-light-chain-enhancer of activated B cells (“NFkB”) (e.g., tumor necrosis factor (“TNF”) signaling) that
leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and
survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (“AD”) and Parkinson’s
disease (“PD”).
The Company is conducting a potentially pivotal Phase 3 randomized, double
blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate AD (NCT04669028).
The study has co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog
12) and function using the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). The program is
fully enrolled and is targeting primary completion in the fourth quarter of the calendar 2023 year.
In
December 2022, topline results were released from the Companys Phase 2 study assessing NE3107s safety and tolerability
and potential pro-motoric impact in PD patients. The NM201 study (NCT05083260) was a double-blind, placebo-controlled, safety, tolerability,
and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. Forty-five patients with a defined L-dopa off
state were randomized 1:1 to placebo:NE3107 20 mg twice daily for 28 days. The trial was launched with two design objectives:
1) the primary objective was safety and a drug-drug interaction study (as requested by the U.S. Food and Drug Administration (FDA))
to demonstrate the absence of adverse interactions of NE3107 with levodopa; and 2) the secondary objective was to determine if preclinical
indications of promotoric activity and apparent enhancement of levodopa activity observed in a Parkinsons disease model in monkeys
can be seen in humans. Both objectives of the study were met. Patients treated with NE3107 experienced greater motor control.
The
Company provided the financial support and the use of our NE3107 formulated drug product for an open-label phase 2, Investigator-Initiated
Trial in mild cognitive impairment (MCI) and Mild AD, NCT05227820, conducted by (The Regenesis Project) of
Sheldon Jordan. The study received FDA authorization on December 12, 2021, and was designed to measure NE3107s effect on cognition,
cerebral spinal fluid (CSF) and blood biomarkers, and neuro-imagining endpoints. Topline results were released September
7, 2022, and additional data was presented at the Clinical Trial in Alzheimers Disease (CTAD) annual conference
in December 2022. The data showed that three months of treatment with NE3107 in patients with MCI and mild AD enhanced cognition compared
to baseline, as measured using multiple rating scales, had improvement in daily function and improvements in inflammation correlated
with improved cognition. No drug-related adverse events were observed.
The
Company acquired the biopharmaceutical assets of NeurMedix, Inc. (NeurMedix), from a related party privately held clinical-stage
pharmaceutical company, in June 2021. The acquired assets included NE3107, a potentially selective inhibitor of inflammatory ERK signaling
that, based on animal studies and Dr. Jordans study, is believed to reduce neuroinflammation. NE3107 is a novel orally administered
small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a
novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental
roles in the development of AD and PD, and NE3107 could, if approved by the FDA represent a new medical approach to treating these devastating
conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD.
Inflammation-driven
insulin resistance is believed to be implicated in a broad range of serious diseases, and we plan to begin exploring these opportunities
in the coming months using NE3107 or related compounds acquired in the NeurMedix asset purchase. NE3107 is patented in the United States
(U.S.), Australia, Canada, Europe and South Korea.
Liver
Disease Program
In
liver disease, our Orphan Drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, has been evaluated in
a U.S. Phase 2b study (NCT04112199) for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a patent-pending
liquid formulation. The study was closed before full enrollment, without clinically meaningful adverse effects associated with BIV201
treatment and data that appeared to show that treatment with BIV201 plus standard-of-care (SOC) resulted in a reduction
in ascites fluid accumulation during treatment versus pre-treatment. In June 2023, we requested guidance from the FDA regarding the design
and endpoints for definitive clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis.
While
the active agent, terlipressin, is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis,
treatment of ascites is not included in these authorizations. Patients with refractory ascites suffer from frequent life-threatening
complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months.
The U.S. FDA has not approved any drug to treat refractory ascites.
The
BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to
its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the
Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc.,
BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT
Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.
The
Securities We May Offer
This
prospectus is part of a Registration Statement that we filed with the SEC utilizing a shelf registration process. Under this shelf registration
process, we may sell any combination of:
| ● | debt
securities, in one or more series; |
| ● | right
to purchase common stock or other securities; and/or |
in
one or more offerings up to a total dollar amount of $300,000,000. This prospectus provides you with a general description of the securities
we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the
terms of that specific offering and include a discussion of any risk factors or other special considerations that apply to those securities.
The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus
and any prospectus supplement together with the additional information described under the heading Where You Can Find More Information.
Securities
Offered by the Selling Securityholders
This
prospectus also relates to the resale from time to time by the Selling Stockholders identified in this prospectus of up to 311,002 shares
of Class A common stock issuable upon the exercise of the Lender Warrants held by the Selling Stockholders. We are registering the offer
and sale of the Shares to satisfy the registration rights they were granted by the Company pursuant to the Loan Agreement.
On
November 30, 2021 (the Loan Closing Date), the Company entered into the Loan Agreement with the Lenders for growth capital
loans in an aggregate principal amount of up to $20,000,000 (the Loan), with (i) $15,000,000 funded on the Loan Closing
Date (Tranche 1) and (ii) up to $5,000,000 to be made available to the Company on or prior to September 15, 2022, subject
to the Companys achievement of certain milestones with respect to certain of its ongoing clinical trials. The Loan bears interest
at an annual rate equal to the greater of (a) the sum of 7.00% plus the prime rate as reported in The Wall Street Journal and (b) 10.75%.
The Loan is secured by a lien upon and security interest in all of the Companys assets, including intellectual property, subject
to agreed exceptions. The maturity date of the Loan is December 1, 2024. Up to $5,000,000 of the principal amount of the Loan outstanding
may be converted, at the option of the Lenders, into shares of the Companys Class A common stock at a conversion price of $6.98
per share.
In
connection with the Loan, pursuant to the funding of Tranche 1 on the Loan Closing Date, the Company issued 361,002 Lender Warrants.
The Lender Warrants, which are exercisable until November 30, 2026, were offered and sold by the Company in reliance on the exemption
from registration provided by Section 4(a)(2) of the Securities Act.
On March 31, 2023, the Company filed a Registration Statement on Form S-3 (File No. 333-271054), that was declared effective by the SEC
on April 10, 2023, which related in part to the offer and resale, from time to time, by the Selling Stockholders of up to 50,000 shares
of Class A common stock issuable upon exercise of the Lender Warrants.
The
Lenders may exercise the Lender Warrants at any time, or from time to time up to and including the Expiration Date, by making a cash
payment equal to the exercise price multiplied by the quantity of shares. The Lenders may also exercise the Lender Warrants on a cashless
or net issuance basis by receiving a net number of shares calculated pursuant to the formula set forth in the Lender Warrants.
The Lender Warrants are subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits. Pursuant to
the terms of the Lender Warrants, the holders of the Lender Warrants are entitled to piggyback registration rights if the Company proposes
to file a new registration statement under the Securities Act for purposes of effecting an underwritten offering of its equity securities,
subject to certain limitations.
Use
of Proceeds
Except
as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with
a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for
working capital and general corporate purposes. We will set forth in the applicable prospectus supplement or free writing prospectus
our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing
prospectus. All of the securities offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders
for their respective accounts. We will not receive any of the proceeds from these sales.
Nasdaq
Listing
Our
Class A common stock is listed on the Nasdaq Capital Market under the symbol BIVI.
Corporate Information
Our
principal executive office is located at 680 W. Nye Lane, Suite 201, Carson City, Nevada 89703, and our phone number is (775) 888-3162.
Our website address is http://www.bioviepharma.com/. The inclusion of our website address does not include or incorporate by reference
into this prospectus supplement or the accompanying prospectus any information on, or accessible through, our website. Our Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, together with amendments to these reports,
are available on the Investor Relations section of our website, free of charge, as soon as reasonably practicable after such
material is electronically filed with, or furnished to, the SEC.
RISK
FACTORS
Investing
in our securities involves risk. The prospectus supplement applicable to a particular offering of securities will contain a discussion
of the risks applicable to an investment in BioVie and to the particular types of securities that we are offering under that prospectus
supplement. Before making an investment decision, you should carefully consider the risks described under Risk Factors
in the applicable prospectus supplement together with all of the other information contained or incorporated by reference in the prospectus
supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions
discussed under Part I—Item 1A—Risk Factors of our most recent Annual Report on Form 10-K
and in Part II—Item 1A—Risk Factors in our most recent Quarterly Report on Form 10-Q filed
subsequent to such Form 10-K that are incorporated herein by reference, as may be amended, supplemented or superseded from time
to time by other reports we file with the SEC in the future. Our business, financial condition or results of operations could be materially
adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose
all or part of your investment.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus, each prospectus supplement and the documents incorporated by reference into this prospectus and each prospectus supplement
contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, that relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking
statements. Such forward-looking statements concern our anticipated results and progress of our operations in future periods, planned
exploration and, if warranted, development of our properties, plans related to our business and other matters that may occur in the future.
These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet
determinable and assumptions of management. All statements contained herein that are not clearly historical in nature are forward-looking,
and the words anticipate, believe, expect, estimate, may, will,
could, leading, intend, contemplate, shall and similar expressions
are generally intended to identify forward-looking statements. Forward-looking statements are subject to a variety of known and unknown
risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking
statements. The section in this prospectus entitled Risk Factors and the sections in our periodic reports, including
the section in the 2023 Form 10-K entitled Business, and the section in the 2023 Form 10-K and any future Quarterly
Report on Form 10-Qs incorporated herein by reference entitled Managements Discussion and Analysis of Financial Condition
and Results of Operations, as well as other sections in this prospectus and the documents or reports incorporated by reference
into this prospectus, discuss some of the factors that could contribute to these differences. Forward-looking statements in this prospectus,
each prospectus supplement, and the documents incorporated by reference herein and therein include, but are not limited to, statements
with respect to:
| ● | our
limited operating history and experience in developing and manufacturing drugs; |
| ● | none
of our products are approved for commercial sale; |
| ● | our
substantial capital needs; |
| ● | product
development risks; |
| ● | our
lack of sales and marketing personnel; |
| ● | regulatory,
competitive and contractual risks; |
| ● | no
assurance that our product candidates will obtain regulatory approval or that the results
of clinical studies will be favorable; |
| ● | risks
related to our intellectual property rights; |
| ● | the
volatility of the market price and trading volume in our common stock; |
| ● | the
absence of liquidity in our common stock; |
| ● | the
risk of substantial dilution from future issuances of our equity securities; and |
| ● | the
other risks set forth herein and in the documents incorporated by reference herein under
the caption Risk Factors. |
The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or
risk factors that we are faced with. The factors set forth above under Risk Factors and other cautionary statements
made in this prospectus should be read and understood as being applicable to all related forward-looking statements wherever they appear
in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as of the date of this prospectus.
We caution readers not to place undue reliance on such statements. You should read this prospectus and the documents that we have filed
as exhibits to this prospectus and incorporated by reference herein completely and with the understanding that our actual future results
may be materially different from the plans, intentions and expectations disclosed in the forward-looking statements we make. Except as
required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information
becomes available or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us
or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout
this prospectus.
This
prospectus and the documents incorporated by reference in this prospectus may contain market data that we obtain from industry sources.
These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable,
we do not independently verify the information. The market data may include projections that are based on a number of other projections.
While we believe these assumptions to be reasonable and sound as of the date of this prospectus, actual results may differ from the projections.
DIVIDEND
POLICY
We
have never declared or paid dividends on our common stock and we do not anticipate paying any cash dividends on our common stock in the
foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend
on applicable law and then-existing conditions, including our financial condition, operating results, contractual restrictions, capital
requirements, business prospects and other factors our board of directors may deem relevant. We currently intend to retain all available
funds and any future earnings to fund the development and growth of our business.
USE
OF PROCEEDS
Except
as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities covered
by this prospectus for general corporate purposes, which may include, but is not limited to, working capital, capital expenditures, research
and development expenditures and acquisitions of new technologies or businesses. The precise amount, use and timing of the application
of such proceeds will depend upon our funding requirements and the availability and cost of other capital. Additional information on
the use of net proceeds from an offering of securities covered by this prospectus may be set forth in the prospectus supplement relating
to the specific offering.
We
will not receive any proceeds from the sales of Shares by the Selling Stockholders.
Upon
any exercise of the Lender Warrants by payment of cash, we will receive the cash exercise price paid by the holders of the Lender Warrants.
We cannot assure you that any of the Lender Warrants will be exercised, or if exercised, of the quantity that will be exercised or the
period in which such Lender Warrants will be exercised.
DESCRIPTION
OF CAPITAL STOCK
The
following sections constitute a summary as of the date of this prospectus and do not purport to be a complete description of our capital
stock. We will describe in the applicable prospectus supplement relating to a particular offering the specific terms of the securities
offered by that prospectus supplement. We will indicate in the applicable prospectus supplement if the terms of the securities differ
from the terms we have summarized below. We will also include in the prospectus supplement information, where applicable, material United
States federal income tax considerations relating to the securities.
General
The
following description of common stock of the Company (the common stock) and preferred stock of the Company (the preferred
stock), together with the additional information we include in any applicable prospectus supplement, summarizes the material terms
and provisions of the common stock and preferred stock that we may offer under this prospectus but is not complete. For the complete
terms of our common stock and preferred stock, please refer to our articles of incorporation, as may be amended from time to time (the
Articles of Incorporation), any certificates of designation for our preferred stock, that may be authorized from time to
time, and our amended and restated bylaws, as amended from time to time (the Bylaws). The Nevada General Corporation Law
may also affect the terms of these securities. While the terms we have summarized below will apply generally to any future common stock
or preferred stock that we may offer, we will describe the specific terms of any series of these securities in more detail in the applicable
prospectus supplement. If we so indicate in a prospectus supplement, the terms of any common stock or preferred stock we offer under
that prospectus supplement may differ from the terms we describe below.
As
of August 17, 2023, our authorized capital stock consists of 800,000,000 shares of Class A common
stock, par value $0.0001 per share (the “Class A common stock”), of which 36,826,648 shares of Common Stock were issued, and
36,803,768 shares were issued and outstanding; and 10,000,000 shares of preferred stock, par value $0.001 per share, none of which were
issued and outstanding. The authorized and unissued shares of Class A common stock and preferred stock are available for issuance without
further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities
may be listed. Unless approval of our stockholders is so required, our board of directors will not seek stockholder approval for the issuance
and sale of our common stock.
Class
A Common Stock
Each
holder of Class A common stock is entitled to one vote for each share of Class A common stock held on all matters submitted to a vote
of the stockholders, including the election of directors. Our Articles of Incorporation and Bylaws do not provide for cumulative voting
rights. Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of our outstanding shares
of Class A common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out
of legally available funds. In the event of our liquidation, dissolution or winding up, holders of Class A common stock will be entitled
to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other
liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred
stock. Holders of our Class A common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking
fund provisions applicable to the Class A common stock. The rights, preferences and privileges of the holders of Class A common stock
are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may
designate and issue in the future. All of our outstanding shares of Class A common stock are fully paid and nonassessable.
Our
Class A common stock is listed on the Nasdaq Capital Market under the symbol BIVI. The transfer agent and registrar for
our Class A common stock is West Coast Stock Transfer, Inc., Encinitas, California.
Options/Warrants/ Restricted Stock Units
As of August 17, 2023, we had outstanding
options to purchase 3,952,864 shares of our Class A common stock at a weighted average exercise price of $7.10 and outstanding
warrants to purchase 7,770,285 shares of our Class A common stock at a weighted exercise price of $2.06 and restricted stock units
totaling 557,727.
Anti-Takeover
Effects of Our Articles of Incorporation and Bylaws
Our
Articles of Incorporation and Bylaws contain certain provisions that may have anti-takeover effects, making it more difficult for or
preventing a third party from acquiring control of us or changing our Board of Directors and management. According to our Articles of
Incorporation and Bylaws, neither the holders of our common stock nor the holders of any preferred stock we may issue in the future have
cumulative voting rights in the election of our directors. The combination of the present ownership by a few stockholders of a significant
portion of our issued and outstanding common stock and lack of cumulative voting makes it more difficult for other stockholders to replace
our Board of Directors or for a third party to obtain control of us by replacing our Board of Directors.
Anti-Takeover
Effects of Nevada Law
Business
Combinations
The
business combination provisions of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes (NRS)
generally prohibit a Nevada corporation with at least 200 stockholders from engaging in various combination transactions
with any interested stockholder for a period of two years after the date of the transaction in which the person became an interested
stockholder, unless the transaction is approved by the board of directors prior to the date the interested stockholder obtained such
status or the combination is approved by the board of directors and thereafter is approved at a meeting of the stockholders by the affirmative
vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond
the expiration of the two-year period, unless:
|
● |
the
combination was approved by the board of directors prior to the person becoming an interested stockholder or the transaction by which
the person first became an interested stockholder was approved by the board of directors before the person became an interested stockholder
or the combination is later approved by a majority of the voting power held by disinterested stockholders; or |
|
● |
if
the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid
by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the
transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock on
the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or
(c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher. |
A
combination is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer,
or other disposition, in one transaction or a series of transactions, with an interested stockholder having: (a) an aggregate
market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal
to 5% or more of the aggregate market value of all outstanding shares of the corporation, (c) 10% or more of the earning power or net
income of the corporation, and (d) certain other transactions with an interested stockholder or an affiliate or associate of an interested
stockholder.
In
general, an interested stockholder is a person who, together with affiliates and associates, owns (or within two years,
did own) 10% or more of a corporations voting stock. The statute could prohibit or delay mergers or other takeover or change in
control attempts and, accordingly, may discourage attempts to acquire our Company even though such a transaction may offer our stockholders
the opportunity to sell their stock at a price above the prevailing market price.
Control
Share Acquisitions
The
control share provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to issuing corporations
that are Nevada corporations with at least 200 stockholders, including at least 100 stockholders of record who are Nevada residents,
and that conduct business directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain circumstances,
from voting its shares of a target corporations stock after crossing certain ownership threshold percentages, unless the acquirer
obtains approval of the target corporations disinterested stockholders. The statute specifies three thresholds: one-fifth or more
but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally, once
an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become control
shares and such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions
also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting
power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment
for the fair value of their shares in accordance with statutory procedures established for dissenters rights.
A
corporation may elect to not be governed by, or opt out of, the control share provisions by making an election in its articles
of incorporation or bylaws, provided that the opt-out election must be in place on the 10th day following the date an acquiring person
has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have not opted out of the control
share statutes, and will be subject to these statutes if we are an issuing corporation as defined in such statutes.
The
effect of the Nevada control share statutes is that the acquiring person, and those acting in association with the acquiring person,
will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special
meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of our Company.
DESCRIPTION
OF WARRANTS
The
following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant
certificates. For the avoidance of doubt, this section relates only to new warrants that we may issue and not any of our outstanding
warrants, such as the Lender Warrants, and we refer to such new warrants in this prospectus for the sake of simplicity as warrants.
While
the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series
of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants
offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional
important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this
prospectus.
General
We
may issue warrants for the purchase of Class A common stock, preferred stock or debt securities, in one or more series. We may issue
warrants independently or together with Class A common stock, preferred stock and/or debt securities, and the warrants may be attached
to or separate from these securities.
We
plan to evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter
into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus
supplement relating to a particular series of warrants.
We
will describe in the applicable prospectus supplement the terms of the series of warrants, including:
| ● | the
offering price and aggregate number of warrants offered; |
| ● | the
currency for which the warrants may be purchased; |
| ● | if
applicable, the designation and terms of the securities with which the warrants are issued
and the number of warrants issued with each such security or each principal amount of such
security; |
| ● | if
applicable, the date on and after which the warrants and the related securities will be separately
transferable; |
| ● | the
number of shares of Class A common stock purchasable upon the exercise of one warrant and
the price at which these shares may be purchased upon such exercise; |
| ● | the
effect of any merger, consolidation, sale or other disposition of our business on the warrant
agreement and the warrants; |
| ● | the
terms of any rights to redeem or call the warrants; |
| ● | any
provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the warrants; |
| ● | the
periods during which, and places at which, the warrants are exercisable; |
| ● | the
dates on which the right to exercise the warrants will commence and expire; |
| ● | the
manner in which the warrant agreement and warrants may be modified; |
| ● | if
applicable, a discussion of certain material U.S. federal income tax considerations of holding
or exercising the warrants; and |
| ● | any
other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
DESCRIPTION
OF DEBT SECURITIES
The
following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material
terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will
generally apply to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities
that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities we offer under a prospectus
supplement may differ from the terms we describe below. As of the date of this prospectus, we have no outstanding registered
debt securities.
We
will issue senior notes under a senior indenture, which we will enter into with the trustee to be named in the senior indenture. We will issue subordinated notes under a subordinated indenture, which we will enter into with the trustee to be named in the subordinated
indenture. We have filed forms of these documents as exhibits to the registration statement of which this prospectus is a part. We use the term indentures to refer to both the senior indenture and the subordinated indenture.
The
indentures will be qualified under the Trust Indenture Act of 1939, as amended (the Trust Indenture Act). We use
the term debenture trustee to refer to either the senior trustee or the subordinated trustee, as applicable.
The
following summaries of material provisions of the senior notes, the subordinated notes and the indentures are subject to, and qualified
in their entirety by reference to, all the provisions of the indenture applicable to a particular series of debt securities. We
urge you to read the applicable prospectus supplements related to the debt securities that we sell under this prospectus, as well as
the complete indentures that contain the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior
and the subordinated indentures are identical.
General
The
terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or
determined in the manner provided in an officers certificate or by a supplemental indenture. Debt securities may be issued in
separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt
securities of any series. The particular terms of each series of debt securities will be described in a prospectus supplement relating
to such series, including any pricing supplement. The prospectus supplement will set forth:
| ● | the
principal amount being offered, and, if a series, the total amount authorized and the total
amount outstanding; |
| ● | any
limit on the amount that may be issued; |
| ● | whether
or not we will issue the series of debt securities in global form and, if so, the terms and
who the depositary will be; |
| ● | whether
and under what circumstances, if any, we will pay additional amounts on any debt securities
held by a person who is not a U.S. person for tax purposes, and whether we can redeem the
debt securities if we have to pay such additional amounts; |
| ● | the
annual interest rate, which may be fixed or variable, or the method for determining the rate,
the date interest will begin to accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for determining such dates; |
| ● | whether
or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
| ● | the
terms of the subordination of any series of subordinated debt; |
| ● | the
place where payments will be payable; |
| ● | restrictions
on transfer, sale or other assignment, if any; |
| ● | our
right, if any, to defer payment of interest and the maximum length of any such deferral period; |
| ● | the
date, if any, after which, the conditions upon which, and the price at which we may, at our
option, redeem the series of debt securities pursuant to any optional or provisional redemption
provisions, and any other applicable terms of those redemption provisions; |
| ● | the
date, if any, on which, and the price at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holders
option to purchase, the series of debt securities and the currency or currency unit in which
the debt securities are payable; |
| ● | whether
the indenture will restrict our ability and/or the ability of our subsidiaries to, among
other things: |
| ● | incur
additional indebtedness; |
| ● | issue
additional securities; |
| ● | pay
dividends and make distributions in respect of our capital stock and the capital stock of
our subsidiaries; |
| ● | place
restrictions on our subsidiaries ability to pay dividends, make distributions or transfer
assets; |
| ● | make
investments or other restricted payments; |
| ● | sell
or otherwise dispose of assets; |
| ● | enter
into sale-leaseback transactions; |
| ● | engage
in transactions with stockholders and affiliates; |
| ● | issue
or sell stock of our subsidiaries; or |
| ● | effect
a consolidation or merger; |
| ● | whether
the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios; |
| ● | a
discussion of any material or special U.S. federal income tax considerations applicable to
the debt securities; |
| ● | information
describing any book-entry features; |
| ● | provisions
for a sinking fund purchase or other analogous fund, if any; |
| ● | whether
the debt securities are to be offered at a price such that they will be deemed to be offered
at an original issue discount as defined in paragraph (a) of Section 1273 of
the Internal Revenue Code; |
| ● | the
procedures for any auction and remarketing, if any; |
| ● | the
denominations in which we will issue the series of debt securities, if other than denominations
of $1,000 and any integral multiple thereof; |
| ● | if
other than dollars, the currency in which the series of debt securities will be denominated;
and |
| ● | any
other specific terms, preferences, rights or limitations of, or restrictions on, the debt
securities, including any events of default that are in addition to those described in this
prospectus or any covenants provided with respect to the debt securities that are in addition
to those described above, and any terms that may be required by us or advisable under applicable
laws or regulations or advisable in connection with the marketing of the debt securities. |
Conversion
or Exchange Rights
We
will set forth in the prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for
Class A common stock or other securities of ours or a third party, including the conversion or exchange rate, as applicable, or how it
will be calculated, and the applicable conversion or exchange period. We will include provisions as to whether conversion or exchange
is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of our securities
or the securities of a third party that the holders of the series of debt securities receive upon conversion or exchange would, under
the circumstances described in those provisions, be subject to adjustment, or pursuant to which those holders would, under those circumstances,
receive other property upon conversion or exchange, for example in the event of our merger or consolidation with another entity.
Consolidation,
Merger or Sale
The
indentures in the forms initially filed as exhibits to the registration statement of which this prospectus is a part do not contain any
covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all
of our assets. However, any successor of ours or the acquirer of such assets must assume all of our obligations under the indentures
and the debt securities.
If
the debt securities are convertible for our other securities, the person with whom we consolidate or merge or to whom we sell all of
our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would
have received if they had converted the debt securities before the consolidation, merger or sale.
Events
of Default Under the Indenture
The
following are events of default under the indentures in the forms initially filed as exhibits to the registration statement with respect
to any series of debt securities that we may issue:
| ● | if
we fail to pay interest when due and payable and our failure continues for 90 days and the
time for payment has not been extended or deferred; |
| ● | if
we fail to pay the principal, sinking fund payment or premium, if any, when due and payable
and the time for payment has not been extended or delayed; |
| ● | if
we fail to observe or perform any other covenant contained in the debt securities or the
indentures, other than a covenant specifically relating to another series of debt securities,
and our failure continues for 90 days after we receive notice from the debenture trustee
or holders of at least 25% in aggregate principal amount of the outstanding debt securities
of the applicable series; and |
| ● | if
specified events of bankruptcy, insolvency or reorganization occur. |
If
an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified
in the last bullet point above, the debenture trustee or the holders of at least 25% in aggregate principal amount of the outstanding
debt securities of that series, by notice to us in writing, and to the debenture trustee if notice is given by such holders, may declare
the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified
in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt
securities then outstanding shall be due and payable without any notice or other action on the part of the debenture trustee or any holder.
The
holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium,
if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure
the default or event of default.
Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be
under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of
the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders
of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and
place of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the
debenture trustee, with respect to the debt securities of that series, provided that:
| ● | the
direction so given by the holder is not in conflict with any law or the applicable indenture;
and |
| ● | subject
to its duties under the Trust Indenture Act, the debenture trustee need not take any action
that might involve it in personal liability or might be unduly prejudicial to the holders
not involved in the proceeding. |
A
holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver
or trustee, or to seek other remedies if:
| ● | the
holder has given written notice to the debenture trustee of a continuing event of default
with respect to that series; |
| ● | the
holders of at least 25% in aggregate principal amount of the outstanding debt securities
of that series have made written request, and such holders have offered reasonable indemnity,
to the debenture trustee to institute the proceeding as trustee; and |
| ● | the
debenture trustee does not institute the proceeding and does not receive from the holders
of a majority in aggregate principal amount of the outstanding debt securities of that series
other conflicting directions within 90 days after the notice, request and offer. |
These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.
We
will periodically file statements with the debenture trustee regarding our compliance with specified covenants in the indentures.
Modification
of Indenture; Waiver
We
and the debenture trustee may change an indenture without the consent of any holders with respect to specific matters, including:
| ● | to
fix any ambiguity, defect or inconsistency in the indenture; |
| ● | to
comply with the provisions described above under Consolidation, Merger or Sale; |
| ● | to
comply with any requirements of the SEC in connection with the qualification of any indenture
under the Trust Indenture Act; |
| ● | to
evidence and provide for the acceptance of appointment hereunder by a successor trustee; |
| ● | to
provide for uncertificated debt securities and to make all appropriate changes for such purpose; |
| ● | to
add to, delete from, or revise the conditions, limitations and restrictions on the authorized
amount, terms or purposes of issuance, authorization and delivery of debt securities or any
series, as set forth in the indenture; |
| ● | to
provide for the issuance of and establish the form and terms and conditions of the debt securities
of any series as provided under General to establish the form of any certifications
required to be furnished pursuant to the terms of the indenture or any series of debt securities,
or to add to the rights of the holders of any series of debt securities; |
| ● | to
add to our covenants such new covenants, restrictions, conditions or provisions for the protection
of the holders, to make the occurrence, or the occurrence and the continuance, of a default
in any such additional covenants, restrictions, conditions or provisions an event of default,
or to surrender any of our rights or powers under the indenture; or |
| ● | to
change anything that does not materially adversely affect the interests of any holder of
debt securities of any series. |
In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with
the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series
that is affected. However, we and the debenture trustee may only make the following changes with the consent of each holder of
any outstanding debt securities affected:
| ● | extending
the fixed maturity of the series of debt securities; |
| ● | reducing
the principal amount, reducing the rate of or extending the time of payment of interest,
or reducing any premium payable upon the redemption of any debt securities; or |
| ● | reducing
the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. |
Discharge
Each
indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
that the following obligations survive until the maturity date or the redemption date:
| ● | register
the transfer or exchange of debt securities of the series; |
| ● | replace
stolen, lost or mutilated debt securities of the series; |
| ● | maintain
paying agencies; |
| ● | hold
monies for payment in trust; and |
| ● | appoint
any successor trustee; |
and
the following obligations survive the maturity date or the redemption date:
| ● | recover
excess money held by the debenture trustee; and |
| ● | compensate
and indemnify the debenture trustee. |
In
order to exercise our rights to be discharged, we must deposit with the debenture trustee money or government obligations sufficient
to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.
Form,
Exchange and Transfer
We
will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable
prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that we may issue debt
securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of,
The Depository Trust Company, New York, New York, known as DTC, or another depositary named by us and identified in a prospectus supplement
with respect to that series.
At
the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities
of the same series, in any authorized denomination and of like tenor and aggregate principal amount.
Subject
to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the
form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar
or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that
the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may
require payment of any taxes or other governmental charges.
We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar,
that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation
of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain
a transfer agent in each place of payment for the debt securities of each series.
If
we elect to redeem the debt securities of any series, we will not be required to:
| ● | issue,
register the transfer of, or exchange any debt securities of any series being redeemed in
part during a period beginning at the opening of business 15 days before the day of mailing
of a notice of redemption of any debt securities that may be selected for redemption and
ending at the close of business on the day of the mailing; or |
| ● | register
the transfer of or exchange any debt securities so selected for redemption, in whole or in
part, except the unredeemed portion of any debt securities we are redeeming in part. |
Information
Concerning the Debenture Trustee
The
debenture trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform
only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture
trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by the indentures at the request
of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that
it might incur.
Payment
and Paying Agents
Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest
payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business
on the regular record date for the interest.
We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that, unless we otherwise indicate in the applicable prospectus supplement, we may make interest payments by check that
we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement, we
will designate the corporate office of the debenture trustee in the State of Nevada as our sole paying agent for payments with respect
to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially
designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt
securities of a particular series.
All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to
us, and the holder of the debt security thereafter may look only to us for payment thereof.
Governing
Law
The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of Nevada, except to the
extent that the Trust Indenture Act is applicable.
Subordination
of Subordinated Debt Securities
The
subordinated debt securities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent
described in a prospectus supplement. The indentures in the forms initially filed as exhibits to the registration statement of
which this prospectus is a part do not limit the amount of indebtedness that we may incur, including senior indebtedness or subordinated
indebtedness, and do not limit us from issuing any other debt, including secured debt or unsecured debt.
DESCRIPTION
OF RIGHTS
The
complete terms of the rights will be contained in the rights agreements we enter into with rights agents. These documents will be included
or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the rights
agreements and any related documents. You also should read the prospectus supplement, which will contain additional information and which
may update or change some of the information below.
This
section describes the general terms of the rights to purchase Class A common stock or other securities that we may offer to stockholders
using this prospectus. Further terms of the rights will be stated in the applicable prospectus supplement (or applicable free writing
prospectus). The following description and any description of the rights in a prospectus supplement (or applicable free writing prospectus)
may not be complete and is subject to and qualified in its entirety by reference to the terms of any agreement relating to the rights.
Rights
may be issued independently or together with any other security and may or may not be transferable. As part of any rights offering, we
may enter into a standby underwriting or other arrangement under which the underwriters or any other person would purchase any securities
that are not purchased in such rights offering. If we issue rights, each series of rights will be issued under a separate rights agreement
to be entered into between us and a bank or trust company, as rights agent, that will be named in the applicable prospectus supplement.
Further terms of the rights will be stated in the applicable prospectus supplement. The rights agent will act solely as our agent and
will not assume any obligation to any holders of rights certificates or beneficial owners of rights. The rights agreements and rights
certificates will be filed with the SEC as an exhibit to the registration statement of which this prospectus is a part or as an exhibit
to a filing incorporated by reference in the registration statement. See Where You Can Find Additional Information
for information on how to obtain copies of the rights agreements and rights certificates.
The
prospectus supplement relating to any rights we offer will describe the specific terms of the offering and the rights, including the
record date for stockholders entitled to the rights distribution, the number of rights issued and the number of shares of Class A common
stock that may be purchased upon exercise of the rights, the exercise price of the rights, the date on which the rights will become effective
and the date on which the rights will expire, and any applicable U.S. federal income tax considerations.
In
general, a right entitles the holder to purchase for cash a specific number of shares of Class A common stock or other securities at
a specified exercise price. The rights are normally issued to stockholders as of a specific record date, may be exercised only for a
limited period of time and become void following the expiration of such period. If we determine to issue rights, we will accompany this
prospectus with a prospectus supplement that will describe, among other things:
| ● | the
record date for stockholders entitled to receive the rights; |
| ● | the
number of shares of Class A common stock or other securities that may be purchased upon exercise
of each right; |
| ● | the
exercise price of the rights; |
| ● | the
terms for changes to or adjustments in the exercise price, if any; |
| ● | whether
the rights are transferable; |
| ● | the
period during which the rights may be exercised and when they will expire; |
| ● | the
steps required to exercise the rights; |
| ● | whether
the rights include oversubscription rights so that the holder may purchase
more securities if other holders do not purchase their full allotments; |
| ● | whether
we intend to sell the shares of Class A common stock or other securities that are not purchased
in the rights offering to an underwriter or other purchaser under a contractual standby
commitment or other arrangement; |
| ● | our
ability to withdraw or terminate the rights offering; |
| ● | any
material United States federal income tax consequences; and |
| ● | other
material terms, including terms relating to transferability, exchange, exercise or amendment
of the rights. |
If
fewer than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons
other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to
standby arrangements, as described in the applicable prospectus supplement. After the close of business on the expiration date, all unexercised
rights will become void.
DESCRIPTION
OF UNITS
We
may issue units comprised of shares of Class A common stock, shares of preferred stock, debt securities, rights and warrants to purchase
Class A common stock in any combination. We may issue units in such amounts and in as many distinct series as we wish. This section outlines
certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered
into between us and a bank or other financial institution, as unit agent. The information described in this section may not be complete
in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The
specific terms of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular
supplement, the specific terms of any series of units may differ from the general description of terms presented below. We urge you to
read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate
that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates relating to such units will be
incorporated by reference as exhibits to the registration statement, which includes this prospectus.
Each
unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus,
the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit
is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time
before a specified date.
The
applicable prospectus supplement may describe:
| ● | the
designation and terms of the units and of the securities comprising the units, including
whether and under what circumstances those securities may be held or transferred separately; |
| ● | any
provisions of the governing unit agreement; |
| ● | the
price or prices at which such units will be issued; |
| ● | the
applicable U.S. federal income tax considerations relating to the units; |
| ● | any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of
the securities comprising the units; and |
| ● | any
other terms of the units and of the securities comprising the units. |
The
provisions described in this section, as well as those described under Description of Capital Stock, Description
of Debt Securities and Description of Warrants will apply to the securities included in each unit, to
the extent relevant and as may be updated in any prospectus supplements. We may issue units in such amounts and in as many distinct series
as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms
of a particular series of units will be described in the applicable prospectus supplement.
Unit
Agreements
We
will issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit
agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of
units will be issued and the unit agent under that agreement in the applicable prospectus supplement.
The
following provisions will generally apply to all unit agreements unless otherwise stated in the applicable prospectus supplement:
Modification
Without Consent
We
and the applicable unit agent may amend any unit or unit agreement without the consent of any holder:
| ● | to
cure any ambiguity in any provisions of the governing unit agreement that differ from those
described below; |
| ● | to
correct or supplement any defective or inconsistent provision; or |
| ● | to
make any other change that we believe is necessary or desirable and will not adversely affect
the interests of the affected holders in any material respect. |
We
do not need any approval to make changes that affect only units to be issued after the changes take effect. We may also make changes
that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect.
In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals
from the holders of the affected units.
Modification
With Consent
We
may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder
of that unit, if the amendment would:
| ● | impair
any right of the holder to exercise or enforce any right under a security included in the
unit if the terms of that security require the consent of the holder to any changes that
would impair the exercise or enforcement of that right; or |
| ● | reduce
the percentage of outstanding units or any series or class the consent of whose holders is
required to amend that series or class, or the applicable unit agreement with respect to
that series or class, as described below. |
| | Any other change
to a particular unit agreement and the units issued under that agreement would require the following approval: |
| ● | if
the change affects only the units of a particular series issued under that agreement, the
change must be approved by the holders of a majority of the outstanding units of that series;
or |
| ● | if
the change affects the units of more than one series issued under that agreement, it must
be approved by the holders of a majority of all outstanding units of all series affected
by the change, with the units of all the affected series voting together as one class for
this purpose. |
These
provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as
the governing document.
In
each case, the required approval must be given by written consent.
Unit
Agreements Will Not be Qualified Under Trust Indenture Act
No
unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture
Act. Therefore, holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to
their units.
Mergers
and Similar Transactions Permitted; No Restrictive Covenants or Events of Default
The
unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity
or to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety
to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We
will then be relieved of any further obligation under these agreements.
The
unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell
our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default.
Form,
Exchange and Transfer
We
will issue each unit in global (i.e., book-entry) form only. Units in book-entry form will be represented by a global security registered
in the name of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests
in a unit will do so through participants in the depositarys system, and the rights of these indirect owners will be governed
solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding
the issuance and registration of the units in the applicable prospectus supplement.
Each
unit and all securities comprising the unit will be issued in the same form.
If
we issue any units in registered, non-global form, the following will apply to them:
| ● | The
units will be issued in the denominations stated in the applicable prospectus supplement.
Holders may exchange their units for units of smaller denominations or combined into fewer
units of larger denominations, as long as the total amount is not changed. |
| ● | Holders
may exchange or transfer their units at the office of the unit agent. Holders may also replace
lost, stolen, destroyed or mutilated units at that office. We may appoint another entity
to perform these functions or perform them ourselves. |
| ● | Holders
will not be required to pay a service charge to transfer or exchange their units, but they
may be required to pay for any tax or other governmental charge associated with the transfer
or exchange. The transfer or exchange, and any replacement, will be made only if our transfer
agent is satisfied with the holders proof of legal ownership. The transfer agent may
also require an indemnity before replacing any units. |
| ● | If
we have the right to redeem, accelerate or settle any units before their maturity, and we
exercise our right as to less than all those units or other securities, we may block the
exchange or transfer of those units during the period beginning 15 days before the day we
mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange
any unit selected for early settlement, except that we will continue to permit transfers
and exchanges of the unsettled portion of any unit being partially settled. We may also block
the transfer or exchange of any unit in this manner if the unit includes securities that
are or may be selected for early settlement. |
Only
the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit.
Payments
and Notices
In
making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus
supplement.
SELLING
STOCKHOLDERS
On
November 30, 2021, we entered into the Loan Agreement pursuant to which we issued and sold to the Selling Stockholders Lender Warrants
to purchase 361,002 shares of Class A common stock. This prospectus covers the sale or other disposition by the Selling Stockholders
and their respective donees, pledgees or other successors-in-interest of up to the total number of Shares registered on behalf of the
Selling Stockholders in the manner contemplated under Plan of Distribution below. Throughout this prospectus, when
we refer to the Shares being registered on behalf of the Selling Stockholders, we are referring to the Shares issuable upon the exercise
of the Lender Warrants issued to the Selling Stockholders in the Loan, and when we refer to the Selling Stockholders in this prospectus,
we are referring to those investors set forth in the table below.
On
March 31, 2023, the Company filed a Registration Statement on Form S-3 (File No. 333-271054), that was declared effective by the SEC
on April 10, 2023, which related in part to the offer and resale, from time to time, by the Selling Stockholders of up to 50,000 shares
of Class A common stock issuable upon exercise of the Lender Warrants.
In
connection with the Loan Agreement, we granted certain registration rights to the Selling Stockholders. The Loan Agreement also provide,
among other things, certain indemnification rights and reimbursement by the Company of certain fees and expenses.
We
have agreed with the Selling Stockholders to keep the registration statement of which this prospectus constitutes a part effective for
a period of at least twelve (12) months after the date that the Selling Stockholders are first given the opportunity to sell all of the
Shares.
Except
as otherwise disclosed herein and in the footnotes below with respect to the Selling Stockholders, the Selling Stockholders do not, and
within the past three years, have not had, any position, office or other material relationship with us.
The
following table sets forth the name of the Selling Stockholders, the number of shares of Class A common stock beneficially owned by the
Selling Stockholders, the number of Shares that may be offered under this prospectus and the number of shares of our Class A common stock
that will be owned by the Selling Stockholders assuming all of the Shares covered hereby are sold. The number of Shares in the column
Number of Shares Being Offered represents all of the Shares that the Selling Stockholders may offer under this prospectus.
Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act (Rule 13(d)), beneficial ownership includes all shares of our Class
A common stock as to which a Selling Stockholder has sole or shared voting power or investment power, and also any shares of our Class
A common stock which the Selling Stockholder has the right to acquire within 60 days of August 17, 2023, but without regard to the
Beneficial Ownership Limitation included in the Lender Warrants (described below). The actual beneficial ownership of certain Selling
Stockholders (determined in accordance with Rule 13d) does not necessarily correspond to the number of Shares reflected below in the
column Number of Shares Being Offered.
Notwithstanding
the presentation of Share ownership in the table below, pursuant to the terms of the Lender Warrants, a holder of a Lender Warrant does
not have the right to exercise any portion of the Lender Warrant held by such holder to the extent (but only to the extent) that after
giving effect to such issuance after exercise, the holder (together with the holders affiliates, and any other persons acting
as a group together with the holder or any of the holders affiliates), would beneficially own in excess of 9.99% of the number
of shares of Class A common stock outstanding immediately after giving effect to the issuance of shares of Class A common stock issued
upon exercise of the Lender Warrants (the Beneficial Ownership Limitation). The holder of a Lender Warrant may, upon notice
to the Company, increase or decrease the Beneficial Ownership Limitation of its Warrant, provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Class A common stock outstanding immediately after giving effect to the issuance
of shares of Class A common stock upon exercise of the Lender Warrant held by the holder. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. No such increase notice has been provided
to the Company as of the date of this prospectus.
The information set forth below is based upon information
obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Shares issuable upon the exercise
of the Lender Warrants to the Selling Stockholders. The percentages of shares of Class A common stock beneficially owned before this offering
are based on 36,803,768 shares of Class A common stock issued and outstanding as of August 17, 2023. The percentages of shares of our
Class A common stock owned after the offering are based on 37,114,770 shares of our Class A common stock outstanding after this offering,
including the 36,803,768 shares of Class A common stock outstanding as of August 17, 2023 plus 311,002 Shares issuable upon the exercise
of the Lender Warrants covered hereby.
The
Shares covered hereby may be offered from time to time by the Selling Stockholders. The Selling Stockholders may sell some, all or none
of their respective Shares. We do not know how long the Selling Stockholders will hold their Shares before selling them, and we currently
have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the
Shares
|
|
Shares
of Class A common stock
Beneficially Owned
Prior To The
Offering |
|
|
Maximum
Number of
Shares
Being Offered |
|
|
Shares
of Class A common stock
Beneficially Owned
After The
Offering(1) |
|
Name
of Selling Stockholder |
|
Number |
|
Percentage |
|
|
Number |
|
|
Percent |
|
Avenue
Venture Opportunities Fund, LP(2) |
|
155,501 |
|
* |
|
|
155,501 |
|
|
0 |
|
|
- |
|
Avenue
Venture Opportunities Fund II, LP(3) |
|
155,501 |
|
* |
|
|
155,501 |
|
|
0 |
|
|
- |
|
Percentages
denoted by * are less than 1%.
| (1) | Assumes
that all Shares being registered in this prospectus are resold to third parties and that
the Selling Stockholders sell all Shares registered under this prospectus held by them. |
| (2) | The
business address for Avenue Venture Opportunities Fund, LP is 11 West 42nd St. 9th Floor,
New York, NY, 10036. |
| (3) | The
business address for Avenue Venture Opportunities Fund II, LP is 11 West 42nd St. 9th Floor,
New York, NY, 10036. |
PLAN
OF DISTRIBUTION
We
may sell the securities described herein, and the Selling Stockholders may sell some or all of the Shares that they hold, from time to
time in one or more offerings, by a variety of methods, including the following:
| ● | on
any national securities exchange or quotation service on which our securities may be listed
at the time of sale, including the Nasdaq Capital Market; |
| ● | in
the over-the-counter market; |
| ● | in
transactions otherwise than on such exchange or in the over-the-counter market, which may
include privately negotiated transactions and sales directly to one or more purchasers; |
| ● | through
one or more agents, including an at the market offering within the meaning
of Rule 415(a)(4) under the Securities Act; |
| ● | through
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| ● | through
purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| ● | to
or through underwriters, broker-dealers, agents, in privately negotiated transactions, or
any combination of these methods; |
| ● | through
the writing or settlement of options or other hedging transactions, whether through an options
exchange or otherwise; |
| ● | by
pledge to secure debts or other obligations; |
| ● | block
trades in which the broker-dealer so engaged will attempt to sell the securities as agent
but may position and resell a portion of the block as principal to facilitate the transaction,
or crosses in which the same broker acts as agent on both sides of the trade; |
| ● | a
combination of any of these methods; or |
| ● | by
any other method permitted pursuant to applicable law. |
As
used in this prospectus, Selling Stockholders includes transferees, pledgees, donees, assignees or successors selling shares
received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other non-sale related
transfer.
We
will not receive any proceeds from the sale of securities that may be sold from time to time pursuant to this prospectus by the Selling
Stockholders. We will bear the costs associated with this registration in accordance with the agreements granting registration rights
to the Selling Stockholders. However, the Selling Stockholders will bear any brokerage commissions, transfer taxes, or underwriting commissions
and discounts attributable to their sale of securities pursuant to this prospectus. To our knowledge, there are currently no plans, arrangements
or understandings between any Selling Stockholders and any underwriter, broker-dealer or agent regarding the sale of securities pursuant
to this prospectus by the Selling Stockholders.
We
or the Selling Stockholders may sell the securities to or through one or more underwriters or dealers (acting as principal or agent),
through agents, or directly to one or more purchasers. We or the Selling Stockholders may distribute the securities from time to time
in one or more transactions:
| ● | at
a fixed price or prices, which may be changed; |
| ● | at
market prices prevailing at the time of sale; |
| ● | at
prices related to such prevailing market prices; |
| ● | at
varying prices determined at the time of sale; or |
We
will describe the terms of the offering of the securities and the specific plan of distribution in a prospectus supplement or supplements
to this prospectus, any related free writing prospectus that we may authorize to be provided to you, an amendment to the registration
statement of which this prospectus is a part or other filings we make with the SEC under the Exchange Act that are incorporated by reference.
Such description may include, to the extent applicable:
| ● | the
name or names of any underwriters, dealers, agents or other purchasers; |
| ● | the
purchase price of the securities or other consideration therefor, and the proceeds, if any,
we or the Selling Stockholders will receive from the sale; |
| ● | any
options to purchase additional shares or other options under which underwriters, dealers,
agents or other purchasers may purchase additional securities from us or the Selling Stockholders; |
| ● | any
agency fees or underwriting discounts and other items constituting agents or underwriters
compensation; |
| ● | any
public offering price; |
| ● | any
discounts or concessions allowed or reallowed or paid to dealers; and |
| ● | any
securities exchange or market on which the securities may be listed. |
Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. The Selling
Stockholders who participate in the sale or distribution of the securities offered by the Selling Stockholders and any dealers and agents
participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of
the securities may be deemed to be underwriting discounts. Any Selling Stockholders identified as registered broker-dealers in the Selling
Stockholders table in the section titled Selling Stockholders are deemed to be underwriters. If such dealers or
agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.
If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to
time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
We or the Selling Stockholders may offer the securities to the public through underwriting syndicates represented by managing underwriters
or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities
offered by the prospectus supplement, other than securities covered by any option to purchase additional shares or other option. If a
dealer is used in the sale of securities, we or the Selling Stockholders, or an underwriter, will sell the securities to the dealer,
as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transaction.
Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We or
the Selling Stockholders may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus
supplement, naming the underwriter, dealer or agent, the nature of any such relationship.
We
or the Selling Stockholders may sell securities directly or through agents we designate from time to time. If required by applicable
law, we will name any agent involved in the offering and sale of securities and we will describe any commissions payable to the agent
in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts basis for the period
of its appointment.
We
may provide agents, dealers and underwriters with indemnification against civil liabilities, including liabilities under the Securities
Act, or contribution with respect to payments that the agents or dealers or underwriters may make with respect to these liabilities.
Agents, dealers and underwriters or their affiliates may engage in transactions with, or perform services for us in the ordinary course
of business.
With
respect to the offering and sale of securities under this prospectus by the Selling Stockholders, we have agreed to indemnify each Selling
Stockholder and any underwriter for such Selling Stockholder (as determined in the Securities Act) against specified liabilities, including
liabilities under the Securities Act. The Selling Stockholders have agreed to indemnify us against specified liabilities, including liabilities
under the Securities Act. In addition, we have agreed to pay substantially all of the expenses incidental to the registration, offering
and sale of securities pursuant to this prospectus by the Selling Stockholders to the public, including the payment of federal securities
law and state blue sky registration fees and the reasonable fees and disbursements of one counsel for the Selling Stockholders, except
that we will not bear any brokers or underwriters discounts and commissions, fees and expenses of counsel to underwriters
or brokers, transfer taxes or transfer fees relating to the sale of securities by the Selling Stockholders.
We
may engage in at-the-market offerings into an existing trading market in accordance with rule 415(a)(4) under the Securities Act. In
addition, we or the Selling Stockholders may enter into derivative transactions with third parties, or sell securities not covered by
this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection
with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including
in short sale transactions. If so, the third party may use securities pledged by us or the Selling Stockholders or borrowed from us,
the Selling Stockholders or others to settle those sales or to close out any related open borrowings of Class A common stock, and may
use securities received from us or the Selling Stockholders in settlement of those derivatives to close out any related open borrowings
of our Shares. In addition, we or the Selling Stockholders may loan or pledge securities to a financial institution or other third party
that in turn may sell the securities using this prospectus and an applicable prospectus supplement. Such financial institution or other
third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other
securities.
The
Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or
other transfer. There can be no assurance that the Selling Stockholders will sell any or all of the securities under this prospectus.
Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the securities by other means
not described in this prospectus. In addition, any securities covered by this prospectus that qualify for sale under Rule 144 of the
Securities Act may be sold under Rule 144 rather than under this prospectus. A
Selling Stockholder that is an entity may elect to make
an in-kind distribution of the securities to its members, partners or shareholders pursuant to this prospectus by delivering a
prospectus. To the extent that such members, partners or shareholders are not affiliates
of ours, such members, partners or stockholders would thereby receive freely tradable shares of the securities pursuant to the distribution
through this prospectus.
All
securities we may offer, other than Class A common stock and the Lender Warrants, will be new issues of securities with no established
trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market
making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.
Any
underwriter may be granted an option to purchase additional shares, and engage in stabilizing transactions, short-covering transactions
and penalty bids in accordance with Regulation M under the Exchange Act. An underwriters option to purchase additional shares
involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions
involve purchases of the securities, either through exercise of the option to purchase additional shares or in the open market after
the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a
dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.
Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.
Any
underwriters, dealers or agents that are qualified market makers on the Nasdaq may engage in passive market making transactions in our
Class A common stock on the Nasdaq in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing
of the offering, before the commencement of offers or sales of the Class A common stock. Passive market makers must comply with applicable
volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid
at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market
makers bid, however, the passive market makers bid must then be lowered when certain purchase limits are exceeded. Passive
market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market
and, if commenced, may be discontinued at any time.
LEGAL
MATTERS
Unless
otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us
by Sherman & Howard L.L.C. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus
are passed upon by counsel for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating
to such offering.
EXPERTS
The
balance sheets of BioVie Inc. as of June 30, 2023 and 2022, and the related statements of operations and comprehensive loss, changes
in stockholders equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent
registered public accounting firm, as stated in their report which is incorporated by reference, which report includes an explanatory
paragraph about the existence of substantial doubt concerning the Companys ability to continue as a going concern. Such financial
statements have been incorporated by reference in reliance on the report of such firm given upon their authority as experts in accounting
and auditing.
LIMITATION
ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person
of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all
the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements
or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement
or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement
or other document. Because we are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended
(the Exchange Act), we file annual, quarterly and current reports, proxy statements and other information with the SEC.
Our SEC filings are available to the public over the Internet at the SECs website at http://www.sec.gov.
You
may also access our SEC filings at our website https://bioviepharma.com/. Our website and the information contained on, or that
can be accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus.
You should not rely on our website or any such information in making your decision whether to purchase our securities.
INFORMATION
INCORPORATED BY REFERENCE
We
have elected to incorporate certain information by reference into this prospectus. By incorporating by reference, we can disclose important
information to you by referring you to other documents we have filed or will file with the SEC. The information incorporated by reference
is deemed to be part of this prospectus, except for information incorporated by reference that is superseded by information contained
in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any statements
in the prospectus or any document previously incorporated by reference have been modified or superseded. This prospectus incorporates
by reference the documents set forth below that we have previously filed with the SEC under the Exchange Act:
| ● | Our
Annual Report on Form 10-K for the year ended June 30, 2023, filed with the SEC on August
16, 2023, including any amendments or supplements thereto; |
| ● | Our
Current Reports on Form 8-K, filed with the SEC on October 5, 2022, November 10, 2022, December
6, 2022 (both filed on such date), December 7, 2022 December 15, 2022, December 23, 2022,
March 6, 2023, March 13, 2023, March 23, 2023 and April 7, 2023; and |
| ● | The
description of our Class A common stock contained in our registration on Form 8-A (File No.
001-39015) filed with the SEC on August 25, 2020, including any amendment or report filed
for the purpose of updating such description. |
All
documents subsequently filed by the Registrant with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after
the date of the initial filing of the registration statement and prior to effectiveness of the registration statement that contains this
prospectus and prior to the termination of the offering (except in each case the information contained in such document to the extent
furnish and not filed), shall be deemed to be incorporated by reference herein and to be a part hereof from
the date of filing of such documents.
Any
statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document
which also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
PROSPECTUS
BIOVIE,
INC.
Primary
Offering of
$300,000,000
Class
A Common Stock
Preferred
Stock
Warrants
Debt
Securities
Rights
Units
and
Secondary
Offering of
Up
to 311,002 Shares of Class A Common Stock Offered by the Selling Stockholders
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
14. Other Expenses of Issuance and Distribution.
The
following table sets forth our costs and expenses in connection with the registration of our securities as described in this registration
statement. All of the amounts shown are estimates except the Commission Registration Fee and the FINRA filing fee.
|
|
AMOUNT |
SEC
registration fee |
|
$ |
33,189.55 |
|
FINRA
filing fee |
|
$ |
45,676.34 |
|
Legal
fees and expenses |
|
|
* |
|
Accounting
fees and expenses |
|
|
* |
|
Transfer
agent fees and expenses |
|
|
* |
|
Miscellaneous
expenses |
|
|
* |
|
Total |
|
$ |
78,865.89 |
|
*
Fees and expenses (other than the SEC registration fee to be paid upon the filing of this registration statement)
will depend on the number and nature of the offerings, and cannot be estimated at this time. An estimate of the aggregate expenses in
connection with the issuance and distribution of securities being offered will be included in any applicable prospectus supplement.
Item
15. Indemnification of Directors and Officers.
We
are a Nevada corporation and generally governed by the Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes, or
NRS.
Section
78.138 of the NRS provides that, unless the corporations articles of incorporation provide otherwise, a director or officer will
not be individually liable as a result of any act or failure to act unless it is proven that (i) the directors or officers
acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach involved intentional misconduct, fraud or
a knowing violation of the law.
Section
78.7502 of the NRS permits a Nevada corporation to indemnify its directors and officers against expenses, judgments, fines, and amounts
paid in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding,
except an action by or on behalf of the corporation, if the officer or director (i) is not liable pursuant to NRS 78.138, or (ii) acted
in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the best interests of the corporation
and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. Section
78.7502 also provides that a corporation may not indemnify a director or officer under this section with respect to an action by or on
behalf of the corporation if such person has been adjudged to be liable to the corporation or for amounts paid to the corporation in
settlement of such claim unless and only to the extent the court determines in view of all circumstances of the case, the person is fairly
and reasonably entitled to indemnification. Indemnification under NRS 78.7502 generally may be made by the corporation only if determined
to be proper under the circumstances. Such determination must be made by the stockholders, directors not a party to the action, or legal
counsel.
Section
78.751 of the NRS requires a corporation to indemnify its officers and directors if they have been successful on the merits or otherwise
in defense of any claim, issue, or matter resulting from their service as a director or officer. Section 78.751 of the NRS allows a corporation
to advance expenses as incurred upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is
ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified by the corporation
if so provided in the corporations articles of incorporation, bylaws, or other agreement. Advancement of expenses as incurred
may be required under corporations articles of incorporation or bylaws or by agreement. Section 78.751 of the NRS further permits
the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws
or other agreement.
Section
78.752 of the NRS provides that a Nevada corporation may purchase and maintain insurance or make other financial arrangements on behalf
of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another company, partnership, joint venture, trust or other enterprise, for any liability
asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising
out of his status as such, whether or not the corporation has the authority to indemnify him against such liability and expenses.
Our
Articles of Incorporation and Bylaws implement the indemnification and insurance provisions permitted by Chapter 78 of the NRS by providing
that:
| ● | We
shall indemnify our directors and officers to the fullest extent permitted by the NRS against
expense, liability and loss reasonably incurred or suffered by them in connection with their
service as an officer or director; and |
| ● | We
may purchase and maintain insurance, or make other financial arrangements, on behalf of any
person who holds or who has held a position as a director, officer, or representative against
liability, cost, payment, or expense incurred by such person. |
At
the present time, there is no pending litigation or proceeding involving a director, officer, employee or other agent of ours in which
indemnification would be required or permitted. We are not aware of any threatened litigation or proceeding which may result in a claim
for such indemnification.
Item
16. Exhibits.
Exhibit
Number |
|
Description
of Document |
1.1** |
|
Form
of Underwriting Agreement. |
2.1 |
|
Agreement
and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC (incorporated by reference
to Exhibit 2.1 the Companys Current Report on Form 8-K filed on April 15, 2016). |
3.1 |
|
Articles
of Incorporation of the Company as filed with the Secretary of State of Nevada (incorporated by reference to Exhibit 3.1 to the Companys
registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635). |
3.2 |
|
Certificate
of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Companys Current Report on Form
8-K filed on July 22, 2016). |
3.3 |
|
Certificate
of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the Companys Information Statement on
Schedule 14C filed on July 13, 2018). |
3.4 |
|
Certificate
of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit
3.1 to the Companys Current Report on Form 8-K filed on July 3, 2018). |
3.5 |
|
Certificate
of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.6 to the Companys registration statement
on Form S-1 filed on November 22, 2019, File No. 333-231136). |
3.6 |
|
Amended
and Restated Bylaws of the Company, dated June 16, 2020 (incorporated by reference to Exhibit 3.5 to the Companys Quarterly
Report on Form 10-Q filed on November 10, 2021). |
4.1 |
|
Specimen
Certificate representing shares of Class A Common Stock (incorporated by reference to Exhibit 4.1 to the Companys registration
statement on Form S-1 filed on April 30, 2019, File No. 333-231136). |
4.2** |
|
Form
of Specimen Certificate for Preferred Stock. |
4.3** |
|
Certificate
of Designation for Preferred Stock. |
4.4** |
|
Form
of Warrant Agreement. |
4.5* |
|
Form
of Indenture for Senior Debt Securities. |
4.6* |
|
Form
of Indenture for Subordinated Debt Securities. |
4.7** |
|
Form
of Debt Securities. |
4.8** |
|
Form
of Rights Agreement. |
4.9** |
|
Form
of Unit and Unit Certificate. |
4.10 |
|
Form
of Lender Warrant (incorporated by reference to Exhibit 10.3 to the Companys Current Report on Form 8-K filed on December
1, 2021). |
5.1* |
|
Opinion
of Sherman & Howard L.L.C. |
10.1 |
|
Loan
and Security Agreement, dated November 30, 2021, among BioVie Inc., Avenue Venture Opportunities Fund II, L.P. and Avenue Venture
Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Companys Current Report on Form 8-K filed on December
1, 2021). |
10.2 |
|
Supplement
to Loan and Security Agreement, dated November 30, 2021, among BioVie Inc., Avenue Venture Opportunities Fund II, L.P. and Avenue
Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Companys Current Report on Form 8-K filed
on December 1, 2021). |
23.1* |
|
Consent
of EisnerAmper LLP, Independent Registered Public Accounting Firm. |
24.1* |
|
Power
of Attorney (included on signature page to this registration statement) |
25.1*** |
|
Form
T-1 Statement of Eligibility and Qualification of Trustee under the Senior Indenture under the Trust Indenture Act of 1939, as amended. |
25.2*** |
|
Form
T-1 Statement of Eligibility and Qualification of Trustee under the Subordinated Indenture under the Trust Indenture Act of 1939,
as amended. |
107* |
|
Filing
Fee Table |
*
Filed herewith.
**
To the extent applicable, to be filed by a post-effective amendment or as an exhibit to a document filed under the Exchange Act and incorporated
by reference herein.
***
To be filed, if necessary, separately under the electronic form type 305B2 pursuant to Section 305(B)(2) of the Trust Indenture Act of
1939, as amended.
Item
17. Undertakings.
The
undersigned registrant hereby undertakes:
1)
To file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement:
a.
To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933, as amended;
b.
To reflect in the prospectus any facts or events
arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to
Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of
Registration Fee table in the effective registration statement; and
c.
To include any material information with respect
to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement.
provided,
however, that paragraphs (1)(a), (b) and
(c) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act
of 1934 that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule
424(b) that is part of the Registration Statement.
2)
That, for the purpose of determining any liability
under the Securities Act of 1933, each such post- effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
3)
To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at
the termination of the offering.
4)
That, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B
or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of
and included in the registration statement as of the date it is first used after effectiveness. Provided, however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such first use,
supersede or modify any statement that was made
in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.
5)
That, for the purpose of determining liability of the registrant under the Securities Act
of 1933 to any purchaser in the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the
securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be
a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
a.
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering
required to be filed pursuant to Rule 424;
b.
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant;
c.
The portion of any other free writing prospectus relating to the offering containing material
information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
d.
Any other communication that is an offer in the offering made by the undersigned registrant
to the purchaser.
6)
The undersigned registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act of 1933, each filing of the registrants annual report pursuant
to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plans
annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof
7)
Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person
of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
8)
That for purposes of determining any liability under
the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon
Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of this registration statement as of the time it was declared effective.
9)
That for the purpose of determining any liability under
the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
10)
To file an application for the purpose of determining
the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and
regulations prescribed by the SEC under Section 305(b)(2) of the Trust Indenture Act.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling person of
the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Carson City, State of Nevada, on the 18th day of August 2023.
|
BIOVIE
INC. |
|
|
|
|
By: |
/s/
Cuong Do |
|
|
Name: |
Cuong
Do |
|
|
Title: |
Chief
Executive Officer |
POWER
OF ATTORNEY
Each
person whose signature appears below constitutes and appoints Cuong Do and Joanne Wendy Kim, and each of them acting individually and
without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for
him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents,
and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause
to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities
and on August 18, 2023.
Person |
|
Capacity |
|
Date |
|
|
|
|
|
/s/
Cuong Do |
|
Chief
Executive Officer |
|
August
18, 2023 |
Cuong
Do |
|
(Principal
Executive Officer) |
|
|
|
|
|
|
|
/s/
Joanne Wendy Kim |
|
Chief
Financial Officer |
|
August
18, 2023 |
Joanne
Wendy Kim |
|
(Principal
Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/
Jim Lang |
|
Chairman |
|
August
18, 2023 |
Jim
Lang |
|
|
|
|
|
|
|
|
|
/s/
Michael Sherman |
|
Director |
|
August
18, 2023 |
Michael
Sherman |
|
|
|
|
|
|
|
|
|
/s/
Richard J. Berman |
|
Director |
|
August
18, 2023 |
Richard
J. Berman |
|
|
|
|
|
|
|
|
|
/s/
Steve Gorlin |
|
Director |
|
August
18, 2023 |
Steve
Gorlin |
|
|
|
|
|
|
|
|
|
/s/
Robert Hariri |
|
Director |
|
August
18, 2023 |
Robert
Hariri |
|
|
|
|
|
|
|
|
|
/s/
Sigmund Rogich |
|
Director |
|
August
18, 2023 |
Sigmund
Rogich |
|
|
|
|
EXHIBIT
4.5
BIOVIE,
INC.
Issuer
AND
[TRUSTEE]
Trustee
INDENTURE
Dated
as of [·], 20[·]
Senior
Debt Securities
TABLE
OF CONTENTS
ARTICLE
1 DEFINITIONS |
1 |
Section
1.01 Definitions of Terms. |
1 |
ARTICLE
2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES |
5 |
Section
2.01 Designation and Terms of Securities. |
5 |
Section
2.02 Form of Securities and Trustee’s Certificate. |
7 |
Section
2.03 Denominations: Provisions for Payment. |
7 |
Section
2.04 Execution and Authentication. |
8 |
Section
2.05 Registration of Transfer and Exchange. |
9 |
Section
2.06 Temporary Securities. |
10 |
Section
2.07 Mutilated, Destroyed, Lost or Stolen Securities. |
10 |
Section
2.08 Cancellation. |
11 |
Section
2.09 Benefits of Indenture. |
11 |
Section
2.10 Authenticating Agent. |
12 |
Section
2.11 Global Securities. |
12 |
ARTICLE
3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS |
13 |
Section
3.01 Redemption. |
13 |
Section
3.02 Notice of Redemption. |
13 |
Section
3.03 Payment Upon Redemption. |
14 |
Section
3.04 Sinking Fund. |
15 |
Section
3.05 Satisfaction of Sinking Fund Payments with Securities. |
15 |
Section
3.06 Redemption of Securities for Sinking Fund. |
15 |
ARTICLE
4 COVENANTS |
16 |
Section
4.01 Payment of Principal, Premium and Interest. |
16 |
Section
4.02 Maintenance of Office or Agency. |
16 |
Section
4.03 Paying Agents. |
16 |
Section
4.04 Appointment to Fill Vacancy in Office of Trustee. |
17 |
Section
4.05 Compliance with Consolidation Provisions. |
17 |
ARTICLE
5 SECURITYHOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE |
18 |
Section
5.01 Company to Furnish Trustee Names and Addresses of Securityholders. |
18 |
Section
5.02 Preservation Of Information; Communications With Securityholders. |
18 |
Section
5.03 Reports by the Company. |
18 |
Section
5.04 Reports by the Trustee. |
19 |
ARTICLE
6 REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT |
19 |
Section
6.01 Events of Default. |
19 |
Section
6.02 Collection of Indebtedness and Suits for Enforcement by Trustee. |
21 |
Section
6.03 Application of Moneys or Property Collected. |
22 |
Section
6.04 Limitation on Suits. |
22 |
Section
6.05 Rights and Remedies Cumulative; Delay or Omission Not Waiver. |
23 |
Section
6.06 Control by Securityholders. |
24 |
Section
6.07 Undertaking to Pay Costs. |
24 |
ARTICLE
7 CONCERNING THE TRUSTEE |
25 |
Section
7.01 Certain Duties and Responsibilities of Trustee. |
25 |
Section
7.02 Certain Rights of Trustee. |
26 |
Section
7.03 Trustee Not Responsible for Recitals or Issuance or Securities. |
27 |
Section
7.04 May Hold Securities. |
27 |
Section
7.05 Moneys Held in Trust. |
27 |
Section
7.06 Compensation and Reimbursement. |
28 |
Section
7.07 Reliance on Officers’ Certificate. |
28 |
Section
7.08 Disqualification; Conflicting Interests. |
28 |
Section
7.09 Corporate Trustee Required; Eligibility. |
28 |
Section
7.10 Resignation and Removal; Appointment of Successor. |
29 |
Section
7.11 Acceptance of Appointment By Successor. |
30 |
Section
7.12 Merger, Conversion, Consolidation or Succession to Business. |
31 |
Section
7.13 Preferential Collection of Claims Against the Company. |
32 |
Section
7.14 Notice of Default |
32 |
ARTICLE
8 CONCERNING THE SECURITYHOLDERS |
32 |
Section
8.01 Evidence of Action by Securityholders. |
32 |
Section
8.02 Proof of Execution by Securityholders. |
33 |
Section
8.03 Who May be Deemed Owners. |
33 |
Section
8.04 Certain Securities Owned by Company Disregarded. |
33 |
Section
8.05 Actions Binding on Future Securityholders. |
34 |
ARTICLE
9 SUPPLEMENTAL INDENTURES |
34 |
Section
9.01 Supplemental Indentures Without the Consent of Securityholders. |
34 |
Section
9.02 Supplemental Indentures With Consent of Securityholders. |
35 |
Section
9.03 Effect of Supplemental Indentures. |
36 |
Section
9.04 Securities Affected by Supplemental Indentures. |
36 |
Section
9.05 Execution of Supplemental Indentures. |
36 |
ARTICLE
10 SUCCESSOR ENTITY |
37 |
Section
10.01 Company May Consolidate, Etc. |
37 |
Section
10.02 Successor Entity Substituted. |
37 |
Section
10.03 Evidence of Consolidation, Etc. to Trustee. |
38 |
ARTICLE
11 SATISFACTION AND DISCHARGE |
38 |
Section
11.01 Satisfaction and Discharge of Indenture. |
38 |
Section
11.02 Discharge of Obligations. |
39 |
Section
11.03 Deposited Moneys to be Held in Trust. |
39 |
Section
11.04 Payment of Moneys Held by Paying Agents. |
39 |
Section
11.05 Repayment to Company. |
39 |
ARTICLE
12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS |
40 |
Section
12.01 No Recourse. |
40 |
ARTICLE
13 MISCELLANEOUS PROVISIONS |
40 |
Section
13.01 Effect on Successors and Assigns. |
40 |
Section
13.02 Actions by Successor. |
40 |
Section
13.03 Surrender of Company Powers. |
40 |
Section
13.04 Notices. |
41 |
Section
13.05 Governing Law. |
41 |
Section
13.06 Treatment of Securities as Debt. |
41 |
Section
13.07 Certificates and Opinions as to Conditions Precedent. |
41 |
Section
13.08 Payments on Business Days. |
42 |
Section
13.09 Conflict with Trust Indenture Act. |
42 |
Section
13.10 Indenture and Securities Solely Corporate Obligations. |
42 |
Section
13.11 Counterparts. |
42 |
Section
13.12 Separability. |
42 |
Section
13.13 Compliance Certificates. |
43 |
|
(1) |
This
Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms
or provisions. |
INDENTURE
INDENTURE,
dated as of [·], 20[·], among BIOVIE, INC., a Nevada corporation (the “Company”), and [TRUSTEE], as trustee
(the “Trustee”).
WHEREAS,
for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance
of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued
from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated
by the certificate of the Trustee;
WHEREAS,
to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized
the execution of this Indenture; and
WHEREAS,
all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done.
NOW,
THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted
and agreed as follows for the equal and ratable benefit of the holders of Securities:
ARTICLE
1
DEFINITIONS
Section
1.01 Definitions of Terms.
The
terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless
the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective
meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that
are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933,
as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires),
shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the
execution of this instrument.
“Authenticating
Agent” means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant
to Section 2.10.
“Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
“Board
of Directors” means the Board of Directors of the Company or any duly authorized committee of such Board.
“Board
Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been
duly adopted by the Board of Directors and to be in full force and effect on the date of such certification.
“Business
Day” means, with respect to any series of Securities, any day other than a day on which federal or state banking institutions
in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated
by law, executive order or regulation to close.
“Certificate”
means a certificate signed by any Officer. The Certificate need not comply with the provisions of Section 13.07.
“Company”
means BioVie, Inc., a corporation duly organized and existing under the laws of the State of Nevada, and, subject to the provisions of
Article Ten, shall also include its successors and assigns.
“Corporate
Trust Office” means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally
administered, which office at the date hereof is located at.
“Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
“Default”
means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default.
“Depositary”
means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global
Security, The Depository Trust Company, New York, New York, another clearing agency, or any successor registered as a clearing agency
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other applicable statute or regulation, which,
in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11.
“Event
of Default” means, with respect to Securities of a particular series, any event specified in Section 6.01, continued for
the period of time, if any, therein designated.
“Global
Security” means, with respect to any series of Securities, a Security executed by the Company and delivered by the Trustee
to the Depositary or pursuant to the Depositary’s instruction, all in accordance with the Indenture, which shall be registered
in the name of the Depositary or its nominee.
“Governmental
Obligations” means securities that are (a) direct obligations of the United States of America for the payment of which
its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality
of the United States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United
States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated
maturity of the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to
any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian
for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized
to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect
of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary
receipt.
“herein”,
“hereof” and “hereunder”, and other words of similar import, refer to this Indenture
as a whole and not to any particular Article, Section or other subdivision.
“Indenture”
means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental
hereto entered into in accordance with the terms hereof.
“Interest
Payment Date”, when used with respect to any installment of interest on a Security of a particular series, means the date
specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date
on which an installment of interest with respect to Securities of that series is due and payable.
“Officer”
means, with respect to the Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial
officer, chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant
treasurer, the controller or any assistant controller or the secretary or any assistant secretary.
“Officers’
Certificate” means a certificate signed by any two Officers. Each such certificate shall include the statements provided
for in Section 13.07, if and to the extent required by the provisions thereof.
“Opinion
of Counsel” means an opinion in writing subject to customary exceptions of legal counsel, who may be an employee of or
counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements
provided for in Section 13.07, if and to the extent required by the provisions thereof.
“Outstanding”,
when used with reference to Securities of any series, means, subject to the provisions of Section 8.04, as of any particular time, all
Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore
canceled by the Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously
been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary
amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside
and segregated in trust by the Company (if the Company shall act as its own paying agent); provided, however, that if such Securities
or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as in
Article Three provided, or provision satisfactory to the Trustee shall have been made for giving such notice; and (c) Securities in lieu
of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07.
“Person”
means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, association, trust, unincorporated
organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.
“Predecessor
Security” of any particular Security means every previous Security evidencing all or a portion of the same debt as that
evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section
2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.
“Responsible
Officer” when used with respect to the Trustee means the chairman of its board of directors, the chief executive officer,
the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer
or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall
be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity
with the particular subject.
“Securities”
means the debt Securities authenticated and delivered under this Indenture.
“Securityholder”,
“holder of Securities”, “registered holder”, or other similar term, means the Person or Persons in whose name
or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of
this Indenture.
“Security
Register” and “Security Registrar” shall have the meanings as set forth in Section 2.05.
“Subsidiary”
means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned,
directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii)
any general partnership, joint venture or similar entity, at least a majority of whose outstanding partnership or similar interests shall
at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and
(iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner.
“Trustee”
means, and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is
more than one Person acting in such capacity hereunder, “Trustee” shall mean each such Person. The term “Trustee”
as used with respect to a particular series of the Securities shall mean the trustee with respect to that series.
“Trust
Indenture Act” means the Trust Indenture Act of 1939, as amended.
“Voting
Stock”, as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest
(however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent)
of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence
of a contingency.
ARTICLE
2
ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES
Section
2.01 Designation and Terms of Securities.
(a)
The aggregate principal amount of Securities that
may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate
principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or
more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant
to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or more indentures supplemental hereto:
(1)
the title of the Securities of the series (which
shall distinguish the Securities of that series from all other Securities);
(2)
any limit upon the aggregate principal amount of
the Securities of that series that may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered
upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series);
(3)
the date or dates on which the principal of the
Securities of the series is payable, any original issue discount that may apply to the Securities of that series upon their issuance,
the principal amount due at maturity, and the place(s) of payment;
(4)
the rate or rates at which the Securities of the
series shall bear interest or the manner of calculation of such rate or rates, if any;
(5)
the date or dates from which such interest shall
accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates,
the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment
Dates or the manner of determination of such record dates;
(6)
the right, if any, to extend the interest payment
periods and the duration of such extension, including the maximum consecutive period during which interest payments may be extended;
(7)
the period or periods within which, the price or
prices at which and the terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option
of the Company;
(8)
the obligation, if any, of the Company to redeem
or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments
made in cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within
which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased,
in whole or in part, pursuant to such obligation;
(9)
the form of the Securities of the series including
the form of the Certificate of Authentication for such series;
(10)
if other than denominations of one thousand U.S.
dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable;
(11)
any and all other terms (including terms, to the
extent applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the
Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture,
as amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations
or advisable in connection with the marketing of Securities of that series;
(12)
whether the Securities are issuable as a Global
Security and, in such case, the terms and the identity of the Depositary for such series;
(13)
whether the Securities will be convertible into
or exchangeable for shares of common stock or other securities of the Company or any other Person and, if so, the terms and conditions
upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how
it will be calculated and may be adjusted, any mandatory or optional (at the Company’s option or the holders’ option) conversion
or exchange features, and the applicable conversion or exchange period;
(14)
if other than the principal amount thereof, the
portion, or methods of determining the portion, of the principal amount of Securities of the series which shall be payable upon declaration
of acceleration of the maturity thereof pursuant to Section 6.01;
(15)
any additional or different Events of Default or
restrictive covenants (which may include, among other restrictions, restrictions on the Company’s ability or the ability of the
Company’s Subsidiaries to: incur additional indebtedness; issue additional securities; create liens; pay dividends or make distributions
in respect of their capital stock; redeem capital stock; place restrictions on such Subsidiaries placing restrictions on their ability
to pay dividends, make distributions or transfer assets; make investments or other restricted payments; sell or otherwise dispose of
assets; enter into sale-leaseback transactions; engage in transactions with stockholders and affiliates; issue or sell stock of their
Subsidiaries; or effect a consolidation or merger) or financial covenants (which may include, among other financial covenants, financial
covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based or asset-based
ratios) provided for with respect to the Securities of the series;
(16)
if other than dollars, the coin or currency in which
the Securities of the series are denominated (including, but not limited to, foreign currency);
(17)
the terms and conditions, if any, upon which the
Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to
any Securityholder that is not a “United States person” for federal tax purposes; and
(18)
any restrictions on transfer, sale or assignment
of the Securities of the series.
All
Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or
pursuant to any such Board Resolution or in any indentures supplemental hereto.
If
any of the terms of the series are established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate
record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or
prior to the delivery of the Officers’ Certificate of the Company setting forth the terms of the series.
Securities
of any particular series may be issued at various times, with different dates on which the principal or any installment of principal
is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different
dates on which such interest may be payable and with different redemption dates.
Section
2.02 Form of Securities and Trustee’s Certificate.
The
Securities of any series and the Trustee’s certificate of authentication to be borne by such Securities shall be substantially
of the tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth
in an Officers’ Certificate, and they may have such letters, numbers or other marks of identification or designation and such legends
or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions
of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule
or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage.
Section
2.03 Denominations: Provisions for Payment.
The
Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral
multiple thereof, subject to Section 2.01(a)(10). The Securities of a particular series shall bear interest payable on the dates and
at the rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities
of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency
of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company
maintained for that purpose in the State of Nevada. Each Security shall be dated the date of its authentication. Interest on the Securities
shall be computed on the basis of a 360-day year composed of twelve 30-day months.
The
interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities
of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close
of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion
thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment
Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security
as provided in Section 3.03.
Any
interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities
of the same series (herein called “Defaulted Interest”) shall forthwith cease to be payable to the registered holder on the
relevant regular record date by virtue of having been such holder; and such Defaulted Interest shall be paid by the Company, at its election,
as provided in clause (1) or clause (2) below:
(1)
The Company may make payment of any Defaulted Interest
on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close
of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the Company
shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the
proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed
to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the
date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted
Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest
which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt
by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and,
in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special
record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security
Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted
Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in
whose names such Securities (or their respective Predecessor Securities) are registered on such special record date.
(2)
The Company may make payment of any Defaulted Interest
on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities
may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the
proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.
Unless
otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities
pursuant to Section 2.01 hereof, the term “regular record date” as used in this Section with respect to a series of Securities
and any Interest Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which
an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the
first day of a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section
2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.
Subject
to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange
for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried
by such other Security.
Section
2.04 Execution and Authentication.
The
Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature.
The
Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at the time the Securities
shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities
may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date
of its authentication by the Trustee.
A
Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such
signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that
the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this
Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with
a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance
with such written order shall authenticate and deliver such Securities.
In
authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the
Trustee shall be entitled to receive, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating
that the form and terms thereof have been established in conformity with the provisions of this Indenture.
The
Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect
the Trustee’s own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably
acceptable to the Trustee.
Section
2.05 Registration of Transfer and Exchange.
(a)
Securities of any series may be exchanged upon presentation
thereof at the office or agency of the Company designated for such purpose in the State of Nevada, for other Securities of such series
of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall
execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the
same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.
(b)
The Company shall keep, or cause to be kept, at
its office or agency designated for such purpose in the State of Nevada, or such other location designated by the Company, a register
or registers (herein referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe,
the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times
shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein
provided shall be appointed as authorized by Board Resolution (the “Security Registrar”).
Upon
surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute,
the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or
Securities of the same series as the Security presented for a like aggregate principal amount.
All
Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so
required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company
or the Security Registrar, duly executed by the registered holder or by such holder’s duly authorized attorney in writing.
(c)
Except as provided pursuant to Section 2.01 pursuant
to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or more indentures supplemental to this
Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in
case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer.
(d)
The Company shall not be required (i) to issue,
exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the
mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business
on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called
for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.05
are, with respect to any Global Security, subject to Section 2.11 hereof.
Section
2.06 Temporary Securities.
Pending
the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary
Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in
the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be
appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed
by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect,
as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities
of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to
the holders), at the office or agency of the Company designated for the purpose in the State of Nevada, and the Trustee shall authenticate
and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities
of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until
further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under
this Indenture as definitive Securities of such series authenticated and delivered hereunder.
Section
2.07 Mutilated, Destroyed, Lost or Stolen Securities.
In
case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding
sentence) shall execute, and upon the Company’s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new
Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security,
or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security
shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and,
in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction
of the destruction, loss or theft of the applicant’s Security and of the ownership thereof. The Trustee may authenticate any such
substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance
of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that
may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.
In
case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead
of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated
Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they may require
to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the
destruction, loss or theft of such Security and of the ownership thereof.
Every
replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company
whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be
entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly
issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with
respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any
and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the
replacement or payment of negotiable instruments or other securities without their surrender.
Section
2.08 Cancellation.
All
Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company
or any paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no
Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. In the
absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate
of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate
as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee
for cancellation.
Section
2.09 Benefits of Indenture.
Nothing
in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties
hereto and the holders of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under
any covenant, condition or provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the
parties hereto and of the holders of the Securities.
Section
2.10 Authenticating Agent.
So
long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities
which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate
Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled
to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All
references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating
Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital
and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized
or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business
and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to
be eligible in accordance with these provisions, it shall resign immediately.
Any
Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may
at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination
to such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent,
the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon
acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if
originally named as an Authenticating Agent pursuant hereto.
Section
2.11 Global Securities.
(a)
If the Company shall establish pursuant to Section
2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee
shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated
in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in
the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary’s
instruction and (iv) shall bear a legend substantially to the following effect: “Except as otherwise provided in Section 2.11 of
the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor
Depositary or to a nominee of such successor Depositary.”
(b)
Notwithstanding the provisions of Section 2.05,
the Global Security of a series may be transferred, in whole but not in part and in the manner provided in Section 2.05, only to another
nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee
of such successor Depositary.
(c)
If at any time the Depositary for a series of the
Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary
for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation,
and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes
aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a
request from the Depositary, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute,
and subject to Section 2.04, the Trustee will authenticate and deliver the Securities of such series in definitive registered form without
coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such
series in exchange for such Global Security. In addition, the Company may at any time determine that the Securities of any series shall
no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of
such series. In such event the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officers’ Certificate
evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form
without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security
of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive registered
form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive
registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall be registered in such names and in
such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall
instruct the Trustee. The Trustee shall deliver such Securities to the Depositary for delivery to the Persons in whose names such Securities
are so registered.
ARTICLE
3
REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS
Section
3.01 Redemption.
The
Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established
for such series pursuant to Section 2.01 hereof.
Section
3.02 Notice of Redemption.
(a)
In case the Company shall desire to exercise such
right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with any right the Company reserved
for itself to do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption
to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less
than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as
they shall appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that
is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder
receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption
in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities
of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption
provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officers’
Certificate evidencing compliance with any such restriction.
Each
such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are
to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or
agency of the Company in the State of Nevada, upon presentation and surrender of such Securities, that interest accrued to the date fixed
for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption
is for a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders
of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.
In
case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount
thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities
of such series in principal amount equal to the unredeemed portion thereof will be issued.
(b)
If less than all the Securities of a series are
to be redeemed, the Company shall give the Trustee at least 45 days’ notice (unless a shorter notice shall be satisfactory to the
Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed,
and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that
may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof)
of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly
notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever
it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all
or any part of the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this
Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any
case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be delivered
to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records,
or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be
required under the provisions of this Section.
Section
3.03 Payment Upon Redemption.
(a)
If the giving of notice of redemption shall have
been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall
become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest
accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after
the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect
to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at
the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such
series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest
payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the
applicable record date pursuant to Section 2.03).
(b)
Upon presentation of any Security of such series
that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the
Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized
denominations in principal amount equal to the unredeemed portion of the Security so presented.
Section
3.04 Sinking Fund.
The
provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except
as otherwise specified as contemplated by Section 2.01 for Securities of such series.
The
minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a “mandatory
sinking fund payment,” and any payment in excess of such minimum amount provided for by the terms of Securities of any series is
herein referred to as an “optional sinking fund payment”. If provided for by the terms of Securities of any series, the cash
amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied
to the redemption of Securities of any series as provided for by the terms of Securities of such series.
Section
3.05 Satisfaction of Sinking Fund Payments with Securities.
The
Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit Securities of a series that have been redeemed
either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking
fund payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with
respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of
such series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such
purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and
the amount of such sinking fund payment shall be reduced accordingly.
Section
3.06 Redemption of Securities for Sinking Fund.
Not
less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory
to the Trustee), the Company will deliver to the Trustee an Officers’ Certificate specifying the amount of the next ensuing sinking
fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering
and crediting Securities of that series pursuant to Section 3.05 and the basis for such credit and will, together with such Officers’
Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date
the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and
cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section
3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in
Section 3.03.
ARTICLE
4
COVENANTS
Section
4.01 Payment of Principal, Premium and Interest.
The
Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that
series at the time and place and in the manner provided herein and established with respect to such Securities.
Section
4.02 Maintenance of Office or Agency.
So
long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency in the State of Nevada, with
respect to each such series and at such other location or locations as may be designated as provided in this Section 4.02, where (i)
Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for
registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series
and this Indenture may be given or served, such designation to continue with respect to such office or agency until the Company shall,
by written notice signed by any officer authorized to sign an Officers’ Certificate and delivered to the Trustee, designate some
other office or agency for such purposes or any of them. If at any time the Company shall fail to maintain any such required office or
agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at
the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations,
notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee located in the State of Nevada as its paying
agent with respect to the Securities.
Section
4.03 Paying Agents.
(a)
If the Company shall appoint one or more paying
agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section:
(1)
that it will hold all sums held by it as such agent
for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such sums have been paid
to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto;
(2)
that it will give the Trustee notice of any failure
by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest
on the Securities of that series when the same shall be due and payable;
(3)
that it will, at any time during the continuance
of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee
all sums so held in trust by such paying agent; and
(4)
that it will perform all other duties of paying
agent as set forth in this Indenture.
(b)
If the Company shall act as its own paying agent
with respect to any series of the Securities, it will on or before each due date of the principal of (and premium, if any) or interest
on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient
to pay such principal (and premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to
such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or
any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of
Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit
with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in
trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee) the
Company will promptly notify the Trustee of this action or failure so to act.
(c)
Notwithstanding anything in this Section to the
contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.05, and (ii)
the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose,
pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held
by the Trustee upon the same terms and conditions as those upon which such sums were held by the Company or such paying agent; and, upon
such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability
with respect to such money.
Section
4.04 Appointment to Fill Vacancy in Office of Trustee.
The
Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10,
a Trustee, so that there shall at all times be a Trustee hereunder.
Section
4.05 Compliance with Consolidation Provisions.
The
Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where
the Company is not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless
the provisions of Article Ten hereof are complied with.
ARTICLE
5
SECURITYHOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE
Section
5.01 Company to Furnish Trustee Names and Addresses
of Securityholders.
The
Company will furnish or cause to be furnished to the Trustee (a) within 15 days after each regular record date (as defined in Section
2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities
as of such regular record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time
that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other
times as the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar form
and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no
such list need be furnished for any series for which the Trustee shall be the Security Registrar.
Section
5.02 Preservation Of Information; Communications With
Securityholders.
(a)
The Trustee shall preserve, in as current a form
as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained in the most recent
list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in
its capacity as Security Registrar (if acting in such capacity).
(b)
The Trustee may destroy any list furnished to it
as provided in Section 5.01 upon receipt of a new list so furnished.
(c)
Securityholders may communicate as provided in Section
312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities,
and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust Indenture
Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act.
Section
5.03 Reports by the Company.
The
Company covenants and agrees to provide a copy to the Trustee, after the Company files the same with the Securities and Exchange Commission,
copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing
as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the Securities
and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; provided, however, the Company shall not be required
to deliver to the Trustee any materials for which the Company has sought and received confidential treatment by the Securities and Exchange
Commission. The Company shall also comply with the requirements of Section 314 of the Trust Indenture Act, but only to the extent then
applicable to the Company.
Section
5.04 Reports by the Trustee.
(a)
On or before July 1 in each year in which any of
the Securities are Outstanding, the Trustee shall transmit by mail, first class postage prepaid, to the Securityholders, as their names
and addresses appear upon the Security Register, a brief report dated as of the preceding May 1, if and to the extent required under
Section 313(a) of the Trust Indenture Act.
(b)
The Trustee shall comply with Section 313(b) and
313(c) of the Trust Indenture Act.
(c)
A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company,
with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission.
The Company agrees to notify the Trustee when any Securities become listed on any securities exchange.
ARTICLE
6
REMEDIES
OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT
Section
6.01 Events of Default.
(a)
Whenever used herein with respect to Securities
of a particular series, “Event of Default” means any one or more of the following events that has occurred and is continuing:
(1)
the Company defaults in the payment of any installment
of interest upon any of the Securities of that series, as and when the same shall become due and payable, and such default continues
for a period of 30 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the
terms of any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose;
(2)
the Company defaults in the payment of the principal
of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity,
upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to
that series; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture
supplemental hereto shall not constitute a default in the payment of principal or premium, if any;
(3)
the Company fails to observe or perform any other
of its covenants or agreements with respect to that series contained in this Indenture or otherwise established with respect to that
series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture
solely for the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written
notice of such failure, requiring the same to be remedied and stating that such notice is a “Notice of Default” hereunder,
shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders
of at least 25% in principal amount of the Securities of that series at the time Outstanding;
(4)
the Company pursuant to or within the meaning of
any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case,
(iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment
for the benefit of its creditors; or
(5)
a court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is for relief against the Company in an involuntary
case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company,
and the order or decree remains unstayed and in effect for 90 days.
(b)
In each and every such case (other than an Event
of Default specified in clause (4) or clause (5) above), unless the principal of all the Securities of that series shall have already
become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that
series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare
the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable
immediately, and upon any such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified
in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all the Securities of that series shall
automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities.
(c)
At any time after the principal of (and premium,
if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared due and payable, and before
any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of
a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company
and the Trustee, may rescind and annul such declaration and its consequences if: (i) the Company has paid or deposited with the Trustee
a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium,
if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration (with interest upon such
principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of
interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit) and the amount payable
to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with respect to such series, other than
the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not
have become due by their terms, shall have been remedied or waived as provided in Section 6.06.
No
such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon.
(d)
In case the Trustee shall have proceeded to enforce
any right with respect to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned
because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every
such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former
positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though no such proceedings
had been taken.
Section
6.02 Collection of Indebtedness and Suits for Enforcement
by Trustee.
(a)
The Company covenants that (i) in case it shall
default in the payment of any installment of interest on any of the Securities of a series, or in any payment required by any sinking
or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall
have continued for a period of 90 Business Days, or (ii) in case it shall default in the payment of the principal of (or premium, if
any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of
a series or upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for
the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all
such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal
(and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon overdue installments
of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall
be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee under Section 7.06.
(b)
If the Company shall fail to pay such amounts forthwith
upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action
or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding
to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities
of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the property of
the Company or other obligor upon the Securities of that series, wherever situated.
(c)
In case of any receivership, insolvency, liquidation,
bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or
property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court
and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may
be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of such series allowed for the
entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional
amount that may become due and payable by the Company after such date, and to collect and receive any moneys or other property payable
or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06;
and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the holders of Securities of such
series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly
to such Securityholders, to pay to the Trustee any amount due it under Section 7.06.
(d)
All rights of action and of asserting claims under
this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without
the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit
or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment
shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the ratable benefit of the holders of
the Securities of such series.
In
case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this
Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights,
either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained
in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested
in the Trustee by this Indenture or by law.
Nothing
contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder
any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder
thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding.
Section
6.03 Application of Moneys or Property Collected.
Any
moneys or property collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied
in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys or property on account
of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment,
if only partially paid, and upon surrender thereof if fully paid:
FIRST:
To the payment of reasonable costs and expenses of collection and of all amounts payable to the Trustee under Section 7.06;
SECOND:
To the payment of the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in
respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according
to the amounts due and payable on such Securities for principal (and premium, if any) and interest, respectively; and
THIRD:
To the payment of the remainder, if any, to the Company or any other Person lawfully entitled thereto as requested by the Company.
Section
6.04 Limitation on Suits.
No
holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any
suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or
trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice of an Event
of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore
provided; (ii) the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall
have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii) such
holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities
to be incurred therein or thereby; (iv) the Trustee for 60 days after its receipt of such notice, request and offer of indemnity, shall
have failed to institute any such action, suit or proceeding and (v) during such 60 day period, the holders of a majority in principal
amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.
Notwithstanding
anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive
payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due
dates expressed in such Security (or in the case of redemption, on the redemption date), or to institute suit for the enforcement of
any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such
holder and by accepting a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security
of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall
have any right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the
rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder,
or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all
holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder
and the Trustee shall be entitled to such relief as can be given either at law or in equity.
Section
6.05 Rights and Remedies Cumulative; Delay or Omission
Not Waiver.
(a)
Except as otherwise provided in Section 2.07, all
powers and remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative
and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings
or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established
with respect to such Securities.
(b)
No delay or omission of the Trustee or of any holder
of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall
impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to
the provisions of Section 6.04, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised
from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.
Section
6.06 Control by Securityholders.
The
holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance
with Section 8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to
the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series; provided, however, that such direction
shall not be in conflict with any rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have
the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee,
determine that the proceeding so directed, subject to the Trustee’s duties under the Trust Indenture Act, would involve the Trustee
in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority
in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with
Section 8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of
the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its consequences, except a default
in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall
become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to
pay all matured installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section
6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company,
the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively;
but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.
Section
6.07 Undertaking to Pay Costs.
All
parties to this Indenture agree, and each holder of any Securities by such holder’s acceptance thereof shall be deemed to have
agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or
in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an
undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’
fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such
party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any
Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any
series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or
interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this
Indenture.
ARTICLE
7
CONCERNING THE TRUSTEE
Section
7.01 Certain Duties and Responsibilities of Trustee.
(a)
The Trustee, prior to the occurrence of an Event
of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the Securities of
that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such
duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the Trustee.
In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee
shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same
degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own
affairs.
(b)
No provision of this Indenture shall be construed
to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct,
except that:
(1)
prior to the occurrence of an Event of Default with
respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that
may have occurred:
(A)
the duties and obligations of the Trustee shall
with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall
not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically
set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and
(B)
in the absence of bad faith on the part of the Trustee,
the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and the correctness
of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this
Indenture; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished
to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirement of
this Indenture;
(i)
the Trustee shall not be liable for any error of
judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee
was negligent in ascertaining the pertinent facts;
(ii)
the Trustee shall not be liable with respect to
any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority
in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture
with respect to the Securities of that series; and
(iii)
None of the provisions contained in this Indenture
shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of
its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds
or liability is not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably
assured to it.
Section
7.02 Certain Rights of Trustee.
Except
as otherwise provided in Section 7.01:
(a)
The Trustee may rely conclusively and shall be protected
in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent,
order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties;
(b)
Any request, direction, order or demand of the Company
mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized
officer of the Company (unless other evidence in respect thereof is specifically prescribed herein);
(c)
The Trustee may consult with counsel and the written
advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken
or suffered or omitted hereunder in good faith and in reliance thereon;
(d)
The Trustee shall be under no obligation to exercise
any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the Securityholders pursuant
to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against
the costs, expenses and liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee
of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or
waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use
the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of
his own affairs;
(e)
The Trustee shall not be liable for any action taken
or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred
upon it by this Indenture;
(f)
The Trustee shall not be bound to make any investigation
into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order,
approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority
in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04);
provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred
by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded
to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such costs, expenses or liabilities as a condition
to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be
repaid by the Company upon demand; and
(g)
The Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible
for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder.
In
addition, the Trustee shall not be deemed to have knowledge of any Default or Event of Default except (1) any Event of Default occurring
pursuant to Sections 6.01(a)(1), 6.01(a)(2) and 4.01 hereof or (2) any Default or Event of Default of which the Trustee shall have received
written notification in the manner set forth in this Indenture or a Responsible Officer of the Trustee shall have obtained actual knowledge.
Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information
and the Trustee’s receipt of the foregoing shall not constitute constructive notice of any information contained therein, or determinable
from information contained therein including the Company’s compliance with any of their covenants thereunder (as to which the Trustee
is entitled to rely conclusively on an Officers’ Certificate).
Section
7.03 Trustee Not Responsible for Recitals or Issuance
or Securities.
(a)
The recitals contained herein and in the Securities
shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same.
(b)
The Trustee makes no representations as to the validity
or sufficiency of this Indenture or of the Securities.
(c)
The Trustee shall not be accountable for the use
or application by the Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys
paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or
application of any moneys received by any paying agent other than the Trustee.
Section
7.04 May Hold Securities.
The
Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities
with the same rights it would have if it were not Trustee, paying agent or Security Registrar.
Section
7.05 Moneys Held in Trust.
Subject
to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust
for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The
Trustee shall be under no liability for interest on any moneys received by it hereunder except such as it may agree with the Company
to pay thereon.
Section
7.06 Compensation and Reimbursement.
(a)
The Company covenants and agrees to pay to the Trustee,
and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services
rendered by it in the execution of the trusts hereby created and in the exercise and performance of any of the powers and duties hereunder
of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for
all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this
Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in
its employ), except any such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company
and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents, directors
and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part
of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the reasonable costs
and expenses of defending itself against any claim of liability in the premises.
(b)
The obligations of the Company under this Section
to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall
constitute additional indebtedness hereunder. Such additional indebtedness shall be secured by a lien prior to that of the Securities
upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular
Securities.
Section
7.07 Reliance on Officers’ Certificate.
Except
as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably
necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder,
such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith
on the part of the Trustee, be deemed to be conclusively proved and established by an Officers’ Certificate delivered to the Trustee
and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for
any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.
Section
7.08 Disqualification; Conflicting Interests.
If
the Trustee has or shall acquire any “conflicting interest” within the meaning of Section 310(b) of the Trust Indenture Act,
the Trustee and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act.
Section
7.09 Corporate Trustee Required; Eligibility.
There
shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and
doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a
corporation or other Person permitted to act as trustee by the Securities and Exchange Commission, authorized under such laws to exercise
corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision
or examination by federal, state, territorial, or District of Columbia authority.
If
such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid
supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other
Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company
may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee.
In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign
immediately in the manner and with the effect specified in Section 7.10.
Section
7.10 Resignation and Removal; Appointment of Successor.
(a)
The Trustee or any successor hereafter appointed
may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the Company and by transmitting
notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear
upon the Security Register.
Upon
receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series
by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to
the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment
within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction
for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been
a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others similarly situated, petition
any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper
and prescribe, appoint a successor trustee.
(b)
In case at any time any one of the following shall
occur:
(1)
the Trustee shall fail to comply with the provisions
of Section 7.08 after written request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security
or Securities for at least six months; or
(2)
the Trustee shall cease to be eligible in accordance
with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or by any such Securityholder;
or
(3)
the Trustee shall become incapable of acting, or
shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property
shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for
the purpose of rehabilitation, conservation or liquidation; then, in any such case, the Company may remove the Trustee with respect to
all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one
copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any Securityholder who
has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly
situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such
court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.
(c)
The holders of a majority in aggregate principal
amount of the Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying
the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.
(d)
Any resignation or removal of the Trustee and appointment
of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective
upon acceptance of appointment by the successor trustee as provided in Section 7.11.
(e)
Any successor trustee appointed pursuant to this
Section may be appointed with respect to the Securities of one or more series or all of such series, and at any time there shall be only
one Trustee with respect to the Securities of any particular series.
Section
7.11 Acceptance of Appointment By Successor.
(a)
In case of the appointment hereunder of a successor
trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company
and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee
shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights,
powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring Trustee
shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers,
and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held
by such retiring Trustee hereunder.
(b)
In case of the appointment hereunder of a successor
trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee
with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor
trustee shall accept such appointment and which (i) shall contain such provisions as shall be necessary or desirable to transfer and
confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to
the Securities of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions
as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect
to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring
Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate
the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental
indenture shall constitute such Trustees co-trustees of the same trust, that each such Trustee shall be trustee of a trust or trusts
hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible
for any act or failure to act on the part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture
the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall
with respect to the Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility
for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture,
and each such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts
and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor
trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver
to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee
hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates.
(c)
Upon request of any such successor trustee, the
Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor trustee all such
rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be.
(d)
No successor trustee shall accept its appointment
unless at the time of such acceptance such successor trustee shall be qualified and eligible under this Article.
(e)
Upon acceptance of appointment by a successor trustee
as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage
prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such
notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be
transmitted at the expense of the Company.
Section
7.12 Merger, Conversion, Consolidation or Succession
to Business.
Any
corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from
any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business
of the Trustee, shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions
of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further act on
the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated,
but not delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to such authenticating Trustee
may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself
authenticated such Securities.
Section
7.13 Preferential Collection of Claims Against the Company.
The
Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b)
of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act
to the extent included therein.
Section
7.14 Notice of Default
If
any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer
of the Trustee, the Trustee shall mail to each Securityholder in the manner and to the extent provided in Section 313(c) of the Trust
Indenture Act notice of the Default or Event of Default within 90 days after it occurs and becomes known to the Trustee, unless such
Default or Event of Default has been cured; provided, however, that, except in the case of a default in the payment of the principal
of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as the
board of directors, the executive committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith
determine that the withholding of such notice is in the interest of the Securityholders.
ARTICLE
8
CONCERNING THE SECURITYHOLDERS
Section
8.01 Evidence of Action by Securityholders.
Whenever
in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities
of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver
or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage
of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such
holders of Securities of that series in person or by agent or proxy appointed in writing.
If
the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver
or other action, the Company may, at its option, as evidenced by an Officers’ Certificate, fix in advance a record date for such
series for the determination of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver
or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization,
direction, notice, consent, waiver or other action may be given before or after the record date, but only the Securityholders of record
at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders
of the requisite proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand,
authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall
be computed as of the record date; provided, however, that no such authorization, agreement or consent by such Securityholders on the
record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six
months after the record date.
Section
8.02 Proof of Execution by Securityholders.
Subject
to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization)
or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner:
(a)
The fact and date of the execution by any such Person
of any instrument may be proved in any reasonable manner acceptable to the Trustee.
(b)
The ownership of Securities shall be proved by the
Security Register of such Securities or by a certificate of the Security Registrar thereof.
The
Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary.
Section
8.03 Who May be Deemed Owners.
Prior
to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar
may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of
such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone
other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject
to Section 2.03) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor
any Security Registrar shall be affected by any notice to the contrary.
Section
8.04 Certain Securities Owned by Company Disregarded.
In
determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any
direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on
the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control with the Company
or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such
determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent
or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned
that have been pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish
to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Securities and that the pledgee is not a
Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other
obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection
to the Trustee.
Section
8.05 Actions Binding on Future Securityholders.
At
any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders
of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection
with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders
of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section
8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall
be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange
therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made
upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of
a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee
and the holders of all the Securities of that series.
ARTICLE
9
SUPPLEMENTAL INDENTURES
Section
9.01 Supplemental Indentures Without the Consent of
Securityholders.
In
addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and
at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act
as then in effect), without the consent of the Securityholders, for one or more of the following purposes:
(a)
to cure any ambiguity, defect, or inconsistency
herein or in the Securities of any series;
(b)
to comply with Article Ten;
(c)
to provide for uncertificated Securities in addition
to or in place of certificated Securities and to make all appropriate changes for such purpose;
(d)
to add to the covenants, restrictions, conditions
or provisions relating to the Company for the benefit of the holders of all or any series of Securities (and if such covenants, restrictions,
conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions,
conditions or provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence
and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to
surrender any right or power herein conferred upon the Company;
(e)
to add to, delete from, or revise the conditions,
limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein
set forth;
(f)
to make any change that does not adversely affect
the rights of any Securityholder in any material respect;
(g)
to provide for the issuance of and establish the
form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications
required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders
of any series of Securities;
(h)
to evidence and provide for the acceptance of appointment
hereunder by a successor trustee; or
(i)
to comply with any requirements of the Securities
and Exchange Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture Act.
The
Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate
agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental
indenture that affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise.
Any
supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent
of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02.
Section
9.02 Supplemental Indentures With Consent of Securityholders.
With
the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities
of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board
Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall
conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any
manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered
by Section 9.01 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental
indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a) extend the fixed maturity
of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest
thereon, or reduce any premium payable upon the redemption thereof, (b) make any Security payable in money other than that stated in
the Security, (c) impair the right of any Holder to receive payment of principal of, premium, if any, and interest, if any, on, such
Holder’s Securities on or after the due dates therefor or to institute suit for the enforcement of any payment, or (d) adversely
change the right to convert or exchange, including decreasing the conversion rate or increasing the conversion price of, any Security,
or (e) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture.
It
shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular
form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.
Section
9.03 Effect of Supplemental Indentures.
Upon
the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with
respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of
rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series
affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments,
and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of
this Indenture for any and all purposes.
Section
9.04 Securities Affected by Supplemental Indentures.
Securities
of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant
to the provisions of this Article or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets
the requirements of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental
indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of
Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated
by the Trustee and delivered in exchange for the Securities of that series then Outstanding.
Section
9.05 Execution of Supplemental Indentures.
Upon
the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon
the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall
join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s
own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be
obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, will be entitled to receive
and will be fully protected in relying upon an Officers’ Certificate and an Opinion of Counsel stating that any supplemental indenture
executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for
the Trustee under the provisions of this Article to join in the execution thereof; provided, however, that such Officers’ Certificate
or Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the terms of
a series of Securities pursuant to Section 2.01 hereof.
Promptly
after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee
shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture,
to the Securityholders of all series affected thereby as their names and addresses appear upon the Security Register. Any failure of
the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental
indenture.
ARTICLE
10
SUCCESSOR ENTITY
Section
10.01 Company May Consolidate, Etc.
The
Company shall not consolidate with or merge into any other Person (in a transaction in which the Company is not the surviving corporation)
or convey, transfer or lease its properties and assets substantially as an entirety to any Person, unless (a) the Person formed by such
consolidation or into which the Company is merged or the Person which acquires by conveyance or transfer, or which leases, the properties
and assets of the Company substantially as an entirety shall expressly assume, by an indenture supplemental hereto, executed and delivered
to the Trustee, in form satisfactory to the Trustee, the due and punctual payment of the principal of and any premium and interest on
all the Securities and the performance or observance of every covenant of this Indenture on the part of the Company to be performed,
by supplemental indenture satisfactory in form to the Trustee, executed and delivered to the Trustee, by the Person (if other than the
Company) formed by such consolidation or into which the Company shall have been merged or by the Person which shall have acquired the
Company’s assets; (b) immediately after giving effect to such transaction and treating any indebtedness which becomes an obligation
of the Company or any Subsidiary as a result of such transaction as having been incurred by the Company or such Subsidiary at the time
of such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default,
shall have happened and be continuing; and (c) the Company has delivered to the Trustee an Officer’s Certificate and an Opinion
of Counsel, each stating that such consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required
in connection with such transaction, such supplemental indenture comply with this Article and that all conditions precedent herein provided
for relating to such transaction have been complied with.
The
restrictions in this Section 10.01 shall not apply to the merger of the Company with or into a single direct or indirect wholly owned
Subsidiary.
Section
10.02 Successor Entity Substituted.
(a)
In case of any such consolidation, merger, sale,
conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered
to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of
all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been
named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this
Indenture and the Securities.
(b)
In case of any such consolidation, merger, sale,
conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance) may be made in the Securities
thereafter to be issued as may be appropriate.
(c)
Nothing contained in this Article shall require
any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of
such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person
(whether or not affiliated with the Company).
Section
10.03 Evidence of Consolidation, Etc. to Trustee.
The
Trustee, subject to the provisions of Section 7.01, may receive an Officers’ Certificate or an Opinion of Counsel as conclusive
evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the
provisions of this Article.
ARTICLE
11
SATISFACTION AND DISCHARGE
Section
11.01 Satisfaction and Discharge of Indenture.
If
at any time: (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated
and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that
shall have been replaced or paid as provided in Section 2.07 and Securities for whose payment money or Governmental Obligations have
theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged
from such trust, as provided in Section 11.05); or (b) all such Securities of a particular series not theretofore delivered to the Trustee
for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called
for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company
shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination
thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification
thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the
Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date
fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with
respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except
for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption
date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of
the Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging
this Indenture with respect to such series.
Section
11.02 Discharge of Obligations.
If
at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become
due and payable as described in Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust
funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series
not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due
to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all
other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations,
as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall
cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that
shall survive until such Securities shall mature and be paid.
Thereafter,
Sections 7.06 and 11.05 shall survive.
Section
11.03 Deposited Moneys to be Held in Trust.
All
moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be
available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to
the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations have
been deposited with the Trustee.
Section
11.04 Payment of Moneys Held by Paying Agents.
In
connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent
under the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall
be released from all further liability with respect to such moneys or Governmental Obligations.
Section
11.05 Repayment to Company.
Any
moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment
of principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by
the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on
such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned
or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Company’s request or (if then held
by the Company) shall be discharged from such trust; and thereupon the paying agent and the Trustee shall be released from all further
liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment
shall thereafter, as a general creditor, look only to the Company for the payment thereof.
ARTICLE
12
IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS
Section
12.01 No Recourse.
No
recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or
otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such,
of the Company or of any predecessor or successor corporation, either directly or through the Company or any such predecessor or successor
corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise;
it being expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no
such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors
as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby
authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities
or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by
constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director
as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements
contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition
of, and as a consideration for, the execution of this Indenture and the issuance of such Securities.
ARTICLE
13
MISCELLANEOUS PROVISIONS
Section
13.01 Effect on Successors and Assigns.
All
the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors
and assigns, whether so expressed or not.
Section
13.02 Actions by Successor.
Any
act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer
of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any
corporation that shall at the time be the lawful successor of the Company.
Section
13.03 Surrender of Company Powers.
The
Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the
powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor
corporation.
Section
13.04 Notices.
Except
as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted
to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on
the Company may be given or served by being deposited in first class mail, postage prepaid, addressed (until another address is filed
in writing by the Company with the Trustee), as follows: 680 W Nye Lane Suite 204, Carson City, NV 89703, with a copy to Reed Smith LLP,
599 Lexington Avenue, New York, NY 10022, Attention: Mark Pedretti. Any notice, election, request or demand by the Company or any Securityholder
or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for
all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.
Section
13.05 Governing Law.
This
Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of Nevada, and for all purposes
shall be construed in accordance with the laws of said State, except to the extent that the Trust Indenture Act is applicable.
Section
13.06 Treatment of Securities as Debt.
It
is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of
this Indenture shall be interpreted to further this intention.
Section
13.07 Certificates and Opinions as to Conditions Precedent.
(a)
Upon any application or demand by the Company to
the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officers’
Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant
to Section 13.13) relating to the proposed action have been complied with and an Opinion of Counsel stating that in the opinion of such
counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which
the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application
or demand, no additional certificate or opinion need be furnished.
(b)
Each certificate or opinion provided for in this
Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a
statement that the Person making such certificate or opinion has read such covenant or condition; (ii) a brief statement as to the nature
and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;
(iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable
him to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to
whether or not, in the opinion of such Person, such condition or covenant has been complied with.
Section
13.08 Payments on Business Days.
Except
as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officers’ Certificate, or established
in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security
or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may
be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption,
and no interest shall accrue for the period after such nominal date.
Section
13.09 Conflict with Trust Indenture Act.
If
and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317,
inclusive, of the Trust Indenture Act, such imposed duties shall control.
Section
13.10 Indenture and Securities Solely Corporate Obligations.
No
recourse for the payment of the principal of, premium, if any, or interest on any Securities, or for any claim based thereon or otherwise
in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental
indenture or in any Security, or because of the creation of any indebtedness represented thereby, shall be had against any incorporator,
shareholder, employee, agent, officer, director or subsidiary, as such, past, present or future, of the Company or of any successor entity,
either directly or through the Company or any successor entity, whether by virtue of any constitution, statute, or rule of law, or by
the enforcement of any assessment or penalty or otherwise; it being expressly understood that all such liability is hereby expressly
waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of the Securities.
Section
13.11 Counterparts.
This
Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute
but one and the same instrument.
Section
13.12 Separability.
In
case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions
of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable
provision had never been contained herein or therein.
Section
13.13 Compliance Certificates.
The
Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were
outstanding, a compliance certificate stating whether or not the signer knows of any Default or Event of Default that occurred during
such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial officer or
principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company’s
performance under this Indenture and that the Company has complied with all conditions and covenants under this Indenture. For purposes
of this Section 13.13, such compliance shall be determined without regard to any period of grace or requirement of notice provided under
this Indenture. If the officer of the Company signing such certificate has knowledge of such a Default or Event of Default, the certificate
shall describe any such Default or Event of Default and its status.
IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written.
|
BIOVIE,
INC. |
|
By: |
|
|
Name: |
|
|
Title: |
|
|
|
|
[TRUSTEE],
as Trustee |
|
By: |
|
|
Name: |
|
|
Title: |
|
CROSS-REFERENCE
TABLE (1)
Section
of Trust Indenture Act of 1939, as Amended |
Section
of Indenture |
310(a) |
7.09 |
310(b) |
7.08 |
|
7.10 |
310(c) |
Inapplicable |
311(a) |
7.13 |
311(b) |
7.13 |
|
|
311(c) |
Inapplicable |
312(a) |
5.01 |
|
5.02(a) |
312(b) |
5.02(c) |
312(c) |
5.02(c) |
313(a) |
5.04(a) |
313(b) |
5.04(b) |
313(c) |
5.04(a) |
|
5.04(b) |
313(d) |
5.04(c) |
314(a) |
5.03 |
|
13.12 |
314(b) |
Inapplicable |
314(c) |
13.07(a) |
314(d) |
Inapplicable |
Section
of Trust Indenture Act of 1939, as Amended |
Section
of Indenture |
314(e) |
13.07(b) |
314(f) |
Inapplicable |
315(a) |
7.01(a) |
|
7.01(b) |
315(b) |
7.14 |
315(c) |
7.01 |
315(d) |
7.01(b) |
|
|
315(e) |
6.07 |
316(a) |
6.06 |
|
8.04 |
316(b) |
6.04 |
316(c) |
8.01 |
317(a) |
6.02 |
317(b) |
4.03 |
318(a) |
13.09 |
|
(1) |
This
Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its
terms or provisions. |
|
|
|
Exhibit
4.6
BIOVIE
INC.
Company
AND
[TRUSTEE]
Trustee
INDENTURE
Dated
as of [·], 20[·]
Subordinated
Debt Securities
TABLE
OF CONTENTS
ARTICLE
1 DEFINITIONS |
1 |
Section
1.01 Definitions of Terms. |
1 |
|
|
ARTICLE
2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES |
5 |
Section
2.01 Designation and Terms of Securities. |
5 |
Section
2.02 Form of Securities and Trustees Certificate. |
7 |
Section
2.03 Denominations: Provisions for Payment. |
8 |
Section
2.04 Execution and Authentication. |
9 |
Section
2.05 Registration of Transfer and Exchange. |
9 |
Section
2.06 Temporary Securities. |
10 |
Section
2.07 Mutilated, Destroyed, Lost or Stolen Securities. |
11 |
Section
2.08 Cancellation. |
11 |
Section
2.09 Benefits of Indenture. |
12 |
Section
2.10 Authenticating Agent. |
12 |
Section
2.11 Global Securities. |
12 |
|
|
ARTICLE
3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS |
13 |
Section
3.01 Redemption. |
13 |
Section
3.02 Notice of Redemption. |
13 |
Section
3.03 Payment Upon Redemption. |
15 |
Section
3.04 Sinking Fund. |
15 |
Section
3.05 Satisfaction of Sinking Fund Payments with Securities. |
15 |
Section
3.06 Redemption of Securities for Sinking Fund. |
16 |
|
|
ARTICLE
4 COVENANTS |
16 |
Section
4.01 Payment of Principal, Premium and Interest. |
16 |
Section
4.02 Maintenance of Office or Agency. |
16 |
Section
4.03 Paying Agents. |
16 |
Section
4.04 Appointment to Fill Vacancy in Office of Trustee. |
17 |
Section
4.05 Compliance with Consolidation Provisions. |
17 |
|
|
ARTICLE
5 SECURITYHOLDERS LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE |
18 |
Section
5.01 Company to Furnish Trustee Names and Addresses of Securityholders. |
18 |
Section
5.02 Preservation Of Information; Communications With Securityholders. |
18 |
Section
5.03 Reports by the Company. |
18 |
Section
5.04 Reports by the Trustee. |
19 |
ARTICLE
6 REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT |
19 |
Section
6.01 Events of Default. |
19 |
Section
6.02 Collection of Indebtedness and Suits for Enforcement by Trustee. |
21 |
Section
6.03 Application of Moneys or Property Collected. |
22 |
Section
6.04 Limitation on Suits. |
22 |
Section
6.05 Rights and Remedies Cumulative; Delay or Omission Not Waiver. |
23 |
Section
6.06 Control by Securityholders. |
23 |
Section
6.07 Undertaking to Pay Costs. |
24 |
|
|
ARTICLE
7 CONCERNING THE TRUSTEE |
24 |
Section
7.01 Certain Duties and Responsibilities of Trustee. |
24 |
Section
7.02 Certain Rights of Trustee. |
25 |
Section
7.03 Trustee Not Responsible for Recitals or Issuance or Securities. |
26 |
Section
7.04 May Hold Securities. |
27 |
Section
7.05 Moneys Held in Trust. |
27 |
Section
7.06 Compensation and Reimbursement. |
27 |
Section
7.07 Reliance on Officers Certificate. |
28 |
Section
7.08 Disqualification; Conflicting Interests. |
28 |
Section
7.09 Corporate Trustee Required; Eligibility. |
28 |
Section
7.10 Resignation and Removal; Appointment of Successor. |
28 |
Section
7.11 Acceptance of Appointment By Successor. |
29 |
Section
7.12 Merger, Conversion, Consolidation or Succession to Business. |
31 |
Section
7.13 Preferential Collection of Claims Against the Company. |
31 |
Section
7.14 Notice of Default |
31 |
|
|
ARTICLE
8 CONCERNING THE SECURITYHOLDERS |
31 |
Section
8.01 Evidence of Action by Securityholders. |
31 |
Section
8.02 Proof of Execution by Securityholders. |
32 |
Section
8.03 Who May be Deemed Owners. |
32 |
Section
8.04 Certain Securities Owned by Company Disregarded. |
32 |
Section
8.05 Actions Binding on Future Securityholders. |
33 |
|
|
ARTICLE
9 SUPPLEMENTAL INDENTURES |
33 |
Section
9.01 Supplemental Indentures Without the Consent of Securityholders. |
33 |
Section
9.02 Supplemental Indentures With Consent of Securityholders. |
33 |
Section
9.03 Effect of Supplemental Indentures. |
35 |
Section
9.04 Securities Affected by Supplemental Indentures. |
35 |
Section
9.05 Execution of Supplemental Indentures. |
35 |
ARTICLE
10 SUCCESSOR ENTITY |
36 |
Section
10.01 Company May Consolidate, Etc. |
36 |
Section
10.02 Successor Entity Substituted. |
36 |
Section
10.03 Evidence of Consolidation, Etc. to Trustee. |
37 |
|
|
ARTICLE
11 SATISFACTION AND DISCHARGE |
37 |
Section
11.01 Satisfaction and Discharge of Indenture. |
37 |
Section
11.02 Discharge of Obligations. |
37 |
Section
11.03 Deposited Moneys to be Held in Trust. |
38 |
Section
11.04 Payment of Moneys Held by Paying Agents. |
38 |
Section
11.05 Repayment to Company. |
38 |
|
|
ARTICLE
12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS |
38 |
Section
12.01 No Recourse. |
38 |
|
|
ARTICLE
13 MISCELLANEOUS PROVISIONS |
39 |
Section
13.01 Effect on Successors and Assigns. |
39 |
Section
13.02 Actions by Successor. |
39 |
Section
13.03 Surrender of Company Powers. |
39 |
Section
13.04 Notices. |
39 |
Section
13.05 Governing Law. |
39 |
Section
13.06 Treatment of Securities as Debt. |
39 |
Section
13.07 Certificates and Opinions as to Conditions Precedent. |
40 |
Section
13.08 Payments on Business Days. |
40 |
Section
13.09 Conflict with Trust Indenture Act. |
40 |
Section
13.10 Indenture and Securities Solely Corporate Obligations. |
40 |
Section
13.11 Counterparts. |
41 |
Section
13.12 Separability. |
41 |
Section
13.13 Compliance Certificates. |
41 |
|
|
ARTICLE
14 SUBORDINATION OF SECURITIES |
41 |
Section
14.01 Subordination Terms. |
41 |
|
(1) |
This
Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms
or provisions. |
INDENTURE
INDENTURE,
dated as of [·], 20[·], among BIOVIE INC., a Nevada corporation (the Company), and [TRUSTEE], as trustee
(the Trustee).
WHEREAS,
for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance
of subordinated debt securities (hereinafter referred to as the Securities), in an unlimited aggregate principal amount
to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated
by the certificate of the Trustee;
WHEREAS,
to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized
the execution of this Indenture; and
WHEREAS,
all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done.
NOW,
THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted
and agreed as follows for the equal and ratable benefit of the holders of Securities:
ARTICLE
1
DEFINITIONS
Section
1.01 Definitions of Terms.
The
terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless
the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective
meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that
are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933,
as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires),
shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the
execution of this instrument.
Authenticating
Agent means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant
to Section 2.10.
Bankruptcy
Law means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
Board
of Directors means the Board of Directors of the Company or any duly authorized committee of such Board.
Board
Resolution means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been
duly adopted by the Board of Directors and to be in full force and effect on the date of such certification.
Business
Day means, with respect to any series of Securities, any day other than a day on which federal or state banking institutions
in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated
by law, executive order or regulation to close.
Certificate
means a certificate signed by any Officer. The Certificate need not comply with the provisions of Section 13.07.
Company
means BioVie Inc., a corporation duly organized and existing under the laws of the State of Nevada, and, subject to the provisions of
Article Ten, shall also include its successors and assigns.
Corporate
Trust Office means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally
administered, which office at the date hereof is located at.
Currency
Agreement means any foreign exchange contract, currency swap agreement or other similar agreement with respect to currency
values.
Custodian
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
Default
means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default.
Depositary
means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global
Security, The Depository Trust Company, New York, New York, another clearing agency, or any successor registered as a clearing agency
under the Securities Exchange Act of 1934, as amended (the Exchange Act), or other applicable statute or regulation, which,
in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11.
Event
of Default means, with respect to Securities of a particular series, any event specified in Section 6.01, continued for
the period of time, if any, therein designated.
Global
Security means, with respect to any series of Securities, a Security executed by the Company and delivered by the Trustee
to the Depositary or pursuant to the Depositarys instruction, all in accordance with the Indenture, which shall be registered
in the name of the Depositary or its nominee.
Governmental
Obligations means securities that are (a) direct obligations of the United States of America for the payment of which
its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality
of the United States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United
States of America that, in either case, are not callable or redeemable at the option of the Company thereof at any time prior to the
stated maturity of the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect
to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such
custodian for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian
is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by
the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation
evidenced by such depositary receipt.
herein,
hereof and hereunder, and other words of similar import, refer to this Indenture
as a whole and not to any particular Article, Section or other subdivision.
Indenture
means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental
hereto entered into in accordance with the terms hereof.
Interest
Payment Date, when used with respect to any installment of interest on a Security of a particular series, means the date
specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date
on which an installment of interest with respect to Securities of that series is due and payable.
Interest
Rate Agreement means any interest rate swap agreement, interest rate cap agreement or other financial agreement or arrangement
with respect to exposure to interest rates.
Officer
means, with respect to the Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial
officer, chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant
treasurer, the controller or any assistant controller or the secretary or any assistant secretary.
Officers
Certificate means a certificate signed by any two Officers. Each such certificate shall include the statements provided
for in Section 13.07, if and to the extent required by the provisions thereof.
Opinion
of Counsel means an opinion in writing subject to customary exceptions of legal counsel, who may be an employee of or
counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements
provided for in Section 13.07, if and to the extent required by the provisions thereof.
Outstanding,
when used with reference to Securities of any series, means, subject to the provisions of Section 8.04, as of any particular time, all
Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore
canceled by the Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously
been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary
amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside
and segregated in trust by the Company (if the Company shall act as its own paying agent); provided, however, that if such Securities
or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as in
Article Three provided, or provision satisfactory to the Trustee shall have been made for giving such notice; and (c) Securities in lieu
of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07.
Person
means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, association, trust, unincorporated
organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.
Predecessor
Security of any particular Security means every previous Security evidencing all or a portion of the same debt as that
evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section
2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.
Responsible
Officer when used with respect to the Trustee means the chairman of its board of directors, the chief executive officer,
the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer
or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall
be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity
with the particular subject.
Securities
means the debt Securities authenticated and delivered under this Indenture.
Securityholder,
holder of Securities, registered holder, or other similar term, means the Person or Persons in whose name
or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of
this Indenture.
Security
Register and Security Registrar shall have the meanings as set forth in Section 2.05.
Senior
Indebtedness of a Person means the principal of, premium, if any, interest on, and any other payment due pursuant to any
of the following, whether outstanding at the date hereof or hereafter incurred or created:
(a)
all of the principal of (and premium, if any) and
interest due on indebtedness of that Person for money borrowed;
(b)
all of the indebtedness of that Person evidenced
by notes, debentures, bonds or other securities sold by that Person for money;
(c)
all of the lease obligations which are capitalized
on the books of that Person in accordance with generally accepted accounting principles;
(d)
all obligations of such Person for the reimbursement
of any obligor on any letter of credit, bankers acceptance or similar credit transaction (other than obligations with respect
to letters of credit securing obligations (other than obligations described in (a) through (c) above) entered into in the ordinary course
of business of such Person to the extent such letters of credit are not drawn upon or, if and to the extent drawn upon, such drawing
is reimbursed no later than the third Business Day following receipt by such Person of a demand for reimbursement following payment on
the letter of credit);
(e)
the amount of all obligations of such Person with
respect to Interest Rate Agreements or Currency Agreements;
(f)
all obligations of the type referred to in clauses
(a) through (e) above of other Persons and all dividends of other Persons for the payment of which, in either case, such Person is responsible
or liable, directly or indirectly, as obligor, guarantor or otherwise, including by means of any guarantee;
(g)
all obligations of the type referred to in clauses
(a) through (f) above of other Persons secured by any Lien on any Property of such Person (whether or not such obligation is assumed
by such Person);
(h)
all renewals, extensions or refundings of indebtedness
of the kinds described in any of the preceding clauses (a), (b), (d), (e), (f) and (g) and all renewals or extensions of leases of the
kinds described in the preceding clause (c) above;
unless,
in the case of any particular indebtedness, lease, renewal, extension or refunding, the instrument or lease creating or evidencing it
or the assumption or guarantee relating to it expressly provides that such indebtedness, lease, renewal, extension or refunding is not
superior in right of payment to the Securities, and provided however that Senior Indebtedness shall not include indebtedness in
respect of Securities or indebtedness of any Subsidiary.
Subsidiary
means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned,
directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii)
any general partnership, joint venture or similar entity, at least a majority of whose outstanding partnership or similar interests shall
at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and
(iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner.
Trustee
means, and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is
more than one Person acting in such capacity hereunder, Trustee shall mean each such Person. The term Trustee
as used with respect to a particular series of the Securities shall mean the trustee with respect to that series.
Trust
Indenture Act means the Trust Indenture Act of 1939, as amended.
Voting
Stock, as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest
(however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent)
of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence
of a contingency.
ARTICLE
2
ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND
EXCHANGE OF SECURITIES
Section
2.01 Designation and Terms of Securities.
(a)
The aggregate principal amount of Securities that
may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate
principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or
more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant
to a Board Resolution, and set forth in an Officers Certificate, or established in one or more indentures supplemental hereto:
(1)
the title of the Securities of the series (which
shall distinguish the Securities of that series from all other Securities);
(2)
any limit upon the aggregate principal amount of
the Securities of that series that may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered
upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series);
(3)
the date or dates on which the principal of the
Securities of the series is payable, any original issue discount that may apply to the Securities of that series upon their issuance,
the principal amount due at maturity, and the place(s) of payment;
(4)
the rate or rates at which the Securities of the
series shall bear interest or the manner of calculation of such rate or rates, if any;
(5)
the date or dates from which such interest shall
accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates,
the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment
Dates or the manner of determination of such record dates;
(6)
the right, if any, to extend the interest payment
periods and the duration of such extension, including the maximum consecutive periods during which interest payments may be extended;
(7)
the period or periods within which, the price or
prices at which and the terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option
of the Company;
(8)
the obligation, if any, of the Company to redeem
or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments
made in cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within
which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased,
in whole or in part, pursuant to such obligation;
(9)
the form of the Securities of the series including
the form of the Certificate of Authentication for such series;
(10)
if other than denominations of one thousand U.S.
dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable;
(11)
any and all other terms (including terms, to the
extent applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the
Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture,
as amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations
or advisable in connection with the marketing of Securities of that series;
(12)
whether the Securities are issuable as a Global
Security and, in such case, the terms and the identity of the Depositary for such series;
(13)
whether the Securities will be convertible into
or exchangeable for shares of common stock or other securities of the Company or any other Person and, if so, the terms and conditions
upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how
it will be calculated and may be adjusted, any mandatory or optional (at the Companys option or the holders option) conversion
or exchange features, and the applicable conversion or exchange period;
(14)
if other than the principal amount thereof, the
portion, or methods of determining the portion, of the principal amount of Securities of the series which shall be payable upon declaration
of acceleration of the maturity thereof pursuant to Section 6.01;
(15)
any additional or different Events of Default or
restrictive covenants (which may include, among other restrictions, restrictions on the Companys ability or the ability of the
Companys Subsidiaries to: incur additional indebtedness; issue additional securities; create liens; pay dividends or make distributions
in respect of their capital stock; redeem capital stock; place restrictions on such Subsidiaries placing restrictions on their ability
to pay dividends, make distributions or transfer assets; make investments or other restricted payments; sell or otherwise dispose of
assets; enter into sale-leaseback transactions; engage in transactions with stockholders and affiliates; issue or sell stock of their
Subsidiaries; or effect a consolidation or merger) or financial covenants (which may include, among other financial covenants, financial
covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based or asset-based
ratios) provided for with respect to the Securities of the series;
(16)
if other than dollars, the coin or currency in which
the Securities of the series are denominated (including, but not limited to, foreign currency);
(17)
the terms and conditions, if any, upon which the
Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to
any Securityholder that is not a United States person for federal tax purposes;
(18)
any restrictions on transfer, sale or assignment
of the Securities of the series; and
(19)
the subordination terms of the Securities of the
series.
All
Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or
pursuant to any such Board Resolution or in any indentures supplemental hereto.
If
any of the terms of the series are established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate
record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or
prior to the delivery of the Officers Certificate of the Company setting forth the terms of the series.
Securities
of any particular series may be issued at various times, with different dates on which the principal or any installment of principal
is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different
dates on which such interest may be payable and with different redemption dates.
Section
2.02 Form of Securities and Trustees Certificate.
The
Securities of any series and the Trustees certificate of authentication to be borne by such Securities shall be substantially
of the tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth
in an Officers Certificate, and they may have such letters, numbers or other marks of identification or designation and such legends
or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions
of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule
or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage.
Section
2.03 Denominations: Provisions for Payment.
The
Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral
multiple thereof, subject to Section 2.01(a)(10). The Securities of a particular series shall bear interest payable on the dates and
at the rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities
of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency
of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company
maintained for that purpose in the State of Nevada. Each Security shall be dated the date of its authentication. Interest on the Securities
shall be computed on the basis of a 360-day year composed of twelve 30-day months.
The
interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities
of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close
of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion
thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment
Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security
as provided in Section 3.03.
Any
interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities
of the same series (herein called Defaulted Interest) shall forthwith cease to be payable to the registered holder on the
relevant regular record date by virtue of having been such holder; and such Defaulted Interest shall be paid by the Company, at its election,
as provided in clause (1) or clause (2) below:
(1)
The Company may make payment of any Defaulted Interest
on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close
of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the Company
shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the
proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed
to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the
date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted
Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest
which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt
by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and,
in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special
record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security
Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted
Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in
whose names such Securities (or their respective Predecessor Securities) are registered on such special record date.
(2)
The Company may make payment of any Defaulted Interest
on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities
may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the
proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.
Unless
otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities
pursuant to Section 2.01 hereof, the term regular record date as used in this Section with respect to a series of Securities
and any Interest Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which
an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the
first day of a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section
2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.
Subject
to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange
for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried
by such other Security.
Section
2.04 Execution and Authentication.
The
Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature.
The
Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at the time the Securities
shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities
may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date
of its authentication by the Trustee.
A
Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such
signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that
the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this
Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with
a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance
with such written order shall authenticate and deliver such Securities.
In
authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the
Trustee shall be entitled to receive, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating
that the form and terms thereof have been established in conformity with the provisions of this Indenture.
The
Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect
the Trustees own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably
acceptable to the Trustee.
Section
2.05 Registration of Transfer and Exchange.
(a)
Securities of any series may be exchanged upon presentation
thereof at the office or agency of the Company designated for such purpose in the State of Nevada, for other Securities of such series
of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall
execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the
same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.
(b)
The Company shall keep, or cause to be kept, at
its office or agency designated for such purpose in the State of Nevada, or such other location designated by the Company, a register
or registers (herein referred to as the Security Register) in which, subject to such reasonable regulations as it may prescribe,
the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times
shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein
provided shall be appointed as authorized by Board Resolution (the Security Registrar).
Upon
surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute,
the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or
Securities of the same series as the Security presented for a like aggregate principal amount.
All
Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so
required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company
or the Security Registrar, duly executed by the registered holder or by such holders duly authorized attorney in writing.
(c)
Except as provided pursuant to Section 2.01 pursuant
to a Board Resolution, and set forth in an Officers Certificate, or established in one or more indentures supplemental to this
Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in
case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer.
(d)
The Company shall not be required (i) to issue,
exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the
mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business
on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called
for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.05
are, with respect to any Global Security, subject to Section 2.11 hereof.
Section
2.06 Temporary Securities.
Pending
the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary
Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in
the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be
appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed
by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect,
as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities
of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to
the holders), at the office or agency of the Company designated for the purpose in the State of Nevada, and the Trustee shall authenticate
and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities
of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until
further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under
this Indenture as definitive Securities of such series authenticated and delivered hereunder.
Section
2.07 Mutilated, Destroyed, Lost or Stolen Securities.
In
case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding
sentence) shall execute, and upon the Companys request the Trustee (subject as aforesaid) shall authenticate and deliver, a new
Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security,
or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security
shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and,
in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction
of the destruction, loss or theft of the applicants Security and of the ownership thereof. The Trustee may authenticate any such
substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance
of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that
may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.
In
case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead
of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated
Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they may require
to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the
destruction, loss or theft of such Security and of the ownership thereof.
Every
replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company
whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be
entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly
issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with
respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any
and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the
replacement or payment of negotiable instruments or other securities without their surrender.
Section
2.08 Cancellation.
All
Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company
or any paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no
Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. In the
absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate
of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate
as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee
for cancellation.
Section
2.09 Benefits of Indenture.
Nothing
in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties
hereto and the holders of the Securities (and, with respect to the provisions of Article Fourteen, the holders of any indebtedness of
the Company to which the Securities of any series are subordinated) any legal or equitable right, remedy or claim under or in respect
of this Indenture, or under any covenant, condition or provision herein contained; all such covenants, conditions and provisions being
for the sole benefit of the parties hereto and of the holders of the Securities (and, with respect to the provisions of Article Fourteen,
the holders of any indebtedness of the Company to which the Securities of any series are subordinated).
Section
2.10 Authenticating Agent.
So
long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities
which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate
Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled
to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All
references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating
Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital
and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized
or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business
and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to
be eligible in accordance with these provisions, it shall resign immediately.
Any
Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may
at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination
to such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent,
the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon
acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if
originally named as an Authenticating Agent pursuant hereto.
Section
2.11 Global Securities.
(a)
If the Company shall establish pursuant to Section
2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee
shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated
in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in
the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositarys
instruction and (iv) shall bear a legend substantially to the following effect: Except as otherwise provided in Section 2.11 of
the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor
Depositary or to a nominee of such successor Depositary.
(b)
Notwithstanding the provisions of Section 2.05,
the Global Security of a series may be transferred, in whole but not in part and in the manner provided in Section 2.05, only to another
nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee
of such successor Depositary.
(c)
If at any time the Depositary for a series of the
Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary
for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation,
and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes
aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a
request from the Depositary, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute,
and subject to Section 2.04, the Trustee will authenticate and deliver the Securities of such series in definitive registered form without
coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such
series in exchange for such Global Security. In addition, the Company may at any time determine that the Securities of any series shall
no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of
such series. In such event the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officers Certificate
evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form
without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security
of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive registered
form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive
registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall be registered in such names and in
such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall
instruct the Trustee. The Trustee shall deliver such Securities to the Depositary for delivery to the Persons in whose names such Securities
are so registered.
ARTICLE
3
REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS
Section
3.01 Redemption.
The
Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established
for such series pursuant to Section 2.01 hereof.
Section
3.02 Notice of Redemption.
(a)
In case the Company shall desire to exercise such
right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with any right the Company reserved
for itself to do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption
to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less
than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as
they shall appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that
is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder
receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption
in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities
of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption
provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officers
Certificate evidencing compliance with any such restriction.
Each
such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are
to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or
agency of the Company in the State of Nevada, upon presentation and surrender of such Securities, that interest accrued to the date fixed
for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption
is for a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders
of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.
In
case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount
thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities
of such series in principal amount equal to the unredeemed portion thereof will be issued.
(b)
If less than all the Securities of a series are
to be redeemed, the Company shall give the Trustee at least 45 days notice (unless a shorter notice shall be satisfactory to the
Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed,
and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that
may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof)
of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly
notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever
it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all
or any part of the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this
Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any
case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be delivered
to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records,
or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be
required under the provisions of this Section.
Section
3.03 Payment Upon Redemption.
(a)
If the giving of notice of redemption shall have
been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall
become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest
accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after
the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect
to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at
the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such
series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest
payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the
applicable record date pursuant to Section 2.03).
(b)
Upon presentation of any Security of such series
that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the
Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized
denominations in principal amount equal to the unredeemed portion of the Security so presented.
Section
3.04 Sinking Fund.
The
provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except
as otherwise specified as contemplated by Section 2.01 for Securities of such series.
The
minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a mandatory
sinking fund payment, and any payment in excess of such minimum amount provided for by the terms of Securities of any series is
herein referred to as an optional sinking fund payment. If provided for by the terms of Securities of any series, the cash
amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied
to the redemption of Securities of any series as provided for by the terms of Securities of such series.
Section
3.05 Satisfaction of Sinking Fund Payments with Securities.
The
Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit Securities of a series that have been redeemed
either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking
fund payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with
respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of
such series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such
purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and
the amount of such sinking fund payment shall be reduced accordingly.
Section
3.06 Redemption of Securities for Sinking Fund.
Not
less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory
to the Trustee), the Company will deliver to the Trustee an Officers Certificate specifying the amount of the next ensuing sinking
fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering
and crediting Securities of that series pursuant to Section 3.05 and the basis for such credit and will, together with such Officers
Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date
the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and
cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section
3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in
Section 3.03.
ARTICLE
4
COVENANTS
Section
4.01 Payment of Principal, Premium and Interest.
The
Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that
series at the time and place and in the manner provided herein and established with respect to such Securities.
Section
4.02 Maintenance of Office or Agency.
So
long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency in the State of Nevada, with
respect to each such series and at such other location or locations as may be designated as provided in this Section 4.02, where (i)
Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for
registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series
and this Indenture may be given or served, such designation to continue with respect to such office or agency until the Company shall,
by written notice signed by any officer authorized to sign an Officers Certificate and delivered to the Trustee, designate some
other office or agency for such purposes or any of them. If at any time the Company shall fail to maintain any such required office or
agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at
the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations,
notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee located in the State of Nevada as its paying
agent with respect to the Securities.
Section
4.03 Paying Agents.
(a)
If the Company shall appoint one or more paying
agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section:
(1)
that it will hold all sums held by it as such agent
for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such sums have been paid
to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto;
(2)
that it will give the Trustee notice of any failure
by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest
on the Securities of that series when the same shall be due and payable;
(3)
that it will, at any time during the continuance
of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee
all sums so held in trust by such paying agent; and
(4)
that it will perform all other duties of paying
agent as set forth in this Indenture.
(b)
If the Company shall act as its own paying agent
with respect to any series of the Securities, it will on or before each due date of the principal of (and premium, if any) or interest
on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient
to pay such principal (and premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to
such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or
any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of
Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit
with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in
trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee) the
Company will promptly notify the Trustee of this action or failure so to act.
(c)
Notwithstanding anything in this Section to the
contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.05, and (ii)
the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose,
pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held
by the Trustee upon the same terms and conditions as those upon which such sums were held by the Company or such paying agent; and, upon
such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability
with respect to such money.
Section
4.04 Appointment to Fill Vacancy in Office of Trustee.
The
Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10,
a Trustee, so that there shall at all times be a Trustee hereunder.
Section
4.05 Compliance with Consolidation Provisions.
The
Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where
the Company is not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless
the provisions of Article Ten hereof are complied with.
ARTICLE
5
SECURITYHOLDERS LISTS AND REPORTS BY
THE COMPANY AND THE TRUSTEE
Section
5.01 Company to Furnish Trustee Names and Addresses
of Securityholders.
The
Company will furnish or cause to be furnished to the Trustee (a) within 15 days after each regular record date (as defined in Section
2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities
as of such regular record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time
that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other
times as the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar form
and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no
such list need be furnished for any series for which the Trustee shall be the Security Registrar.
Section
5.02 Preservation Of Information; Communications With
Securityholders.
(a)
The Trustee shall preserve, in as current a form
as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained in the most recent
list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in
its capacity as Security Registrar (if acting in such capacity).
(b)
The Trustee may destroy any list furnished to it
as provided in Section 5.01 upon receipt of a new list so furnished.
(c)
Securityholders may communicate as provided in Section
312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities,
and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust Indenture
Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act.
Section
5.03 Reports by the Company.
The
Company covenants and agrees to provide a copy to the Trustee, after the Company files the same with the Securities and Exchange Commission,
copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing
as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the Securities
and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; provided, however, the Company shall not be required
to deliver to the Trustee any materials for which the Company has sought and received confidential treatment by the Securities and Exchange
Commission. The Company shall also comply with the requirements of Section 314 of the Trust Indenture Act, but only to the extent then
applicable to the Company.
Section
5.04 Reports by the Trustee.
(a)
On or before July 1 in each year in which any of
the Securities are Outstanding, the Trustee shall transmit by mail, first class postage prepaid, to the Securityholders, as their names
and addresses appear upon the Security Register, a brief report dated as of the preceding May 1, if and to the extent required under
Section 313(a) of the Trust Indenture Act.
(b)
The Trustee shall comply with Section 313(b) and
313(c) of the Trust Indenture Act.
(c)
A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with
each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The
Company agrees to notify the Trustee when any Securities become listed on any securities exchange.
ARTICLE
6
REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS
ON EVENT OF DEFAULT
Section
6.01 Events of Default.
(a)
Whenever used herein with respect to Securities
of a particular series, Event of Default means any one or more of the following events that has occurred and is continuing:
(1)
the Company defaults in the payment of any installment
of interest upon any of the Securities of that series, as and when the same shall become due and payable, and such default continues
for a period of 30 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the
terms of any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose;
(2)
the Company defaults in the payment of the principal
of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity,
upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to
that series; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture
supplemental hereto shall not constitute a default in the payment of principal or premium, if any;
(3)
the Company fails to observe or perform any other
of its covenants or agreements with respect to that series contained in this Indenture or otherwise established with respect to that
series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture
solely for the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written
notice of such failure, requiring the same to be remedied and stating that such notice is a Notice of Default hereunder,
shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders
of at least 25% in principal amount of the Securities of that series at the time Outstanding;
(4)
the Company pursuant to or within the meaning of
any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case,
(iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment
for the benefit of its creditors; or
(5)
a court of competent jurisdiction enters an order
under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company
for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed
and in effect for 90 days.
(b)
In each and every such case (other than an Event
of Default specified in clause (4) or clause (5) above), unless the principal of all the Securities of that series shall have already
become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that
series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare
the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable
immediately, and upon any such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified
in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all the Securities of that series shall
automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities.
(c)
At any time after the principal of (and premium,
if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared due and payable, and before
any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of
a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company
and the Trustee, may rescind and annul such declaration and its consequences if: (i) the Company has paid or deposited with the Trustee
a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium,
if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration (with interest upon such
principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of
interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit) and the amount payable
to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with respect to such series, other than
the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not
have become due by their terms, shall have been remedied or waived as provided in Section 6.06.
No
such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon.
(d)
In case the Trustee shall have proceeded to enforce
any right with respect to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned
because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every
such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former
positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though no such proceedings
had been taken.
Section
6.02 Collection of Indebtedness and Suits for Enforcement
by Trustee.
(a)
The Company covenants that (i) in case it shall
default in the payment of any installment of interest on any of the Securities of a series, or in any payment required by any sinking
or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall
have continued for a period of 90 Business Days, or (ii) in case it shall default in the payment of the principal of (or premium, if
any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of
a series or upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for
the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all
such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal
(and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon overdue installments
of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall
be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee under Section 7.06.
(b)
If the Company shall fail to pay such amounts forthwith
upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action
or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding
to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities
of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the property of
the Company or other obligor upon the Securities of that series, wherever situated.
(c)
In case of any receivership, insolvency, liquidation,
bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or
property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court
and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may
be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of such series allowed for the
entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional
amount that may become due and payable by the Company after such date, and to collect and receive any moneys or other property payable
or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06;
and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the holders of Securities of such
series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly
to such Securityholders, to pay to the Trustee any amount due it under Section 7.06.
(d)
All rights of action and of asserting claims under
this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without
the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit
or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment
shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the ratable benefit of the holders of
the Securities of such series.
In
case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this
Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights,
either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained
in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested
in the Trustee by this Indenture or by law.
Nothing
contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder
any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder
thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding.
Section
6.03 Application of Moneys or Property Collected.
Any
moneys or property collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied
in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys or property on account
of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment,
if only partially paid, and upon surrender thereof if fully paid:
FIRST:
To the payment of reasonable costs and expenses of collection and of all amounts payable to the Trustee under Section 7.06;
SECOND:
To the payment of all indebtedness of the Company to which such series of Securities is subordinated to the extent required by Section
7.06 and Article Fourteen;
THIRD:
To the payment of the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in
respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according
to the amounts due and payable on such Securities for principal (and premium, if any) and interest, respectively; and
FOURTH:
To the payment of the remainder, if any, to the Company or any other Person lawfully entitled thereto, as requested by the Company.
Section
6.04 Limitation on Suits.
No
holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any
suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or
trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice of an Event
of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore
provided; (ii) the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall
have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii) such
holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities
to be incurred therein or thereby; (iv) the Trustee for 60 days after its receipt of such notice, request and offer of indemnity, shall
have failed to institute any such action, suit or proceeding and (v) during such 60 day period, the holders of a majority in principal
amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.
Notwithstanding
anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive
payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due
dates expressed in such Security (or in the case of redemption, on the redemption date), or to institute suit for the enforcement of
any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such
holder and by accepting a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security
of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall
have any right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the
rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder,
or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all
holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder
and the Trustee shall be entitled to such relief as can be given either at law or in equity.
Section
6.05 Rights and Remedies Cumulative; Delay or Omission
Not Waiver.
(a)
Except as otherwise provided in Section 2.07, all
powers and remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative
and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings
or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established
with respect to such Securities.
(b)
No delay or omission of the Trustee or of any holder
of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall
impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to
the provisions of Section 6.04, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised
from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.
Section
6.06 Control by Securityholders.
The
holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance
with Section 8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to
the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series; provided, however, that such direction
shall not be in conflict with any rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have
the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee,
determine that the proceeding so directed, subject to the Trustees duties under the Trust Indenture Act, would involve the Trustee
in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority
in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with
Section 8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of
the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its consequences, except a default
in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall
become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to
pay all matured installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section
6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company,
the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively;
but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.
Section
6.07 Undertaking to Pay Costs.
All
parties to this Indenture agree, and each holder of any Securities by such holders acceptance thereof shall be deemed to have
agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or
in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an
undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys
fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such
party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any
Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any
series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or
interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this
Indenture.
ARTICLE
7
CONCERNING THE TRUSTEE
Section
7.01 Certain Duties and Responsibilities of Trustee.
(a)
The Trustee, prior to the occurrence of an Event
of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the Securities of
that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such
duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the Trustee.
In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee
shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same
degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own
affairs.
(b)
No provision of this Indenture shall be construed
to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct,
except that:
(1)
prior to the occurrence of an Event of Default with
respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that
may have occurred:
(A)
the duties and obligations of the Trustee shall
with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall
not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically
set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and
(B)
in the absence of bad faith on the part of the Trustee,
the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and the correctness
of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this
Indenture; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished
to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirement of
this Indenture;
(2)
the Trustee shall not be liable for any error of
judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee
was negligent in ascertaining the pertinent facts;
(3)
the Trustee shall not be liable with respect to
any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority
in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture
with respect to the Securities of that series; and
(4)
None of the provisions contained in this Indenture
shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of
its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds
or liability is not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably
assured to it.
Section
7.02 Certain Rights of Trustee.
Except
as otherwise provided in Section 7.01:
(a)
The Trustee may rely conclusively and shall be protected
in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent,
order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties;
(b)
Any request, direction, order or demand of the Company
mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized
officer of the Company (unless other evidence in respect thereof is specifically prescribed herein);
(c)
The Trustee may consult with counsel and the written
advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken
or suffered or omitted hereunder in good faith and in reliance thereon;
(d)
The Trustee shall be under no obligation to exercise
any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the Securityholders pursuant
to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against
the costs, expenses and liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee
of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or
waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use
the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of
his own affairs;
(e)
The Trustee shall not be liable for any action taken
or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred
upon it by this Indenture;
(f)
The Trustee shall not be bound to make any investigation
into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order,
approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority
in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04);
provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred
by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded
to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such costs, expenses or liabilities as a condition
to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be
repaid by the Company upon demand; and
(g)
The Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible
for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder.
In
addition, the Trustee shall not be deemed to have knowledge of any Default or Event of Default except (1) any Event of Default occurring
pursuant to Sections 6.01(a)(1), 6.01(a)(2) and 4.01 hereof or (2) any Default or Event of Default of which the Trustee shall have received
written notification in the manner set forth in this Indenture or a Responsible Officer of the Trustee shall have obtained actual knowledge.
Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information
and the Trustees receipt of the foregoing shall not constitute constructive notice of any information contained therein, or determinable
from information contained therein including the Companys compliance with any of their covenants thereunder (as to which the Trustee
is entitled to rely conclusively on an Officers Certificate).
Section
7.03 Trustee Not Responsible for Recitals or Issuance
or Securities.
(a)
The recitals contained herein and in the Securities
shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same.
(b)
The Trustee makes no representations as to the validity
or sufficiency of this Indenture or of the Securities.
(c)
The Trustee shall not be accountable for the use
or application by the Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys
paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or
application of any moneys received by any paying agent other than the Trustee.
Section
7.04 May Hold Securities.
The
Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities
with the same rights it would have if it were not Trustee, paying agent or Security Registrar.
Section
7.05 Moneys Held in Trust.
Subject
to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust
for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The
Trustee shall be under no liability for interest on any moneys received by it hereunder except such as it may agree with the Company
to pay thereon.
Section
7.06 Compensation and Reimbursement.
(a)
The Company covenants and agrees to pay to the Trustee,
and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services
rendered by it in the execution of the trusts hereby created and in the exercise and performance of any of the powers and duties hereunder
of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for
all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this
Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in
its employ), except any such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company
and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents, directors
and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part
of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the reasonable costs
and expenses of defending itself against any claim of liability in the premises.
(b)
The obligations of the Company under this Section
to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall
constitute indebtedness of the Company to which the Securities are subordinated. Such additional indebtedness shall be secured by a lien
prior to that of the Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for
the benefit of the holders of particular Securities.
Section
7.07 Reliance on Officers Certificate.
Except
as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably
necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder,
such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith
on the part of the Trustee, be deemed to be conclusively proved and established by an Officers Certificate delivered to the Trustee
and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for
any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.
Section
7.08 Disqualification; Conflicting Interests.
If
the Trustee has or shall acquire any conflicting interest within the meaning of Section 310(b) of the Trust Indenture Act,
the Trustee and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act.
Section
7.09 Corporate Trustee Required; Eligibility.
There
shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and
doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a
corporation or other Person permitted to act as trustee by the Securities and Exchange Commission, authorized under such laws to exercise
corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision
or examination by federal, state, territorial, or District of Columbia authority.
If
such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid
supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other
Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company
may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee.
In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign
immediately in the manner and with the effect specified in Section 7.10.
Section
7.10 Resignation and Removal; Appointment of Successor.
(a)
The Trustee or any successor hereafter appointed
may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the Company and by transmitting
notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear
upon the Security Register. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect
to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument
shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed
and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any
court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder
of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others
similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if
any, as it may deem proper and prescribe, appoint a successor trustee.
(b)
In case at any time any one of the following shall
occur:
(1)
the Trustee shall fail to comply with the provisions
of Section 7.08 after written request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security
or Securities for at least six months; or
(2)
the Trustee shall cease to be eligible in accordance
with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or by any such Securityholder;
or
(3)
the Trustee shall become incapable of acting, or
shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property
shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for
the purpose of rehabilitation, conservation or liquidation;
then,
in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument,
in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed
and one copy to the successor trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least
six months may, on behalf of that holder and all others similarly situated, petition any court of competent jurisdiction for the removal
of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper
and prescribe, remove the Trustee and appoint a successor trustee.
(c)
The holders of a majority in aggregate principal
amount of the Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying
the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.
(d)
Any resignation or removal of the Trustee and appointment
of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective
upon acceptance of appointment by the successor trustee as provided in Section 7.11.
(e)
Any successor trustee appointed pursuant to this
Section may be appointed with respect to the Securities of one or more series or all of such series, and at any time there shall be only
one Trustee with respect to the Securities of any particular series.
Section
7.11 Acceptance of Appointment By Successor.
(a)
In case of the appointment hereunder of a successor
trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company
and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee
shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights,
powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring Trustee
shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers,
and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held
by such retiring Trustee hereunder.
(b)
In case of the appointment hereunder of a successor
trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee
with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor
trustee shall accept such appointment and which (i) shall contain such provisions as shall be necessary or desirable to transfer and
confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to
the Securities of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions
as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect
to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring
Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate
the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental
indenture shall constitute such Trustees co-trustees of the same trust, that each such Trustee shall be trustee of a trust or trusts
hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible
for any act or failure to act on the part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture
the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall
with respect to the Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility
for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture,
and each such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts
and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor
trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver
to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee
hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates.
(c)
Upon request of any such successor trustee, the
Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor trustee all such
rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be.
(d)
No successor trustee shall accept its appointment
unless at the time of such acceptance such successor trustee shall be qualified and eligible under this Article.
(e)
Upon acceptance of appointment by a successor trustee
as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage
prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such
notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be
transmitted at the expense of the Company.
Section
7.12 Merger, Conversion, Consolidation or Succession
to Business.
Any
corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from
any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business
of the Trustee, shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions
of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further act on
the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated,
but not delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to such authenticating Trustee
may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself
authenticated such Securities.
Section
7.13 Preferential Collection of Claims Against the Company.
The
Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b)
of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act
to the extent included therein.
Section
7.14 Notice of Default
If
any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer
of the Trustee, the Trustee shall mail to each Securityholder in the manner and to the extent provided in Section 313(c) of the Trust
Indenture Act notice of the Default or Event of Default within 90 days after it occurs and becomes known to the Trustee, unless such
Default or Event of Default has been cured; provided, however, that, except in the case of a default in the payment of the principal
of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as the
board of directors, the executive committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith
determine that the withholding of such notice is in the interest of the Securityholders.
ARTICLE
8
CONCERNING
THE SECURITYHOLDERS
Section
8.01 Evidence of Action by Securityholders.
Whenever
in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities
of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver
or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage
of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such
holders of Securities of that series in person or by agent or proxy appointed in writing.
If
the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver
or other action, the Company may, at its option, as evidenced by an Officers Certificate, fix in advance a record date for such
series for the determination of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver
or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization,
direction, notice, consent, waiver or other action may be given before or after the record date, but only the Securityholders of record
at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders
of the requisite proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand,
authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall
be computed as of the record date; provided, however, that no such authorization, agreement or consent by such Securityholders on the
record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six
months after the record date.
Section
8.02 Proof of Execution by Securityholders.
Subject
to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization)
or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner:
(a)
The fact and date of the execution by any such Person
of any instrument may be proved in any reasonable manner acceptable to the Trustee.
(b)
The ownership of Securities shall be proved by the
Security Register of such Securities or by a certificate of the Security Registrar thereof.
The
Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary.
Section
8.03 Who May be Deemed Owners.
Prior
to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar
may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of
such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone
other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject
to Section 2.03) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor
any Security Registrar shall be affected by any notice to the contrary.
Section
8.04 Certain Securities Owned by Company Disregarded.
In
determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any
direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on
the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control with the Company
or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such
determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent
or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned
that have been pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish
to the satisfaction of the Trustee the pledgees right so to act with respect to such Securities and that the pledgee is not a
Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other
obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection
to the Trustee.
Section
8.05 Actions Binding on Future Securityholders.
At
any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders
of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection
with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders
of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section
8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall
be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange
therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made
upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of
a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee
and the holders of all the Securities of that series.
ARTICLE
9
SUPPLEMENTAL INDENTURES
Section
9.01 Supplemental Indentures Without the Consent of
Securityholders.
In
addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and
at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act
as then in effect), without the consent of the Securityholders, for one or more of the following purposes:
(a)
to cure any ambiguity, defect, or inconsistency
herein or in the Securities of any series;
(b)
to comply with Article Ten;
(c)
to provide for uncertificated Securities in addition
to or in place of certificated Securities and to make all appropriate changes for such purpose;
(d)
to add to the covenants, restrictions, conditions
or provisions relating to the Company for the benefit of the holders of all or any series of Securities (and if such covenants, restrictions,
conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions,
conditions or provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence
and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to
surrender any right or power herein conferred upon the Company;
(e)
to add to, delete from, or revise the conditions,
limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein
set forth;
(f)
to make any change that does not adversely affect
the rights of any Securityholder in any material respect;
(g)
to provide for the issuance of and establish the
form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications
required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders
of any series of Securities;
(h)
to evidence and provide for the acceptance of appointment
hereunder by a successor trustee; or
(i)
to comply with any requirements of the Securities
and Exchange Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture Act.
The
Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate
agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental
indenture that affects the Trustees own rights, duties or immunities under this Indenture or otherwise.
Any
supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent
of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02.
Section
9.02 Supplemental Indentures With Consent of Securityholders.
With
the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities
of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board
Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall
conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any
manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered
by Section 9.01 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental
indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a) extend the fixed maturity
of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest
thereon, or reduce any premium payable upon the redemption thereof, (b) make any Security payable in money other than that stated in
the Security, (c) impair the right of any Holder to receive payment of principal of, premium, if any, and interest, if any, on, such
Holders Securities on or after the due dates therefor or to institute suit for the enforcement of any payment, or (d) adversely
change the right to convert or exchange, including decreasing the conversion rate or increasing the conversion price of, any Security,
or (e) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture.
It
shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular
form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.
Section
9.03 Effect of Supplemental Indentures.
Upon
the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with
respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of
rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series
affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments,
and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of
this Indenture for any and all purposes.
Section
9.04 Securities Affected by Supplemental Indentures.
Securities
of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant
to the provisions of this Article or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets
the requirements of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental
indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of
Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated
by the Trustee and delivered in exchange for the Securities of that series then Outstanding.
Section
9.05 Execution of Supplemental Indentures.
Upon
the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon
the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall
join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustees
own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be
obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, will be entitled to receive
and will be fully protected in relying upon an Officers Certificate and an Opinion of Counsel stating that any supplemental indenture
executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for
the Trustee under the provisions of this Article to join in the execution thereof; provided, however, that such Officers Certificate
or Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the terms of
a series of Securities pursuant to Section 2.01 hereof.
Promptly
after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee
shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture,
to the Securityholders of all series affected thereby as their names and addresses appear upon the Security Register. Any failure of
the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental
indenture.
ARTICLE
10
SUCCESSOR ENTITY
Section
10.01 Company May Consolidate, Etc.
The
Company shall not consolidate with or merge into any other Person (in a transaction in which the Company is not the surviving corporation)
or convey, transfer or lease its properties and assets substantially as an entirety to any Person, unless (a) the Person formed by such
consolidation or into which the Company is merged or the Person which acquires by conveyance or transfer, or which leases, the properties
and assets of the Company substantially as an entirety shall expressly assume, by an indenture supplemental hereto, executed and delivered
to the Trustee, in form satisfactory to the Trustee, the due and punctual payment of the principal of and any premium and interest on
all the Securities and the performance or observance of every covenant of this Indenture on the part of the Company to be performed,
by supplemental indenture satisfactory in form to the Trustee, executed and delivered to the Trustee, by the Person (if other than the
Company) formed by such consolidation or into which the Company shall have been merged or by the Person which shall have acquired the
Companys assets; (b) immediately after giving effect to such transaction and treating any indebtedness which becomes an obligation
of the Company or any Subsidiary as a result of such transaction as having been incurred by the Company or such Subsidiary at the time
of such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default,
shall have happened and be continuing; and (c) the Company has delivered to the Trustee an Officers Certificate and an Opinion
of Counsel, each stating that such consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required
in connection with such transaction, such supplemental indenture comply with this Article and that all conditions precedent herein provided
for relating to such transaction have been complied with.
The
restrictions in this Section 10.01 shall not apply to the merger of the Company with or into a single direct or indirect wholly owned
Subsidiary.
Section
10.02 Successor Entity Substituted.
(a)
In case of any such consolidation, merger, sale,
conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered
to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of
all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been
named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this
Indenture and the Securities.
(b)
In case of any such consolidation, merger, sale,
conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance) may be made in the Securities
thereafter to be issued as may be appropriate.
(c)
Nothing contained in this Article shall require
any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of
such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person
(whether or not affiliated with the Company).
Section
10.03 Evidence of Consolidation, Etc. to Trustee.
The
Trustee, subject to the provisions of Section 7.01, may receive an Officers Certificate or an Opinion of Counsel as conclusive
evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the
provisions of this Article.
ARTICLE
11
SATISFACTION AND DISCHARGE
Section
11.01 Satisfaction and Discharge of Indenture.
If
at any time: (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated
and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that
shall have been replaced or paid as provided in Section 2.07 and Securities for whose payment money or Governmental Obligations have
theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged
from such trust, as provided in Section 11.05); or (b) all such Securities of a particular series not theretofore delivered to the Trustee
for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called
for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company
shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination
thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification
thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the
Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date
fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with
respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except
for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption
date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of
the Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging
this Indenture with respect to such series.
Section
11.02 Discharge of Obligations.
If
at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become
due and payable as described in Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust
funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series
not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due
to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all
other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations,
as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall
cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that
shall survive until such Securities shall mature and be paid.
Thereafter,
Sections 7.06 and 11.05 shall survive.
Section
11.03 Deposited Moneys to be Held in Trust.
All
moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be
available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to
the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations have
been deposited with the Trustee.
Section
11.04 Payment of Moneys Held by Paying Agents.
In
connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent
under the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall
be released from all further liability with respect to such moneys or Governmental Obligations.
Section
11.05 Repayment to Company.
Any
moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment
of principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by
the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on
such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned
or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Companys request or (if then held
by the Company) shall be discharged from such trust; and thereupon the paying agent and the Trustee shall be released from all further
liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment
shall thereafter, as a general creditor, look only to the Company for the payment thereof.
ARTICLE
12
IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS
Section
12.01 No Recourse.
No
recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or
otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such,
of the Company or of any predecessor or successor corporation, either directly or through the Company or any such predecessor or successor
corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise;
it being expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no
such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors
as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby
authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities
or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by
constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director
as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements
contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition
of, and as a consideration for, the execution of this Indenture and the issuance of such Securities.
ARTICLE
13
MISCELLANEOUS PROVISIONS
Section
13.01 Effect on Successors and Assigns.
All
the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors
and assigns, whether so expressed or not.
Section
13.02 Actions by Successor.
Any
act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer
of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any
corporation that shall at the time be the lawful successor of the Company.
Section
13.03 Surrender of Company Powers.
The
Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the
powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor
corporation.
Section
13.04 Notices.
Except
as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted
to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on
the Company may be given or served by being deposited in first class mail, postage prepaid, addressed (until another address is filed
in writing by the Company with the Trustee), as follows: 680 W Nye Lane Suite 204, Carson City, NV 89703, with a copy to Reed Smith LLP,
599 Lexington Avenue, New York, NY 10022, Attention: Mark Pedretti. Any notice, election, request or demand by the Company or any Securityholder
or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for
all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.
Section
13.05 Governing Law.
This
Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of Nevada, and for all purposes
shall be construed in accordance with the laws of said State, except to the extent that the Trust Indenture Act is applicable.
Section
13.06 Treatment of Securities as Debt.
It
is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of
this Indenture shall be interpreted to further this intention.
Section
13.07 Certificates and Opinions as to Conditions Precedent.
(a)
Upon any application or demand by the Company to
the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officers
Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant
to Section 13.13) relating to the proposed action have been complied with and an Opinion of Counsel stating that in the opinion of such
counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which
the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application
or demand, no additional certificate or opinion need be furnished.
(b)
Each certificate or opinion provided for in this
Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a
statement that the Person making such certificate or opinion has read such covenant or condition; (ii) a brief statement as to the nature
and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;
(iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable
him to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to
whether or not, in the opinion of such Person, such condition or covenant has been complied with.
Section
13.08 Payments on Business Days.
Except
as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officers Certificate, or established
in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security
or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may
be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption,
and no interest shall accrue for the period after such nominal date.
Section
13.09 Conflict with Trust Indenture Act.
If
and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317,
inclusive, of the Trust Indenture Act, such imposed duties shall control.
Section
13.10 Indenture and Securities Solely Corporate Obligations.
No
recourse for the payment of the principal of, premium, if any, or interest on any Securities, or for any claim based thereon or otherwise
in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental
indenture or in any Security, or because of the creation of any indebtedness represented thereby, shall be had against any incorporator,
shareholder, employee, agent, officer, director or subsidiary, as such, past, present or future, of the Company or of any successor entity,
either directly or through the Company or any successor entity, whether by virtue of any constitution, statute, or rule of law, or by
the enforcement of any assessment or penalty or otherwise; it being expressly understood that all such liability is hereby expressly
waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of the Securities.
Section
13.11 Counterparts.
This
Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute
but one and the same instrument.
Section
13.12 Separability.
In
case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions
of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable
provision had never been contained herein or therein.
Section
13.13 Compliance Certificates.
The
Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were
outstanding, a compliance certificate stating whether or not the signer knows of any Default or Event of Default that occurred during
such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial officer or
principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Companys
performance under this Indenture and that the Company has complied with all conditions and covenants under this Indenture. For purposes
of this Section 13.13, such compliance shall be determined without regard to any period of grace or requirement of notice provided under
this Indenture. If the officer of the Company signing such certificate has knowledge of such a Default or Event of Default, the certificate
shall describe any such Default or Event of Default and its status.
ARTICLE
14
SUBORDINATION OF SECURITIES
Section
14.01 Agreement of Subordination.
The
Company covenants and agrees, and each holder of Securities issued hereunder by his acceptance thereof likewise covenants and agrees,
that all Securities shall be issued subject to the provisions of this Article 14; and each Securityholder, whether upon original issue
or upon transfer or assignment thereof, accepts and agrees to be bound by such provisions.
The
payment of the principal of, premium, if any, and interest on all Securities issued hereunder shall, to the extent and in the manner
hereinafter set forth, be subordinated and subject in right of payment to the prior payment in full of all Senior Indebtedness of the
Company, whether outstanding at the date of this Indenture or thereafter incurred.
The
provisions of this Article 14 define the subordination of the Securities, as obligations of the Company, with respect to Senior Indebtedness
of the Company.
No
provision of this Article 14 shall prevent the occurrence of any default or Event of Default hereunder.
Section
14.02 Payments to Securityholders.
In
the event and during the continuation of any default in the payment of principal, premium, interest or any other payment due on any Senior
Indebtedness of the Company continuing beyond the period of grace, if any, specified in the instrument or lease evidencing such Senior
Indebtedness of the Company, then, unless and until such default shall have been cured or waived or shall have ceased to exist, no payment
shall be made by the Company with respect to the principal of, or premium, if any, or interest on the Securities, except payments made
pursuant to Article 11 hereof from monies deposited with the Trustee pursuant thereto prior to the happening of such default.
Upon
any payment by the Company, or distribution of assets of the Company of any kind or character, whether in cash, property or securities,
to creditors upon any dissolution or winding-up or liquidation or reorganization of the Company, whether voluntary or involuntary or
in bankruptcy, insolvency, receivership or other proceedings, all amounts due or to become due upon all Senior Indebtedness of the Company
shall first be paid in full, or payment thereof provided for in money in accordance with its terms, before any payment is made on account
of the principal (and premium, if any) or interest on the Securities (except payments made pursuant to Article 11 hereof from monies
deposited with the Trustee pursuant thereto prior to the happening of such dissolution, winding-up, liquidation or reorganization); and
upon any such dissolution or winding-up or liquidation or reorganization any payment by the Company, or distribution of assets of the
Company of any kind or character, whether in cash, property or securities, to which the holders of the Securities or the Trustee would
be entitled, except for the provisions of this Article 14, shall (except as aforesaid) be paid by the Company or by any receiver, trustee
in bankruptcy, liquidating trustee, agent or other Person making such payment or distribution, or by the holders of the Securities or
by the Trustee under this Indenture if received by them or it, directly to the holders of Senior Indebtedness of the Company (pro rata
to such holders on the basis of the respective amounts of Senior Indebtedness of the Company held by such holders, as calculated by the
Company) or their representative or representatives, or to the trustee or trustees under any indenture pursuant to which any instruments
evidencing any Senior Indebtedness of the Company may have been issued, as their respective interests may appear, to the extent necessary
to pay all Senior Indebtedness of the Company in full, in money or moneys worth, after giving effect to any concurrent payment
or distribution to or for the holders of Senior Indebtedness of the Company, before any payment or distribution is made to the holders
of the Securities or to the Trustee.
In
the event that, notwithstanding the foregoing, any payment or distribution of assets of the Company of any kind or character, whether
in cash, property or securities, prohibited by the foregoing, shall be received by the Trustee or the holders of the Securities before
all Senior Indebtedness of the Company is paid in full, or provision is made for such payment in money in accordance with its terms,
such payment or distribution shall be held in trust for the benefit of and shall be paid over or delivered to the holders of Senior Indebtedness
of the Company or their representative or representatives, or to the trustee or trustees under any indenture pursuant to which any instruments
evidencing any Senior Indebtedness of the Company may have been issued, as their respective interests may appear, as calculated by the
Company, for application to the payment of all Senior Indebtedness of the Company remaining unpaid to the extent necessary to pay all
Senior Indebtedness of the Company in full in money in accordance with its terms, after giving effect to any concurrent payment or distribution
to or for the holders of such Senior Indebtedness.
For
purposes of this Article 14, the words, cash, property or securities shall not be deemed to include shares of stock of
the Company as reorganized or readjusted, or securities of the Company or any other corporation provided for by a plan of reorganization
or readjustment, the payment of which is subordinated at least to the extent provided in this Article 14 with respect to the Securities
to the payment of all Senior Indebtedness of the Company which may at the time be outstanding; provided that (i) the Senior Indebtedness
of the Company is assumed by the new corporation, if any, resulting from any such reorganization or readjustment, and (ii) the rights
of the holders of the Senior Indebtedness of the Company (other than leases) and of leases which are assumed are not, without the consent
of such holders, altered by such reorganization or readjustment. The consolidation of the Company with, or the merger of the Company
into, another corporation or the liquidation or dissolution of the Company following the conveyance or transfer of its property as an
entirety, or substantially as an entirety, to another corporation upon the terms and conditions provided for in Article 10 hereof shall
not be deemed a dissolution, winding-up, liquidation or reorganization for the purposes of this Section 14.02 if such other corporation
shall, as a part of such consolidation, merger, conveyance or transfer, comply with the conditions stated in Article 10 hereof. Nothing
in this Section 14.02 shall apply to claims of, or payments to, the Trustee under or pursuant to Article 7.
Section
14.03 Subrogation of Securities.
Subject
to the payment in full of all Senior Indebtedness of the Company, the rights of the holders of the Securities shall be subrogated to
the rights of the holders of Senior Indebtedness of the Company to receive payments or distributions of cash, property or securities
of the Company applicable to the Senior Indebtedness of the Company until the principal of (and premium, if any) and interest on the
Securities shall be paid in full; and, for the purposes of such subrogation, no payments or distributions to the holders of the Senior
Indebtedness of the Company of any cash, property or securities to which the holders of the Securities or the Trustee would be entitled
except for the provisions of this Article 14 to or for the benefit of the holders of Senior Indebtedness of the Company by holders of
the Securities or the Trustee, shall, as between the Company, its creditors other than holders of Senior Indebtedness of the Company,
and the holders of the Securities, be deemed to be a payment by the Company to or on account of the Senior Indebtedness of the Company.
It is understood that the provisions of this Article 13 are and are intended solely for the purpose of defining the relative rights of
the holders of the Securities, on the one hand, and the holders of the Senior Indebtedness of the Company, on the other hand.
Nothing
contained in this Article 14 or elsewhere in this Indenture or in the Securities is intended to or shall impair, as between the Company,
its creditors other than the holders of its Senior Indebtedness, and the holders of the Securities, the obligation of the Company, which
is absolute and unconditional, to pay to the holders of the Securities the principal of (and premium, if any) and interest on the Securities
as and when the same shall become due and payable in accordance with their terms, or is intended to or shall affect the relative rights
of the holders of the Securities and creditors of the Company other than the holders of its Senior Indebtedness, nor shall anything herein
or therein prevent the Trustee or the holder of any Security from exercising all remedies otherwise permitted by applicable law upon
default under this Indenture, subject to the rights, if any, under this Article 14 of the holders of Senior Indebtedness of the Company
in respect of cash, property or securities of the Company received upon the exercise of any such remedy.
Upon
any payment or distribution of assets of the Company referred to in this Article 14, the Trustee, subject to the provisions of Article
7, and the holders of the Securities shall be entitled to rely upon any order or decree made by any court of competent jurisdiction in
which such dissolution, winding-up, liquidation or reorganization proceedings are pending, or a certificate of the receiver, trustee
in bankruptcy, liquidating trustee, agent or other Person making such payment or distribution, delivered to the Trustee or to the holders
of the Securities, for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the Senior
Indebtedness and other indebtedness of the Company, the amount thereof or payable thereon, the amount or amounts paid or distributed
thereon and all other facts pertinent thereto or to this Article 14.
Section
14.04 Authorization by Securityholders.
Each holder of a Security by his acceptance thereof authorizes and directs the Trustee on his behalf to take such action as may be
necessary or appropriate to effectuate the subordination provided in this Article 14 appoints the Trustee his attorney-in-fact for any
and all such purposes.
Section
14.05 Notice to Trustee.
The Company shall give promptly written notice to a Responsible Officer of the Trustee of any fact known to the Company which would
prohibit the making of any payment of monies to or by the Trustee in respect of the Securities pursuant to the provisions of this Article
14. Notwithstanding the provisions of this Article 14 or any other provision of this Indenture, the Trustee shall not be charged with
knowledge of the existence of any facts which would prohibit the making of any payment of monies to or by the Trustee in respect of the
Securities pursuant to the provisions of this Article 14, unless and until a Responsible Officer of the Trustee shall have received written
notice thereof at the Corporate Trust Office of the Trustee from the Company or a holder or holders of Senior Indebtedness of the Company
or from any trustee therefor; and before the receipt of any such written notice, the Trustee, subject to the provisions of Article 7,
shall be entitled in all respects to assume that no such facts exist; provided that if on a date not fewer than three Business
Days prior to the date upon which by the terms hereof any such monies may become payable for any purpose (including, without limitation,
the payment of the principal of (or premium, if any) or interest on any Security) the Trustee shall not have received, with respect to
such monies, the notice provided for in this Section 14.05, then, anything herein contained to the contrary notwithstanding, the Trustee
shall have full power and authority to receive such monies and to apply the same to the purpose for which they were received, and shall
not be affected by any notice to the contrary which may be received by it on or after such prior date. Notwithstanding anything to the
contrary hereinbefore set forth, nothing shall prevent any payment by the Company or the Trustee to the Securityholders of monies in
connection with a redemption of Securities if (i) notice of such redemption has been given in accordance herewith prior to the receipt
by the Trustee of written notice as aforesaid, and (ii) such notice of redemption is given not earlier than 60 days before the redemption
date.
The
Trustee conclusively shall be entitled to rely on the delivery to it of a written notice by a Person representing himself to be a holder
of Senior Indebtedness of the Company (or a trustee on behalf of such holder) to establish that such notice has been given by a holder
of Senior Indebtedness of the Company or a trustee on behalf of any such holder or holders. In the event that the Trustee determines
in good faith that further evidence is required with respect to the right of any Person as a holder of Senior Indebtedness of the Company
to participate in any payment or distribution pursuant to this Article 14, the Trustee may request such Person to furnish evidence to
the reasonable satisfaction of the Trustee as to the amount of Senior Indebtedness of the Company held by such Person, the extent to
which such Person is entitled to participate in such payment or distribution and any other facts pertinent to the rights of such Person
under this Article 14, and if such evidence is not furnished the Trustee may defer any payment to such Person pending judicial determination
as to the right of such Person to receive such payment.
Section
14.06 Trustees Relation to Senior Indebtedness.
The Trustee in its individual capacity shall be entitled to all the rights set forth in this Article 14 in respect of any Senior
Indebtedness of the Company at any time held by it, to the same extent as any other holder of Senior Indebtedness of the Company and
nothing elsewhere in this Indenture shall deprive the Trustee of any of its rights as such holder.
With
respect to the holders of Senior Indebtedness of the Company, the Trustee undertakes to perform or to observe only such of its covenants
and obligations as are specifically set forth in this Article 14, and no implied covenants or obligations with respect to the holders
of Senior Indebtedness of the Company shall be read into this Indenture against the Trustee. The Trustee shall not be deemed to owe any
fiduciary duty to the holders of Senior Indebtedness of the Company and the Trustee shall not be liable to any holder of Senior Indebtedness
of the Company if it shall pay over or deliver to holders of Securities, the Company or any other Person money or assets to which any
holder of Senior Indebtedness of the Company shall be entitled by virtue of this Article 14 or otherwise.
Section
14.07 No Impairment of Subordination.
No right of any present or future holder of any Senior Indebtedness of the Company to enforce subordination as herein provided shall
at any time in any
way
be prejudiced or impaired by any act or failure to act on the part of the Company or by any act or failure to act, in good faith, by
any such holder, or by any noncompliance by the Company with the terms, provisions and covenants of this Indenture, regardless of any
knowledge thereof which any such holder may have or otherwise be charged with.
Section
14.08 Rights of Trustee.
Nothing in this Article 14 shall apply to claims of or payments to, the Trustee pursuant to Article 7.
IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written.
|
BIOVIE
Inc. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
|
|
[TRUSTEE],
as Trustee |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
CROSS-REFERENCE
TABLE (1)
Section
of Trust Indenture Act Of 1939, as Amended |
|
Section
of Indenture |
310(a) |
|
7.09 |
310(b) |
|
7.08 |
|
|
7.10 |
310(c) |
|
Inapplicable |
311(a) |
|
7.13 |
311(b) |
|
7.13 |
311(c) |
|
Inapplicable |
312(a) |
|
5.01 |
|
|
5.02(a) |
312(b) |
|
5.02(c) |
312(c) |
|
5.02(c) |
313(a) |
|
5.04(a) |
313(b) |
|
5.04(b) |
313(c) |
|
5.04(a) |
|
|
5.04(b) |
313(d) |
|
5.04(c) |
314(a) |
|
5.03 |
|
|
13.12 |
314(b) |
|
Inapplicable |
314(c) |
|
13.07(a) |
314(d) |
|
Inapplicable |
314(e) |
|
13.07(b) |
Section
of Trust Indenture Act Of 1939, as Amended |
|
Section
of Indenture |
314(f) |
|
Inapplicable |
315(a) |
|
7.01(a) |
|
|
7.01(b) |
315(b) |
|
7.14 |
315(c) |
|
7.01 |
315(d) |
|
7.01(b) |
315(e) |
|
6.07 |
316(a) |
|
6.06 |
|
|
8.04 |
316(b) |
|
6.04 |
316(c) |
|
8.01 |
317(a) |
|
6.02 |
317(b) |
|
4.03 |
318(a) |
|
13.09 |
|
(1) |
This
Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its
terms or provisions. |
|
|
|
Exhibit
5.1
|
Sherman
& Howard L.L.C.
50
West Liberty Street, Suite 1000, Ren NV 89501
Phone: 775.323.1980 |
|
3960
Howard Hughes Parkway, Suite 500
Las
Vegas, NV 89169 Phone: 702.387.6073 |
ShermanHoward.com |
August
18, 2023
BioVie
Inc.
680
West Nye Lane, Suite201
Carson
City, Nevada 489703
| Re: | BioVie
Inc./Registration Statement on Form S-3 |
Ladies
and Gentlemen:
We
have acted as special Nevada counsel to BioVie Inc., a Nevada corporation (the Company), in connection with the Companys
Registration Statement on Form S-3, filed as of the date hereof, as amended from time-to-time (the Registration Statement),
under the Securities Act of 1933, as amended (the Securities Act), as filed by the Company with the Securities and Exchange
Commission (the Commission) of:
(a)
up to $300,000,000 of the Companys Securities (as defined below) to be issued from time-to-time by the Company in one or more
offerings and in any combination of the Securities; and
(b)
up to 311,002 shares (the Resale Shares) of its Class A common stock, $0.0001 par value per share (the Common Stock),
to be issued upon exercise of the Lender Warrants (as defined in the Registration Statement) and sold by selling stockholders of the
Company.
The
prospectus (the Prospectus) that forms part of the Registration Statement provides that it will be supplemented in the
future by one or more prospectus supplements (each, a Prospectus Supplement) in connection with the registration of any
Securities. The Registration Statement, including the Prospectus as supplemented from time-to-time by one or more Prospectus Supplements,
covers the offering and issuance by the Company of:
(a)
shares of Common Stock;
(b)
shares of preferred stock, $0.001 par value per share (the Preferred Stock);
(c)
warrants to purchase Common Stock, Preferred Stock, or Debt Securities (as defined below) (the
Warrants);
(d)
debt securities, in one or more series (the Debt Securities), which may be issued
pursuant to an indenture to be dated on or about the date of the first issuance of Debt Securities thereunder (an Indenture),
by and between a trustee to be selected by the Company (the Trustee) and the Company;
August
18, 2023
Page
2
|
|
|
(e)
subscription rights to purchase shares of Common Stock, shares of Preferred Stock, Debt Securities, or Units (as defined below) (the
Rights); and
(f)
units comprised of any combination of Common Stock, shares of Preferred Stock, Debt Securities,
Warrants, or Rights (the Units and collectively with the Common Stock, the Preferred Stock, the Warrants, the Debt Securities,
and the Rights, the Securities).
The
Securities may be issued in an unspecified number and the Debt Securities may be issued in an unspecified principal amount. The
Registration Statement provides that the Securities may be offered separately or together, in separate series, in amounts, at prices,
and on terms to be set forth in one or more Prospectus Supplements. The Securities are to be sold pursuant to a purchase, underwriting,
subscription, placement agency, or similar agreement, which will be in substantially the forms previously filed or to be filed under
a Current Report on Form 8-K.
For
purposes of these opinions, we have examined originals or copies, certified or otherwise identified to our satisfaction, of:
(a)
the Registration Statement;
(b)
a form of Indenture;
(c) Loan and Security Agreement and Supplement thereto among the Company, Avenue Venture Opportunities Fund, L.P., and Avenue Venture Opportunities
Fund II, L.P. dated November 30, 2021 (the Loan Agreement);
(d)
a form of the Lender Warrants;
(e)
resolutions of the Board of Directors and such other matters as relevant related to the (i) registration of the Securities, (ii) approval
of the Loan Agreement and issuance of the Lender Warrants and authorization of the Company to execute, deliver, and perform its obligations
under the Loan Agreement and the Lender Warrants, (iii) issuance and the registration of the Resale Shares under the Securities Act,
and (iv) such other matters as relevant.
We
have also examined such other corporate charter documents, records, certificates, and instruments (the Documents) as we
deem necessary or advisable to render the opinions set forth herein.
August
18, 2023
Page
3
|
|
|
In
our examination, we have assumed:
(a)
the legal capacity of all natural persons executing the Documents;
(b)
the genuineness of all signatures on the Documents;
(c)
the authenticity of all Documents submitted to us as originals, and the conformity to original documents of all Documents submitted to
us as copies;
(d)
that the parties to such Documents, other than the Company, had the power, corporate or other, to enter into and perform all obligations
thereunder;
(e)
other than with respect to the Company, the due authorization by all requisite action, corporate or other, of the execution, delivery
and performance by all parties of the Documents, and the validity and binding effect thereof on such parties;
(f)
that: (i) the Registration Statement and any amendments thereto shall have become effective under the Securities Act and will remain
effective at the time of issuance of any Securities thereunder; (ii) a Prospectus Supplement describing each class of Securities offered
pursuant to the Registration Statement will be timely filed with the Commission; (iii) the definitive terms of each class or series of
Securities shall have been established in accordance with resolutions (each, a Board Action) duly adopted by the Companys
Board of Directors, the Companys Articles of Incorporation, and applicable law; (iv) the Company will issue and deliver the Securities
identified in any applicable Prospectus Supplement in the manner contemplated by the Registration Statement, the Prospectus, the applicable
Prospectus Supplement, and any applicable underwriting, subscription, placement agency, or similar agreement; (v) the total number of
shares of Common Stock issuable (including upon conversion, exchange, or exercise of any other security) will not exceed the total number
of shares of Common Stock that the Company is authorized to issue under its Articles of Incorporation at the time of issuance; (vi) the
total number of shares of Preferred Stock issuable (including upon conversion, exchange, or exercise of any other security) will not
exceed the total number of shares of Preferred Stock that the Company is authorized to issue under its Articles of Incorporation at the
time of issuance; (vii) the Board Action authorizing the Company to offer, issue, and sell the Securities will have been adopted by the
Board and will be in full force and effect at the time the Securities are offered and sold by the Company; and (viii) all Securities
will have been issued in compliance with federal and state securities law.
(g)
with respect to Debt Securities, that: (i) such Debt Security shall have been issued pursuant to an Indenture and the terms of the Indenture
are in compliance with the Trust Indenture Act of 1939 (the TIA); (ii) the Trustee under such Indenture (A) is qualified
to act as a trustee of the Indenture under the TIA and any applicable state law, and is in compliance with such laws with respect to
acting as trustee of the Indenture, (B) is organized, validly existing, and in good standing under the laws of its jurisdiction of organization,
(C) has duly authorized, executed, and delivered such Indenture and such Indenture constitutes the legally valid and binding obligation
of such Trustee, and (D) has the requisite organizational and legal power and authority to perform its obligations under the Indenture;
(iii) such Indenture shall have been duly authorized, executed, and delivered by the Company; (iv) such Indenture will be governed by
the laws of the State of Nevada; (v) any terms of such Debt Securities not provided for in the Indenture shall have been established
in accordance with the applicable provisions of the Indenture and reflected in appropriate documentation executed and delivered by the
Company and the Trustee; (vi) such Debt Securities shall have been duly executed, authenticated, issued, and delivered in accordance
with the provisions of such Indenture; (vii) such Debt Securities do not violate any law applicable to the Company or result in a default
under or breach of any agreement binding on the Company; and (viii) such Debt Securities comply with all requirements and restrictions,
if any, applicable to the Company.
August
18, 2023
Page
4
|
|
|
(h)
With respect to Warrants, Rights, and Units, that: (i) such Securities have been issued pursuant to an agreement (Agreement)
between the company and an agent identified in the applicable Agreement (the Agent); (ii) the Agent under such Agreement
(A) is qualified to act as an agent under the Agreement under any applicable federal or state law, and is in compliance with such laws
with respect to acting as agent under the Agreement, (B) is organized, validly existing, and in good standing under the laws of its jurisdiction
of organization, (C) has duly authorized, executed, and delivered such Agreement and such Agreement constitutes the legally valid and
binding obligation of such Agent, and (D) has the requisite organizational and legal power and authority to perform its obligations under
the Agreement; (iii) such Agreement shall have been duly authorized, executed, and delivered by the Company; (iv) such Agreement will
be governed by the laws of the State of Nevada; (v) any terms of Warrants, Rights, or Units not provided for in the Agreement shall have
been established in accordance with the applicable provisions of the Agreement and reflected in appropriate documentation executed and
delivered by the Company and the Agent; (vi) such Warrants, Rights, or Units shall have been duly executed, authenticated, issued, and
delivered in accordance with the provisions of such Agreement; (vii) such Warrants, Rights, or Units do not violate any law applicable
to the Company or result in a default under or breach of any agreement binding on the Company; and (viii) such Warrants, Rights, or Units
comply with all requirements and restrictions, if any, applicable to the Company.
The
opinions in paragraphs 3, 4, 5 and 6 below with respect to the enforceability of the Warrants, Debt Securities, Rights, and Units are
subject to:
(a)
the effect of applicable bankruptcy, insolvency, reorganization, receivership, moratorium,
fraudulent transfer, and other similar laws affecting the rights and remedies of creditors generally;
(b)
the effect of general principles of equity, including, without limitation, limitations on the
availability of equitable remedies and concepts of materiality, reasonableness, good faith and fair dealing, and other similar doctrines
affecting the enforceability of agreements generally (regardless of whether considered in a proceeding in equity or at law); and
August
18, 2023
Page
5
|
|
|
(c)
the effect of public policy considerations that may limit the rights of the parties to obtain further remedies.
We
express no opinion as to the validity or enforceability of the provisions of any Indenture or Agreement related to choice of law, choice
of venue, jurisdiction, waivers of any defense, or waivers of jury trial.
The
opinions expressed below are limited to the matters specifically set forth herein and no other opinion shall be inferred beyond the matters
expressly stated. We disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed for purposes of
delivering these opinions expressed herein or any changes in applicable law that may come to our attention after the date the Registration
Statement is declared effective.
On
the basis of the foregoing and in reliance thereon, and subject to the assumptions, limitations, and qualifications set forth herein,
we are of the opinion that:
1.
The Common Stock to be sold by the Company, including any Common Stock duly issued upon the exchange or conversion of any duly issued
preferred stock or debt securities, including the Preferred Stock or Debt Securities offered and issued under the Registration Statement
or the exercise of any warrants or rights, including any Warrants or Rights offered and issued under the Registration Statement, upon
issuance and delivery of certificates (or book-entry notation) against payment therefor as set forth in the Registration Statement, Prospectus,
or a Prospectus Supplement will be validly issued, fully paid, and non-assessable.
2.
The Preferred Stock to be sold by the Company, including any Preferred Stock duly issued upon the exchange or conversion of any duly
issued debt securities, including the Debt Securities offered and issued under the Registration Statement or the exercise of any warrants
or rights, including any Warrants or Rights offered and issued under the Registration Statement, upon issuance and delivery of certificates
(or book-entry notation) against payment therefor as set forth in the Registration Statement, Prospectus, or a Prospectus Supplement
will be validly issued, fully paid, and non-assessable.
3.
The Warrants, upon issuance and delivery of certificates (or book-entry notation) against payment therefor as set forth in the Registration
Statement, Prospectus, or a Prospectus Supplement, will constitute valid and legally binding obligations of the Company.
4.
The Debt Securities, upon issuance and delivery of certificates (or book-entry notation) against payment therefor as set forth in the
Registration Statement, Prospectus, or a Prospectus Supplement, will constitute valid and legally binding obligations of the Company.
August
18, 2023
Page
6
|
|
|
5.
The Rights, upon issuance and delivery of certificates (or book-entry notation) against payment therefor as set forth in the Registration
Statement, Prospectus, or a Prospectus Supplement, will constitute valid and legally binding obligations of the Company.
6.
The Units, upon issuance and delivery of certificates (or book-entry notation) against payment therefor as set forth in the Registration
Statement, Prospectus, or a Prospectus Supplement, will constitute valid and legally binding obligations of the Company.
7.
The Resale Shares have been duly authorized, and when issued against payment of the exercise price in accordance with the terms of the
Lender Warrants, the Resale Shares will be validly issued, fully paid, and nonassessable.
While
certain members of this firm are admitted to practice in certain jurisdictions other than Nevada, in rendering the foregoing opinions
we have not examined the laws of any jurisdiction other than Nevada. Accordingly, we express no opinion regarding the effect of the laws
of any other jurisdiction or state, including any federal laws. The opinions we express herein are limited solely to the laws of the
State of Nevada, other than the securities laws and regulations of the State of Nevada (as to which we express no opinion).
We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement and we consent to the reference of our name
under the caption Legal Matters in the Registration Statement and the Prospectus Supplement. In giving the foregoing consent,
we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the
rules and regulations of the Commission thereunder.
|
Very
truly yours, |
|
|
|
/s/Sherman
& Howard L.L.C. |
|
|
|
SHERMAN
& HOWARD L.L.C. |
CONSENT
OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
We
consent to the incorporation by reference in this Registration Statement of BioVie, Inc. on Form S-3 to be filed on or about August 18,
2023, of our report dated August 16, 2023, on our audits of the financial statements as of June 30, 2023 and 2022 and for each of the
years then ended, which report was included in the Annual Report on Form 10-K filed August 16, 2023. Our report includes an explanatory
paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. We also consent
to the reference to our firm under the caption “Experts” in this Registration Statement.
/s/
EISNERAMPER LLP
Iselin,
New Jersey
August
18, 2023
Exhibit
107
Calculation
of Filing Fee Tables
Form
S-3
(Form
Type)
BioVie
Inc.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered and Carry Forward Securities
|
|
Security
Type |
|
Security
Class Title |
|
Fee
Calculation
or
Carry
Forward
Rule |
|
|
Amount
Registered |
|
|
Proposed
Maximum
Offering
Price
Per
Unit |
|
|
Maximum
Aggregate
Offering
Price |
|
|
Fee
Rate |
|
|
Amount
of
Registration
Fee |
|
|
Carry
Forward
Form
Type |
|
|
Carry
Forward
File
Number |
|
|
Carry
Forward
Initial
effective
date |
|
|
Filing
Fee
Previously
Paid
In
Connection
with
Unsold
Securities
to
be Carried
Forward |
|
Newly
Registered Securities |
Fees
to Be Paid |
|
Primary
Offerings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt |
|
Debt
Securities(1) |
|
|
|
|
|
|
|
(2) |
|
|
|
(3) |
|
|
|
(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Preferred
Stock, par value $0.0001 per share(1) |
|
|
|
|
|
|
|
(2) |
|
|
|
(3) |
|
|
|
(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Class
A Common Stock, par value $0.0001 per share(1) |
|
|
|
|
|
|
|
(2) |
|
|
|
(3) |
|
|
|
(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Rights(1) |
|
|
|
|
|
|
|
(2) |
|
|
|
(3) |
|
|
|
(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other |
|
Warrants(1) |
|
|
|
|
|
|
|
(2) |
|
|
|
(3) |
|
|
|
(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unallocated
(Universal) Shelf |
|
|
|
|
457(o) |
|
|
|
|
(2) |
|
|
|
(3) |
|
$ |
300,000,000 |
|
|
$ |
0.00011020 |
|
|
$ |
33,060 |
(4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Secondary
Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Class
A common stock, par value $0.0001 per share(5) |
|
|
457(c) |
|
|
|
311,002 |
|
|
|
$3.780 |
|
|
$ |
1,175,587.56 |
|
|
$ |
0.00011020 |
|
|
$ |
129.55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees
Previously Paid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carry
Forward Securities |
Carry
Forward Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Offering Amounts |
|
|
|
|
|
|
$ |
301,175,587.56 |
|
|
$ |
0.00011020 |
|
|
$ |
33,189.55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Fees Previously Paid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Fee Offsets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,189.55 |
(6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Fee Due |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
0.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Separate
consideration may or may not be received for securities that are issuable upon the conversion or exercise of, or in exchange for,
other securities offered hereby. |
(2) |
There
are being registered hereunder such indeterminate number of shares of common stock and preferred stock, such indeterminate number
of rights and units, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase
common stock, preferred stock, rights, units and/or debt securities to be sold by the Registrant from time to time at unspecified
prices which shall have an aggregate initial offering price not to exceed $300,000,000. If any debt securities are issued at an original
issue discount, then the principal amount of such debt securities shall be in such greater amount as shall result in an aggregate
initial offering price not to exceed $300,000,000, less the aggregate dollar amount of all securities previously issued hereunder.
The securities registered for sale also include such indeterminate number of shares of common stock and preferred stock and amount
of debt securities as may be issued upon conversion of or exchange for preferred stock or debt securities that provide for conversion
or exchange, upon exercise of warrants or rights or pursuant to the antidilution provisions of any such securities. In addition,
pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares being registered
hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the
shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. |
(3) |
The
proposed maximum offering price per share will be determined, from time to time, by the Registrant in connection with the issuance
by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to Instruction
2.A.iii.b. to the Calculation of Filing Fee Tables and Related Disclosure on Item 16(b) of Form S-3 under the Securities Act. |
(4) |
The
proposed maximum aggregate offering price has been calculated pursuant to Rule 457(o) under the Securities Act. |
(5) |
Estimated
solely for the purpose of calculating the registration fee according to Rule 457(c) under the Securities Act of 1933, as amended,
based on the average of the high ($4.00) and low ($3.56) prices of the registrant’s common stock reported on the Nasdaq Capital
Market on August 14, 2023, which is within five business days prior to filing this registration statement. |
(6) |
The
offsetting fee was paid previously by the Registrant as part of the filing fee of $344,090 in connection with the Preliminary Information
Statement on Schedule 14C (File No. 001-39015) filed by the registration as of May 4, 2021, which filing fee was later reduced to
$40,297 pursuant to Amendment No. 1 to the Information Statement on Schedule 14C (File No. 001-39015) filed by the registrant as
of May 10, 2021. |
|
|
v3.23.2
Cover
|
Aug. 18, 2023 |
Entity Addresses [Line Items] |
|
Document Type |
S-3
|
Amendment Flag |
false
|
Entity Registrant Name |
BIOVIE
INC.
|
Entity Central Index Key |
0001580149
|
Entity Tax Identification Number |
46-2510769
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
680
W Nye Lane Suite 204
|
Entity Address, City or Town |
Carson City
|
Entity Address, State or Province |
NV
|
Entity Address, Postal Zip Code |
89703
|
City Area Code |
(775)
|
Local Phone Number |
888-3162
|
Entity Filer Category |
Non-accelerated Filer
|
Entity Small Business |
true
|
Entity Emerging Growth Company |
false
|
Business Contact [Member] |
|
Entity Addresses [Line Items] |
|
Entity Address, Address Line One |
680 W Nye Lane Suite 204
|
Entity Address, City or Town |
Carson City
|
Entity Address, State or Province |
NV
|
Entity Address, Postal Zip Code |
89703
|
Contact Personnel Name |
Cuong
Do
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
BioVie (NASDAQ:BIVI)
過去 株価チャート
から 12 2024 まで 1 2025
BioVie (NASDAQ:BIVI)
過去 株価チャート
から 1 2024 まで 1 2025